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Abstract 
Parkinson disease (PD) is the most common neurodegenerative movement disorder in 
humans and is strongly associated with the selective loss of dopaminergic (DA) neurons. 
The clinical features include motor dysfunction, resting tremor and in some cases non-
motor features such as autonomic, cognitive and psychiatric disorders. The 
neuropathologic hallmarks are Lewy bodies and Lewy neurites in surviving neurons 
which are composed of proteinaceous inclusions comprised of α-synuclein, ubiquitin and 
other proteins. Pathological mechanisms implicated in PD include aberrant protein 
aggregation, mitochondrial dysfunction, oxidative stress, and failed cellular processes 
such as apoptosis, autophagy, proteasomal pathway, and several cellular stressors. To 
analyse the implication and contribution of some of these cellular processes, we altered 
the expression of the; classical apoptotic genes namely Buffy and Debcl; autophagy genes 
Atg6 and Pi3K59F; the antiapoptotic transmembrane Bax inhibitor-1 containing motif 
(TMBIM) family Bax inhibitor-1, Lifeguard and GHITM; mitochondrial genes such as 
HtrA2, MICU1, porin/VDAC, Pink1 and parkin; and an increased disease risk gene 
pyridoxal kinase in DA neurons and in the developing eye. We show that the altered 
expression of key genes can either be detrimental or beneficial to the health of DA 
neurons as determined by lifespan and locomotor function, in addition to supportive 
results obtained from biometric analysis of phenotypes from the neuron rich eye. We 
found that the overexpression of Buffy, the sole pro-survival Bcl-2 homologue in 
Drosophila could suppress the loss of function-induced phenotypes.
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Chapter 1 - Introduction and Overview  
Parkinson Disease  
Parkinson disease (PD) is a neurodegenerative disease that is characterized by the 
progressive loss of specific populations of dopaminergic neurons and can result in 
substantial disability and early death [1]. PD is the most common movement disorder and 
afflicts about 1 to 2% of the population over 50 years of age [1, 2]. Patients with PD show 
profound motor, psychological and emotional dysfunction owing to degeneration and 
death of dopaminergic (DA) neurons in the Substantia Nigra pars compacta (SNpc) [3, 
4]. Some of its more common symptoms include muscle rigidity, resting tremors, postural 
instability, and bradykinesia paired in some cases with non-motor symptoms such as 
autonomic, cognitive and psychiatric problems [3, 5]. The neuropathological hallmarks 
exhibited by PD patients are Lewy Bodies (LB) and Lewy neurites (LN) in surviving 
neurons, which show the presence of eosinophilic, intracytoplasmic proteinaceous 
inclusions comprised of α-synuclein and ubiquitin as the major components, and other 
proteins [3, 6, 7]. The identification of familial forms of the disease; of which at least 20 
gene loci associated with PD have been identified [8, 9] shows that, together with the 
sporadic forms, increased oxidative stress, dysfunction in cellular clearance system, 
mitochondrial dysfunction, and inflammation are common hallmarks in the pathology of 
both forms of PD. 
Genetics of Parkinson disease 
Most cases of PD are sporadic with no known causative factor though environmental and 
genetic factors are known to contribute to the development of the disease [9]. The 
  
2 
 
identification of inheritable forms of PD, caused by monogenic mutations have been 
pivotal to understand the underlying disease process at the molecular level, and in the 
generation of model systems [10-12]. The complexity of the genetics of PD are 
highlighted by the numerous gene loci identified, together with a host of disease risk 
factors. Currently, 15 genes that cause Mendelian forms of PD have been confirmed that 
display autosomal dominant or autosomal recessive form of inheritance, in addition to at 
least 25 genetic risk factors that were discovered through genome wide association 
studies [12]. The PD-linked genes along with the risk factors are implicated in a plethora 
of cellular functions that are biologically important and include, regulation of miRNAs, 
vesicular trafficking, mitochondrial homeostasis and biogenesis, cellular clearance 
systems, ER homeostasis, Golgi homeostasis, among many other cellular processes [9, 
11, 12]. The dysfunction of many of these pathways contribute to the disease pathology in 
both sporadic and familial forms of PD. 
Currently, at least 20 distinct gene loci PARK1 to PARK20 have been described for 
familial PD (see Appendix 4) that include; α-synuclein/ PARK1/4 [6], parkin/ PARK2 [13], 
Ubiquitin C-terminal hydrolase-1 (Uchl-1)/ PARK5 [7], Phosphatase and tensin 
homologue [PTEN] induced kinase 1 (Pink1)/ PARK6 [14], DJ-1/PARK7 [15], Leucine 
rich repeat kinase 2 (LRRK2)/ PARK8 [16, 17]. Other mutated gene loci that have been 
implicated in rare FPD are Adenosine triphosphate 13A2 (a P-type ATPase)/ PARK9 [18], 
Grb10-Interacting GYF Protein-2 (GIGYF2)/ PARK11 [19], High temperature 
requirement A2 (HtrA2)/ PARK 13 [20], Phospholipase A2 (PLA2G6)/ PARK14 [21], F-
box only protein 7 (FBXO7)/ PARK15 [22], Vacuolar sorting protein 35 (VPS35)/ 
PARK17 [23, 24], eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)/ PARK18 
  
3 
 
[25], dnaJ homologue subfamily C member 6 (DNAJC6)/ PARK19 [26], synaptojanin 1 
(SYNJ1)/ PARK20 [27, 28]. Additional genes have been identified that cause PD; dnaJ 
homologue subfamily C member 13 (DNAJC13) [29], ATPase H+ transporting lysosomal 
accessory protein 2 (ATP6AP2) [30], and coenzyme Q2 4-hydroxybenzoate 
polyprenyltransferase (CoQ2) [31] but require further replication, or lack conclusive 
linkage, or whose replication studies have not yielded the same results as the original 
findings [12]. Other FPD causative gene loci exist (PARK) whose mutated gene is 
currently unknown and include PARK3, PARK10, PARK12 and PARK16 [8]. The 
characterization of these genes has led to advances in the understanding of disease 
pathogenesis and produced robust models in experimental organisms. 
Drosophila models of Parkinson disease 
A majority of the genes associated with PD show high conservation in a wide variety of 
organisms and as such can be modelled to study the consequences of their altered 
expression by assessment of the resultant phenotypes [12, 32, 33]. Drosophila possesses 
an array of advantages as a model organism that include; a complex nervous system with 
a DA neuron cluster, large collections of mutant strains, an array of genetic manipulation 
techniques, easy transgenesis and mutagenesis, and large numbers of approaches for 
genetic screens. Most of the identified PD genes, at least 15, have a homologue in 
Drosophila, except for SNCA and FBXO7: a putative homologue has been reported in our 
laboratory (Merzetti and Staveley, unpublished work) but nonetheless the expression of 
the human versions in Drosophila neurons has been achieved [9]. Briefly, a few 
Drosophila PD models will be described. 
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The α-synuclein model  
The first gene to be identified associated with autosomal dominant PD was α-synuclein 
(SNCA/ PARK1/PARK4) and encodes a small and soluble presynaptic nerve terminal 
protein with as yet unknown function; that constitute the main component of Lewy bodies 
(LB) in both sporadic and familial forms of PD and its aggregation is believed to be the 
main neuropathogenic cause of PD [3, 6, 34]. Types of mutations in the α-synuclein gene 
include point mutations, duplications, triplications, and multiplications and are implicated 
in PD [8]. These mutations and high levels of α-synuclein seems to aid in the generation 
of insoluble protein aggregates and high order fibrils that are implicated in neurotoxicity 
and PD pathogenesis [8, 10, 11]. The aggregation of α-synuclein has been shown to 
mediate DA neuron toxicity and specifically, the non-β-amyloid component (NAC) is 
essential for the aggregation and neurotoxicity in DA neurons. This aggregation is 
worsened by post-translational modifications such as phosphorylation on serine 129, 
calpain-mediated cleavage, O-glycosylation, tyrosine nitration, methionine oxidation, and 
C-terminal truncation [8, 35]. The mechanisms for α-synuclein toxicity are numerous and 
suggest that; α-synuclein oligomers alters plasma membrane stability or permeability by 
formation of pores that increase intracellular calcium, α-synuclein interacts with the 
mitochondria and its components to induce mitochondrial dysfunction that increase ROS 
and oxidative stress [36, 37], α-synuclein interferes with synaptic transmission to cause 
accumulation of docked vesicles at the presynaptic membrane and thus reduce the 
recycling vesicle pool that increases cytosolic levels of dopamine [38], and through its 
association with cellular pathways, α-synuclein inhibits the ubiquitin-proteasome system, 
endosomal-lysosomal system, autophagy, ER-Golgi trafficking, Golgi homeostasis, and 
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promotes apoptosis [39]. The pathways disrupted by α-synuclein may be indicative of 
how α-synuclein achieves neuronal toxicity and contributes to the aetiology of PD. 
Although Drosophila seem to lack a clear α-synuclein orthologue, the gain of function 
was achieved by the expression of human wild type and two mutant forms of α-synuclein, 
A30P and A53T [40]. This model, and others that were developed later were able to 
reproduce the key features of PD such as, adult-onset degeneration and loss of DA 
neurons, accumulation of proteinaceous inclusions containing α-synuclein that were 
similar to Lewy bodies, and locomotor dysfunction [40, 41]. The most controversial 
finding was the degeneration and loss of DA neurons in the Drosophila brain, with 
inconsistent reports by different groups [33, 42]. This shows a remarkable and robust 
model system that has been used to understand the pathophysiology of PD. In early 
studies, the directed expression of Hsp70, a molecular chaperone up-regulated in stress 
responses that refolds misfolded proteins, mitigated DA neuronal loss induced by α-
synuclein [41]. The propensity for α-synuclein to form aggregates is increased on 
phosphorylation, α-synuclein is found heavily phosphorylated in the brains of patients 
with PD, was shown to be conserved in Drosophila [43] and that α-synuclein toxicity may 
be modulated by phosphorylation. Several studies have shown the suppression of the α-
synuclein-induced phenotypes, such as the co-expression of the α-synuclein transgene 
with; parkin, a ubiquitin E3 ligase [44], Rab1, a guanosine triphosphate [45], Sirtuin2, a 
histone deacetylase [46], and PTEN induced putative kinase1 (Pink1), a mitochondrial 
kinase [47]. Investigation of the interaction of α-synuclein with other proteins has been an 
attractive area of stimulated research and may be important in the formulation of 
therapies and in management of PD. 
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The impact of antioxidants on α-synuclein flies has been investigated, the co-expression 
of human Cu/Zn superoxide dismutase (SOD) with α-synuclein A30P reduced the 
observed neurodegeneration [48]. Moreover, flies fed with antioxidants slightly altered 
the α-synuclein-induced phenotypes such as reported on a blueberry extract [49]. This 
showed that lowered cytoplasmic levels of oxidative stress confers protection to DA 
neurons. The treatment of α-synuclein fly models with certain pharmacological agents 
such as L-Dopa restored the PD phenotype to normal, whereas the dopamine agonists 
pergolide, bromocriptine and SK & F 38393 were substantially effective [50]. Atropine 
was found to be effective but to a lesser extent than the other anti-Parkinson compounds. 
Genomic investigation of the transcriptional program of α-synuclein models at pre- 
symptomatic, early and advanced stages revealed 51 signature transcripts that include 
lipid, energy & membrane mRNAs that were highly distinct and either up-regulated or 
down-regulated in common cellular pathways [51] and the dysregulated proteins are 
associated with membranes, ER, actin cytoskeleton, mitochondria and ribosomes [52]. 
These variations show the complexity of biological systems that are modified by α-
synuclein in a model of Parkinson’s disease. 
The Parkin model 
The parkin/PARK2 gene encodes a cytosolic ubiquitin E3 ligase that selectively targets 
misfolded proteins to the ubiquitin proteasome system (UPS) for degradation [53, 54]. 
Parkin consists of an N-terminal ubiquitin-like domain (Ubl), and four zinc-coordinating 
RING-like domains: RING0, RING1, an in-between RING (IBR), and RING2 [55]. Over 
170 mutations in this gene have been identified which are responsible for familial early-
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onset PD (EOPD) [7, 13, 56] and has been implicated in dysfunction in a number of 
cellular processes such as UPS, autophagy and endosomal-lysosomal pathway. Parkin is 
involved in the ubiquitination of substrates in cooperation with ubiquitin E2 enzymes, it 
first needs to be activated from its inactive or auto-inhibited form [55, 56]. Pink1 and 
parkin are implicated in the same pathway that clears dysfunctional mitochondria via a 
specialized form of autophagy called mitophagy [55-57]. Parkin is activated through 
phosphorylation on ser65 by Pink1 and by phospho-ubiquitin. Upon activation, parkin 
modifies numerous cytosolic and outer mitochondrial membrane (OMM) proteins [56], 
key to mitophagy is its ability to add phospho-ubiquitin chains to defective mitochondria 
and target it for clearance [56, 58], and ER-associated degradation-like extraction of 
proteins from the OMM (OMMAD) [56, 59]. There is consensus that parkin and Pink1 
participates in the same pathway to rid cells of defective mitochondria and that Pink1 
senses the damage and recruit parkin. Other functions of parkin are discussed elsewhere 
in this chapter. 
The generation of parkin transgenic flies has contributed to the wealth of information 
available on the biological functions of parkin to date [33, 60]. Mutant parkin flies are 
viable, show reduced longevity, a slight developmental delay, male sterility from a defect 
in spermatogenesis, locomotor defects due to apoptotic muscle degeneration [61], reduced 
body size and cell size, sensitivity to oxidative and environmental stress [62], and 
degeneration and loss of DA neurons in the adult brain [63]. In addition, the 
overexpression of a human parkin mutant variant (R375W) in Drosophila resulted in an 
age-dependent degeneration of specific DA neuronal clusters, concomitant locomotor 
deficits that accelerated with age due to mitochondrial abnormalities [64]. The insights 
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from studying Drosophila parkin mutants are immense and have highlighted the 
importance of this model organism in modelling human neurodegenerative diseases. 
The Pink1 model 
The second autosomal recessive EOPD gene to be identified was PARK6/Pink1 that 
encodes the Phosphatase and tensin homologue (PTEN)-induced kinase1 (Pink1) [14, 65, 
66], the protein sequence of which contains an N-terminal mitochondrial targeting signal 
sequence (MTS) and a highly conserved serine/threonine protein kinase domain of the 
Ca2+ calmodulin family. Mutations in Pink1 gene resulted in nigrostriatal neuronal loss 
with Lewy bodies as observed in post-mortem brains of patients with PD due to loss of its 
kinase activity [67]. Pink1 is a nuclear encoded gene that is translated in the cytosol and 
via the MTS is imported into the mitochondria where it is believed to act as a 
mitochondria damage sensor [68]. Studies have demonstrated different localization, with 
some to the inner mitochondrial membrane, intermembrane space, or to the outer 
mitochondrial membrane [67]. Pink1 is important in mitochondrial function as it is 
involved in the removal of dysfunctional mitochondria. 
 Drosophila Pink1 is found to localize in the mitochondria and is detected at all 
developmental stages with high levels in the adult brain and testes, and show significant 
homology and functional conservation with the human version [69, 70]. The Pink1 
mutant flies have a host of phenotypes that included viability, abnormally positioned 
wings, male sterility, short lifespan, apoptotic degeneration, mitochondrial defects, energy 
depletion, increased sensitivity to multiple stresses including oxidative stress, indirect 
flight muscle, ommatidial and DA neuron degeneration and finally locomotor defects. 
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These phenotypes were remarkably similar to those found in parkin mutant flies [69-73]; 
It is the similarity between the phenotypes of parkin and Pink1 flies that led to the 
suggestion that the two proteins function in the same pathway. The sterility in Pink1 
mutant flies was due to mitochondrial defects in the spermatids, showing vacuolated 
nebenkerns and individualization defects. This male sterility was rescued upon expression 
of Drosophila Pink1, human Pink1 and parkin. Pink1 has a role in spermatogenesis to 
regulate mitochondrial morphology [69]. Mitochondrial dysfunction was also implicated 
in locomotor deficit and IFM degeneration with the IFM having disorganized myofibrils 
that were highly vacuolated with swollen impaired mitochondria. In addition, these 
mitochondria had low levels of mitochondrial DNA (mtDNA), mitochondrial proteins, 
ATP and had fragmented cristae. Expression of Drosophila Pink1, human Pink1, and 
parkin restored the muscle integrity with normal mitochondrial ATP levels and myofibril 
morphology [69, 70, 73]. This indicated that suppression of Drosophila Pink1 could lead 
to age-dependent muscle degeneration characterized by extensive dysfunction and DNA 
fragmentation that is indicative of apoptotic cell death. 
Further studies in Drosophila and cell systems demonstrated that parkin is recruited by 
Pink1 to depolarized mitochondria to mediate selective autophagic removal of the 
damaged mitochondria [60]. The finding that Pink1 directly phosphorylates parkin [74] or 
phosphorylates ubiquitin which in turn activates parkin, led to the unravelling of the 
Pink1/Parkin pathway, in which Pink1 detected the damaged mitochondria and signals 
parkin to ubiquitinate the defective mitochondria and thus target them for autophagic 
removal [56, 75]. An alternative mechanism for parkin recruitment is the phosphorylation 
of mitofusin 2 (Mfn2) by Pink1 which then acts as a parkin receptor [76]. Upon 
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recruitment to the outer mitochondria membrane, parkin ubiquitinates numerous targets 
that are degraded through the proteasome and attaches chains of ubiquitin to the damaged 
mitochondria in readiness for mitophagy. The Pink1/Parkin pathway has been implicated 
in the regulation of mitochondrial quality control by interaction with the fission/fusion 
machinery [77-79], regulates localized translation of select nuclear-encoded respiratory 
chain complex mRNAs [80], regulates selective mitochondrial respiratory chain turnover 
[81], and retards mitochondrial motility by regulation of Miro, a component of the 
motor/adaptor complex, that quarantines damaged mitochondria [82]. Pink1 can modify 
other PD-associated phenotypes, such as its rescue of α-synuclein [47], or HtrA2 [83], 
and possible association with DJ-1 [53]. The fly model was first to demonstrate that 
Pink1 and parkin are key regulators of mitochondrial quality control through genetic 
epistatic studies. 
The HtrA2 model 
Loss of function mutations in the PARK13/HtrA2 gene that encodes High temperature 
requirement A2 (HtrA2 also known as Omi) that interfere with its protease activity are 
strongly associated with PD [20]. HtrA2 is a nuclear encoded mitochondrial localized 
serine protease with an N-terminal mitochondrial targeting signal and exhibits 
proapoptotic and cell protective properties; it is very closely related to the Drosophila 
Reaper, Hid and Grim proapoptotic proteins by the presence of the inhibitor of apoptosis 
(IAP) inhibitory Reaper-like motif [84]. A141S and G399S are two mutant alleles that 
were found in PD patients and were determined to be causative to PD [20], but have since 
been challenged after being found to segregate in non-PD population [85, 86]. In a 
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subsequent study, a new mutation R404W was characterized in the PDZ domain that 
abrogated the protease function of HtrA2 [87], and thus confirmed its role in PD 
susceptibility. Briefly, HtrA2 is sequestered within the mitochondrial intermembrane 
space and is released into the cytosol during apoptosis where it binds IAPs and thus 
blocks them from inhibiting caspases [88]. The binding of Omi/HtrA2 to IAPs activates 
the protease function. The common facet of PD is mitochondrial dysfunction and 
especially the loss of mitochondrial Complex I function in the midbrain of PD patients 
highlights the importance of the mitochondria in the pathology of PD [37, 89, 90]. This 
protein may play a role in cellular protection due to stress. 
In Drosophila melanogaster, HtrA2 has been shown to have apoptotic functions through 
cleavage of IAP1 in the vicinity of the mitochondria, lending credence to the 
mitochondrial cell death pathway [60, 91, 92]. Modelling of PD in Drosophila is robust 
and has been insightful in understanding the role of several PD-linked genes in disease 
pathology [33, 93, 94]. The link between HtrA2 and other PD-linked genes has been 
demonstrated in both mammals and the fly, including the Pink1 kinase [83, 95] which 
was found to phosphorylate HtrA2 in response to p38 SAPK activated pathway, and the 
E3 ubiquitin ligase, parkin [83, 96]. The link between HtrA2 and the Pink1/Parkin 
pathway has been challenged by an in vivo study that relied on a loss of function [97]. 
Whether HtrA2 functions downstream of the Pink1/Parkin pathway or if it affects 
mitochondrial homeostasis, the loss of its protease activity is known to lead to neuronal 
degeneration. Phenotypic analysis of HtrA2 mutants revealed male infertility, stress-
mediated apoptosis [96], and mild mitochondrial defects [97]. The release of HtrA2 from 
the mitochondria in Drosophila is dependent upon cellular stress such as UV irradiation 
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and cleaves Drosophila inhibitor of apoptosis (DIAP1) to activate apoptosis [91, 92, 98]. 
HtrA2 was found to interact with the Pink1 but this association was independent of 
parkin, it was determined that the HtrA2-induced phenotypes were of a mild nature than 
those of Pink1 [83], though a different study did not find this association [97]. The studies 
so far reveal the strong association between HtrA2 loss of function and susceptibility to 
PD. 
Mitochondrial dysfunction in Parkinson disease 
Mitochondrial dysfunction is one of the mechanisms implicated in the pathogenesis of PD 
where post-mortem studies have revealed evidence for oxidative stress [99, 100] as a 
result of defective mitochondrial Complex I function [101, 102], and oxidative damage in 
nigrostriatal DA neurons in the pathology of PD. The identification of mutations in genes 
strongly associated with familial forms of PD that have a mitochondrial function has 
highlighted the role of defective mitochondrial function in the pathogenesis of PD [103, 
104]. Mitochondrial dysfunction appears to be a common hallmark in both sporadic and 
familial forms of PD, that include impaired electron transport chain, damaged 
mitochondrial DNA, defective calcium buffering and abnormal mitochondrial 
morphology and dynamics [36, 37, 75]. The effects of dysfunctional mitochondria are 
widespread in DA neurons that consequently result in cellular oxidative stress, apoptosis, 
autophagy and inflammation. 
Mitochondrial electron transport chain complexes in PD 
Earliest evidence on the involvement of mitochondria in the pathology of PD was from 
the discovery that MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) causes PD-like 
  
13 
 
symptoms in humans [105]; MPTP is metabolized to its toxic form MPP+ (1-methyl-4-
phenylpyridinium ion) by mitochondrial monoamine oxidase B (MAO B) and is 
concentrated in the mitochondria through an energy-dependent process. It then 
specifically inhibits the oxidation of nicotinamide adenine dinucleotide (NAD)-linked 
substrates by blocking the electron transfer through Complex I [68]. Complex I (NADH-
ubiquinone oxidoreductase) is a catalyst for electron transfer from NADH into ETC 
subunits (Figure 1.1) and therefore, acts as one of the entry point for electrons from the 
mitochondrial matrix into the ETC, which makes it an important site for ROS production 
[90]. MPP+ also inhibits the activity of α-ketoglutarate dehydrogenase complex 
(KGDHC), a key tricarboxylic acid (TCA) enzyme and thus impedes ATP synthesis to 
possibly induce an “energy crisis” [68]. 
Compounds such as rotenone, paraquat, and maneb, among others interfere with Complex 
I activity and result in elevated ROS levels that increases oxidative stress, and have been 
linked to parkinsonism. The presence of deletions in mitochondrial DNA (mtDNA) of 
patients with PD are known to affect other respiratory chain enzymes such as cytochrome 
c oxidase [106]. It appears the close proximity of mtDNA to ROS generated by the 
impaired respiratory chain, and a lack of efficient DNA repair mechanism, contributes to 
the vulnerability of mtDNA to mutations [90]. A generalized defect in the assembly of 
complexes I to V has been observed, and has been implicated in the elevated levels of 
ROS and the subsequent oxidative stress.  A direct association between a subunit of  
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Figure 1.1 Mitochondrial respiratory chain 
A simplified representation of the mitochondrial electron transport chain (ETC) in which 
Complex I to IV and Complex V also known as ATP synthase are shown. The ETC is 
coupled to the oxidative phosphorylation (OxPhos) by a proton gradient across the inner 
mitochondrial membrane. In Complex I (NADH: ubiquinone oxidoreductase), two 
electrons are removed from NADH and transferred to Ubiquinone (UQ) which is reduced 
to ubiquinol (UQH2). Complex I then translocate four protons from the matrix to the 
intermembrane space (IMS). Complex II (Succinate dehydrogenase) transfers more 
electrons to the UQH2 pool from succinate (a TCA intermediate) via FAD. No protons are 
generated into the IMS in this pathway. Cytochrome c reductase or Complex III 
sequentially transfers two electrons from UQH2 to two molecules of cytochrome c. Four 
electrons are then removed from four molecules of cytochrome c by Complex IV 
(cytochrome c oxidase) and transferred to molecular oxygen to form water. Protons are 
released to the IMS. This forms a proton gradient or electrochemical gradient that is 
utilised by ATP synthase or Complex V to make ATP via a proton flux back into the 
matrix. These redox reactions can be leaky and as thus prematurely release electrons to 
oxygen forming superoxide radicals. The main sites for reactive oxygen formation are 
Complex I and III. 
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Complex I (composed of at least 49 different subunits), GRIM-19 and a PD susceptibility 
gene, HtrA2 has been shown [68, 105]; GRIM-19 enhances the pro-apoptotic activity of 
HtrA2. 
Mitochondrial permeability transition pore (mPTP) and PD 
The mitochondrion is composed of an outer membrane (OMM), that is permeable to 
small molecules, and an inner membrane (IMM), that is selectively permeable to many 
molecules [107, 108] and only allow specific substrates into the matrix by use of 
transporters. Mitochondrial membrane transition results from an increase in IMM 
permeability to molecules that have a molecular mass of less than 1500 Da due to the 
reversible opening of a large protein complex pore [107, 109, 110]. This opening is 
facilitated by depletion of ATP and ADP, calcium overload, fatty acid levels, phosphate 
levels, and oxidative stress [108]. This causes the non-specific entry of water and solutes 
into the mitochondria which cause the mitochondrial matrix to swell, disruption of 
oxidative phosphorylation, loss of mitochondrial membrane potential and reduction in 
respiratory chain function [108-110]. In addition to the dissipation of the mitochondrial 
transmembrane electrochemical proton gradient, termination of ATP synthesis, loss of 
respiratory substrates and nucleotides from the matrix, excess generation of ROS, release 
of calcium and apoptogenic proteins, the sustained opening of the mPTP results in cell 
death. 
The molecular constituents of the mPTP complex remain controversial but studies show 
the major proteins thought to comprise the mPTP are: voltage-dependent anion channel 
(VDAC) located in the OMM, adenine nucleotide translocator (ANT) present in the IMM, 
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and cyclophilin D (cypD) found in the matrix [108, 109]. Other proteins believed to be 
components of the mPTP are F0-F1 ATP synthase (Complex V), translocator protein 
(TSPO), mitochondrial phosphate carrier (PiC), and paraplegin, among others. This area 
remains controversial and only future studies will confirm the components of the mPTP. 
What is not in dispute is the role the mPTP plays in disease pathogenesis, by being a key 
component of mechanisms such as apoptosis, autophagy, necrosis and “necroptosis”. The 
strongest connection of mPTP to PD was the observation that calcium-induced 
mitochondrial dysfunction in PD-related neuronal death by MPP+ and dopamine which 
stimulated the release of calcium from the mitochondria [68], caused mitochondria to 
swell, release cytochrome c, and membrane depolarization. 
Role of PD-linked genes in mitochondrial dysfunction 
Monogenic causes of PD are known to contribute to less than 10% of the total cases, and 
the gene products seem to have a direct or indirect role in mitochondrial function and 
consequently in disease pathogenesis [68]. The non-amyloid beta component of α-
synuclein makes it prone to aggregate into fibrils which are the main component of Lewy 
bodies found in both sporadic and familial forms of PD [6, 7]. The effects of α-synuclein 
on mitochondrial dysfunction are both direct and indirect, for example, the application of 
mitochondrial toxins is known to result in the formation of α-synuclein aggregates and 
inclusions [111], while the inhibition of the proteasomal pathway causes the accumulation 
of α-synuclein leading to mitochondrial dysfunction [112]. The mitochondrial import and 
accumulation of α-synuclein impairs Complex I in the SNpc and striatum of PD patients 
[113]. In vivo and in vitro studies have highlighted a strong pathogenic role of α-
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synuclein in mitochondrial dysfunction, mutant α-synuclein causes mitochondrial 
degeneration, mtDNA damage, and an impaired ETC [114]. Within the mitochondria, α-
synuclein is known to interact with components of the ETC in a deleterious manner, such 
as Complex I, Complex IV cytochrome oxidase [115], and adenylate translocator [116]. 
The presence of a cryptic mitochondrial targeting signal in the N-terminus of α-synuclein 
facilitates its translocation into the mitochondria [113]. In addition,  α-synuclein 
selectively conforms to the mitochondria [117] due to the physiological environment 
present in neurons. This leads to mitochondrial fragmentation and decreased respiration 
[118]. In a similar way, α-synuclein appears to regulate mitochondrial calcium levels as it 
enhances ER-mitochondrial interactions [119]. The association of α-synuclein with the 
mitochondria, especially Complex I, has been shown to lead to increased apoptosis 
through caspase-dependent and caspase-independent pathways, with most neuronal death 
occurring by autophagy [120, 121]. The association of α-synuclein with the adenylate 
translocator (ANT), a component of the permeability transition pore complex (PTPC), 
leads to membrane depolarization and mitochondrial morphological changes that result in 
translocation of AIF to the nucleus and increased neuronal apoptosis [116]. The blocking 
of the chaperone-mediated autophagy by α-synuclein results in cellular stress that 
activates apoptosis [122]. In brief, α-synuclein seems to alter mitochondrial homeostasis, 
cellular bioenergetics and disrupt several cellular systems that are critical to cell survival. 
The loss of the E3 ubiquitin ligase activity of parkin, responsible for an early onset 
juvenile form of autosomal recessive parkinsonism, is known to result in accumulation of 
toxic protein aggregates by a failure of the clearance system [13, 123] and gross 
mitochondrial defects [61, 62]. Parkin-dependent ubiquitination is known to control 
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several pathways that mediate transcriptional regulation, protein trafficking, and 
neuroprotection. Parkin mutations have been shown to impair mitochondrial Complex I 
and IV activities in human leukocytes of patients with PD [124], and in parkin knock out 
mice [125]. Parkin mediates mitochondrial biogenesis through transcription and 
translation by direct import into the mitochondria and interaction with TFAM [126]. 
Parkin-mediated biogenesis and promotion of cell survival occurs via its proteasomal 
degradation of PARIS [55]. Importantly parkin is pivotal in mitochondrial dynamics and 
mitophagy [127], as it is selectively recruited to impaired mitochondria by Pink1, and 
facilitates their removal via mitophagy [59]. In the Pink1/Parkin pathway, Pink1 senses 
mitochondrial damage and recruit’s parkin, which ubiquitinates the damaged 
mitochondria and targets it for cellular clearance through mitophagy. Another model for 
parkin recruitment to damaged mitochondria involve the voltage-dependent anion 
channels (VDAC) [128], which serve as mitochondrial docking sites. The Pink1/Parkin 
pathway promotes mitochondrial fission/fusion and controls mitochondrial dynamics [69, 
77, 78]. Parkin plays an important role in mitochondria homeostasis, by being directly 
involved in the biogenesis and clearance of defective mitochondria. 
Mutations in Pink1/PARK6 cause EOAR PD and result in severe mitochondrial 
dysfunction [14, 69]. Pink1 has a mitochondrial targeting signal, it has been shown to 
localize to the IMM, intermembrane space [67, 129] and the OMM [67]. Studies have 
shown a wide range of mitochondrial defects in Pink1 mutants, that include abnormal 
mitochondrial morphology, reduced membrane potential, elevated generation of ROS, 
deficits in respiratory chain complexes I to IV activity, and ATP synthesis defects [68]. 
As previously discussed, Pink1 is a sensor of damaged mitochondria, and as such, is 
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pivotal in mitochondrial quality control [56]. Pink1 accumulates on dysfunctional 
mitochondria, and its kinase activity is essential for parkin recruitment [130]. In healthy 
mitochondria, Pink1 is rapidly degraded but on defective mitochondria, Pink1 
accumulates and becomes stabilized on the OMM where it recruits parkin and activates 
its E3 ubiquitin ligase activity [59]. 
Apoptosis is one of the mechanisms suggested for the progression of PD and 
investigation of neuronal apoptosis in PD has found elevated levels of anti-apoptotic 
proteins, Bcl-2 and Par-4 in DA neurons [131]. Other gene products believed to have a 
vital function in the maintenance of mitochondrial integrity and turnover, such as, Pink-1, 
parkin, and HtrA2 have been implicated in the aetiology of PD [8]. Pink1 can also 
activate parkin indirectly through phosphorylation of ubiquitin, which in turn activates 
parkin. Pink1 has other substrates that promote mitophagy, such as: Miro1 [82] whose 
phosphorylation and degradation arrests mitochondrial motility; Mitofusin2 which upon 
phosphorylation by Pink1 binds parkin and leads to its degradation; others include HtrA2 
and tumour necrosis factor receptor-associated protein 1 (TRAP-1). 
DJ-1/PARK7, a susceptibility gene that cause rare cases of EOAR parkinsonism, has 
antioxidant and transcription modulation activity and is thought to localize to the 
mitochondria [15, 132]. DJ-1 translocates to the mitochondria upon oxidative stress and 
promotes neuroprotection. Mutant DJ-1 DA neurons show a deficiency in Complex I 
activity and consequently generates more ROS, reduction in mitochondrial membrane 
potential, abnormal morphology and leads to accumulated dysfunctional mitochondria 
[133].  
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Mutations in Lrrk2/PARK8 cause autosomal dominant PD [16, 17], Lrrk2 is a multi-
functional protein, it is thought to localize to the mitochondria [134]. PD patients show a 
decrease in mitochondrial membrane potential, low ATP levels and elongated 
mitochondria. Lrrk2 interacts with DLP1 to induce mitochondrial fission, it further 
stimulate mitophagy through its interaction with ULK1, a key component in the initiation 
of autophagy [135]. There seems to be an intricate relationship between mitochondrial 
dysfunction and PD-associated gene products, to maintain mitochondrial fidelity, 
homeostasis and dynamics. 
Molecular mechanisms of Parkinson disease 
Neuronal apoptosis 
The term apoptosis was coined by Kerr and his colleagues in 1972, a Greek word used to 
describe leaves falling from trees or petals from flowers, in reference to the particular 
morphology of physiological cell death [136]. By definition apoptosis refers to the 
morphologic features of cell death that manifest through cell shrinkage, nuclear 
condensation, membrane blebbing, fragmentation into membrane bound apoptotic bodies, 
and membrane changes that targets the dying cells for phagocytosis [137, 138]. These are 
the distinct characteristics that differentiate apoptosis from other types of cell death. The 
three successive stages of apoptosis are: 1) commitment to death triggered by extrinsic or 
intrinsic signals; 2) cell killing by activation of caspases and other proteases; and 3) 
engulfment of dead neurons by phagocytic cells such as macrophages and glial cells [138, 
139]. Apoptosis is an important cellular mechanism that is tightly controlled. 
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Extrinsic death pathway 
The sensors mediating neuronal apoptotic signals from the extracellular to the 
intracellular death machinery are known as death receptors [140]. Neuronal apoptosis 
induced via the surface death receptors is mediated by the tumor necrosis factor receptor 
(TNFR) superfamily that is composed of Fas/Apo-1, TNFR-1 and p75NTR (Figure 1.2) 
[141]. The receptors contain an extracellular ligand binding cysteine motif and an 
intracellular death domain. Upon ligand binding for example FasL, TNF-related 
apoptosis-inducing ligand (TRAIL), TNF-α, or NGF to their respective surface receptors 
(Figure 1.2), the assembly of the death-inducing signaling complex (DISC) is initiated 
and induces the clustering of the death domains of the receptor [140]. Fas-associated 
death domain (FADD), an adapter protein, binds through its death domain to the clustered 
death domains of the receptor. FADD has a death effector domain (DED, which is a type 
of caspase activation and recruitment domain or CARD) which it uses to recruit the 
procaspase-8 (FLICE/MACH) and auto-cleaves the DED that releases the active form of 
caspase-8. Activated caspase-8 cleaves effector caspases, such as caspase-3 and mediates 
neuronal killing [140, 142]. One of the substrates for caspase-8 is the pro-apoptotic Bcl-2 
member Bid; when cleaved (tBid), it translocates to the mitochondria where it mediates 
the disruption of the OMM [143]. This is one of the key evidences for crosstalk between 
the two mechanisms of neuronal apoptosis. This extracellular pathway appears less 
important in neurons than the one mediated by p75NTR/p75-NGFR/TNFR2 (Figure 1.2), 
which cooperates with Trk receptors [144]. Several modifiers of this pathway in neurons 
have been identified, key among them is the anti-apoptotic Lifeguard (LFG/TMBIM2) 
also known as neural membrane protein 35 (nmp35), that is predominantly expressed in  
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Figure 1.2 The extrinsic cell death pathway 
A schematic representation of the extrinsic death pathway that show the key molecules. 
The assembly of the death inducing signalling complex (DISC) starts with the binding of 
a ligand to the TNF or FAS receptors. FADD has death domains which it uses to bind to 
the receptor’s death domains and death effector domains (DED, a type of a caspase 
activation and recruitment domain) which it uses to recruit pro-caspase-8. Once pro-
caspase-8 binds to FADD, it is auto-cleaved at the DED and the active form released that 
activates caspase-3. Caspase-8 can also activate the mitochondrial death pathway via 
activation of the Bcl-2 protein Bid. 
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the nervous system and has been shown to block cell death induced by the FasL but not 
by TNFα [145]. This demonstrates the specificity of extracellular death receptors and 
their ligands to highlight the divergence of death pathways. Extracellular death signals 
promote neuronal death by the inhibition of survival pathways and the promotion of the 
activation of pro-apoptotic molecules that ultimately elicit an intrinsic death signal that 
activates caspases or other proteases involved in cell death. 
Intrinsic death pathway 
The intrinsic pathway that is mostly controlled by the Bcl-2 proteins depends on a 
complex interplay between the anti-apoptotic and the pro-apoptotic members of this 
family of proteins [146]. The intrinsic pathway, also known as the Bcl-2-regulated death 
pathway (Figure 1.3), monitors the intracellular environment and relays this information 
mostly through the Bcl-2 proteins to the mitochondria [147]. When death-inducing 
signals, such as damaged DNA, oxidative stress, or other cytotoxic stress outweigh the 
survival signals, then the mitochondrial membrane is breached through a concerted effort 
of pro-apoptotic Bcl-2 proteins and cytochrome c and additional death inducing 
molecules are released [143, 148]. The death effectors in this pathway can either proceed 
by a caspase-dependent or caspase-independent pathway. 
The Bcl-2 family of proteins have a central role in the regulation of the intrinsic apoptotic 
pathway. Whereas in mammals they exist as a family of proteins [149], there are only two 
members in Drosophila: anti-apoptotic Buffy [150] and pro-apoptotic debcl [151-154]. 
This protein family has both anti-apoptotic and pro-apoptotic members that contain one or 
more Bcl-2 homology (BH) domains [144, 155, 156]. The major anti-apoptotic members  
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Figure 1.3 The intrinsic cell death pathway 
The pathway is initiated upon induction of death signals from damaged DNA, oxidative 
stress, or cytotoxic stress that surpasses the survival signals. This then leads to a 
breaching of the outer mitochondrial membrane that results in the release of apoptogenic 
molecules such as cytochrome c that induces the formation of the apoptosome together 
with apoptosis protease activating factor (Apaf-1). The apoptosome then recruits pro-
caspase-9 which is activated and in turn cleave pro-caspase-3 to activate it. A non-caspase 
cell death pathway can be initiated by calcium signalling through calpains which may 
ultimately activate caspases. Apoptosis inducing factor (AIF) is also caspase-independent 
and initiates death by causing chromatin condensation and DNA fragmentation. 
Endonuclease G (EndoG) once released from the mitochondria translocate to the nucleus 
and nicks DNA and RNA. 
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are Bcl-2, Bcl-xL, Bcl-W, A1 and Mcl-1, which are normally characterized by the 
presence of four BH domains [148, 149, 157]. These anti-apoptotic members localize to 
the outer mitochondrial membrane (OMM), as does the single fly homologue Buffy. In 
addition, the mammalian and fly proteins have been shown to localize to the endoplasmic 
reticulum and to the perinuclear membrane. The pro-apoptotic members of the Bcl-2 
family are categorized into two subgroups, the first is the multi-domain proteins made up 
of Bax, Bak, Bok and Bcl-xS consisting of between three and four BH domains, and the 
second subgroup that has more structural diversity and is often referred to as BH3 only 
proteins (BOP) made up of proteins such as Bad, Bid, Bim, DP5/Hrk, Puma, Noxa among 
others [155]. In mammals the Bcl-2 proteins have a dual role, being both anti- and pro-
apoptotic and not only bind and inactivate Apaf-1, but also stabilize the mitochondria 
membranes preventing the release of a plethora of death molecules [148, 158]. In flies, 
Buffy, the anti-apoptotic Bcl-2 homologue has been shown to suppress death from 
various stimuli [157], but it is the RHG proteins; reaper, HID (head involution defective) 
and grim that regulate cell death by interacting with IAPs [159]. The anti-apoptotic 
members of Bcl-2 action is to inhibit the pro-apoptotic proteins through 
heterodimerization, and the BH3 domain has been shown to be central to this role, 
especially in BOP pro-apoptotic members, that form heterodimers with anti-apoptotic 
members of the Bcl-2 family [138, 144]. These proteins appear to be cellular rheostats 
that balance death or survival signals, and alter the permeability or conductance of 
mitochondrial membranes which result in the release of death molecules among which 
cytochrome c is key to the formation of the apoptosome [156]. The Bcl-2 proteins have 
been shown to suppress death in neurons after the withdrawal of NGF, and block 
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developmental cell death and neuronal injury, showing expression of these proteins can 
override the extrinsic death signal and trophic factor withdrawal. 
On induction of apoptosis from intrinsic signals, Apoptosis protease activating factor 
(Apaf-1) forms a multimeric complex with mitochondrial- released cytochrome c, and 
recruits and activates procaspase-9 [160, 161]. The interaction between Apaf-1 and 
procaspase-9 is mediated through the caspases-activating recruitment domains (CARD) 
present in both proteins. The activated caspase-9 then cleaves and activates caspase-3. 
The formation of the apoptosome requires ATP [162] and cytochrome c, the controlled 
release of cytochrome c from the mitochondria therefore offers a key step in the 
regulation of neuronal apoptosis. Several molecules have been shown that physically 
interact with cytochrome c in the mitochondria and blocks its release, even during Bax-
induced apoptosis. One such molecule is a member of the Transmembrane Bax inhibitor-
1 containing motif 5 (TMBIM5) [145] or growth hormone-inducible transmembrane 
protein (GHITM), also known as mitochondrial morphology and cristae structure 
(MICS1) [163]. Inhibitors of apoptosis proteins (IAPs) were first identified in viruses as 
suppressors of apoptosis that functionally interact and antagonize the enzymatic activity 
of mature caspases [164]. IAPs contain the baculoviral IAP repeat (BIR) domains which 
bind and inhibit both initiator and effector caspases. IAPs such as XIAP, cIAP1 and 
cIAP2 seem to exert their effect by the ubiquitination of caspases, through an additional 
domain the RING finger domain. This IAP-mediated inhibition may be released by 
proteins such as Smac/DIABLO and Omi/HtrA2, both of which are released from the 
mitochondria upon initiation of an apoptotic signal [165]. Ultimately, cytochrome c, 
apoptosis inducing factor (AIF), Smac/DIABLO, HtrA2/omi, and EndoG are released 
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from the mitochondria. Cytochrome c participates in the formation of the apoptosome and 
the activation of caspases, Smac/DIABLO and HtrA2/omi are inhibitors of IAPs and 
potentiate killing by caspases. AIF is cleaved at the mitochondria (tAIF) which makes it 
soluble and through its NLS translocate to the nucleus where it interacts with DNA and 
leads to chromatin condensation and DNA degradation. EndoG, once released from the 
mitochondria, translocate to the nucleus, where it nicks DNA and RNA [166]. Numerous 
other pathways are activated by intrinsic death signals; these include the tumour 
suppressor and transcription factor p53 [167] and calpains that are non-caspase cysteine 
proteases which are calcium-regulated and participate in neuronal cell death as a result of 
cytotoxic stress [142]. The calcium signaling pathway may also bring about crosstalk 
between mitochondria and the endoplasmic reticulum (ER), the major intracellular 
calcium store by interaction with the Bcl-2 family of proteins [168]. ER stress is coupled 
to the extrinsic and intrinsic pathways, as well as other independent pathways, that are yet 
controversial like the caspase-12 activation by IRE1, which recruit caspase-12 through 
the TNFR-associated factor 2 protein (TRAF2). 
The role of apoptosis in PD 
The implication of defective mitochondrial Complex I in the pathology of PD may arise 
from, or contribute to, increased cellular oxidative stress that may lead to DNA damage, 
apoptosis –related gene expression, and the breaching of mitochondrial OM, with the 
release of death-inducing molecules such as cytochrome c leading to caspase activation 
[169, 170]. Investigation of neuronal apoptosis in PD has found elevated levels of anti-
apoptotic proteins, Bcl-2 and Par-4, in DA neurons [170, 171]. PD-associated gene 
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products have been determined to have a vital function in the maintenance of 
mitochondrial integrity and turnover, such as, Pink1, parkin, and HtrA2 [37]. The 
association of α-synuclein with the mitochondria, especially Complex I, has been shown 
to increase apoptosis through caspase-dependent and caspase-independent pathways [120, 
121]. The association of α-synuclein with the adenylate translocator, a component of the 
PTPC, leads to membrane depolarization and, mitochondrial morphological changes that 
result in translocation of AIF to the nucleus and increased neuronal apoptosis [172]. The 
blocking of the chaperone-mediated autophagy by α-synuclein results in cellular stress 
that activates neuronal apoptosis [173]. Mutations in parkin result in the accumulation of 
Pael-R, a substrate of parkin, that result in the accumulation of unfolded proteins in the 
ER and the activation of the ER-stress-induced cell death [174]. Pink1 and parkin have 
also been shown to play a role in neuronal apoptosis via the JNK signalling pathway and, 
p38/MAPK pathway by either the inhibition or promotion of apoptosis when 
overexpressed or suppressed [68]. Thus, neuronal apoptosis results chiefly by 
mitochondrial dysfunction that promote generation of ROS and leads to cellular oxidative 
stress, this potentially releases major death-inducing proteins from the mitochondria. 
Endosomal-lysosomal system 
The functioning of cellular clearance systems in neurons in an efficient and timely 
manner is crucial to survival as it aid in the removal of misfolded proteins and damaged 
organelles [39]. The clearance of aggregated and accumulated α-synuclein depends on the 
endosome-lysosome pathway and especially autophagy [175]. Evidence for the 
involvement of the endo-lysosomal system in the etiology of PD is the increased number 
  
29 
 
of autophagic vacuoles and presence of autophagy-related proteins in LBs, in addition to 
the down-regulation of lysosome-associated membrane protein type 2A (LAMP-2A) and 
heat shock cognate protein 70 (Hsc70) in the SNpc and cell lines [175, 176]. Briefly 
described below is autophagy and the specialized mitophagy in the context of PD and 
neuronal death. 
Autophagy 
This mechanism is responsible for the removal of soluble, aggregated and misfolded 
proteins as well as old and dysfunctional organelles through one of the two cellular 
proteolytic systems [177, 178]. It is mostly involved in the turnover of long lived proteins 
and organelles that are recycled into small peptides. The major autophagy subtypes are 
microautophagy, chaperone mediated autophagy (CMA) and macroautophagy which is 
commonly known as autophagy and form the wider autophagy-lysosome pathway [179, 
180]. Microautophagy involves the engulfment of portions of the cytoplasm within 
lysosomes through invagination of lysosomal membranes; CMA involves degradation of 
target proteins mediated by HSC70 that recognizes amino acid motifs specified by 
KFERQ, this allows the target protein to bind LAMP2A and be translocated across 
lysosomal membranes; macroautophagy (commonly referred to as autophagy) is the most 
common and main subtype of autophagy, that involves the degradation of most cytosolic 
proteins and aged and damaged organelles [181]. Defective autophagy either by failure or 
excessive function can result in disease states as a result of neurodegeneration and 
neuronal death. 
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Mechanisms of Autophagy 
The importance of this cellular process is exemplified by the conservation of autophagy-
related genes in a wide variety of organisms, from yeast to mammals [182, 183]. 
Autophagy proceeds in four essential steps, namely, initiation or induction, expansion of 
the autophagosome, maturation of the autophagosome, and degradation (Figure 1.4). The 
initiation of autophagy is a tightly regulated step, with several complexes involved in the 
initiation or inhibition of this step, importantly the nutrient sensor; mammalian target of 
Rapamycin (mTOR) that negatively regulates the pathway by phosphorylation of ULK1, 
Atg13 and FIP200 that form part of the initiation complex; and AMP-activated protein 
kinase that negatively regulates mTOR to positively impact initiation of autophagy [183, 
184]. The Bcl-2/ Bcl-XL inhibition of the Beclin1/ class III PI3K complex forms another 
layer of regulation that includes the p53 tumour suppressor protein among others that 
respond to the absence or presence of nutrients, growth factors, and energy levels [177, 
185]. The Beclin1 (Atg6)-interacting complex acts in a regulatory step, with Atg6-
binding proteins like AMBRA1, UVRAG and Bif-1 promoting autophagy and Rubicon 
and Bcl-2/Bcl-XL inhibiting autophagy [186].The formation of the phagophore marks the 
initiation of autophagy and the ULK1-Atg13-FIP200 complex is an important step, the 
origin is still unclear but the ER, Golgi complex, mitochondria or plasma membrane are 
possible sources [181]. The nucleation phase of initial phagophore formation requires the 
interaction of the ULK1 complex with the Atg6-interacting complex, composed of Atg6, 
class III PI3K, Vps15 and Atg14L. Stimulation of this complex generates 
phosphatidylinositol-3-phosphate that promotes autophagosomal membrane nucleation 
[185, 187, 188]. This is followed by autophagosomal elongation or expansion that  
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involves two ubiquitin-like conjugating systems, the Atg5/Atg12/Atg16L and MAP1LC3 
conjugation to phosphatidylethanolamine (PE) that promote autophagosome elongation 
and membrane tethering  [177, 181]. The maturation of the complete autophagosome 
involves fusion with either lysosomes or late stage endosomes to form autolysosomes or 
amphisomes [181]. Additional factors are required for the successful completion of these 
fusions, but the terminal step is the degradation of cytoplasmic components to recycle 
nutrients and molecules. 
Endo-lysosomal aetiology of PD 
Loss of function mutations in genes encoding proteins involved in the endo-lysosomal 
system, Glucocerebrosidase (GBA1), synaptojanin (SYNJ1), ATP13A2 
(ATP13A2/PARK9), auxilin (DNAJC6), GAK (PARK17), Lrrk2 (PARK8), Vps35 
(VPS35), RME-8 (DNAJC13), Rab7L1 (RAB7L1), parkin (PARK2) and Pink1 (PARK6) 
are directly associated with higher risk or susceptibility to PD [178, 189]. The 
accumulation and aggregation of α-synuclein impairs the endo-lysosomal system, and 
especially autophagy by inhibition of Rab1a and a reduction of autophagosome 
biogenesis [178, 180]. Furthermore, while wild type α-synuclein is degraded by the 
CMA, the two common PD mutations A30P and A53T, while they bind LAMP-2A, they 
are not internalized nor degraded but rather contribute to the accumulation of other 
substrates and dysfunction of CMA [177, 181]. In summary, mutations in; Lrrk2 are 
known to cause an impairment of the endo-lysosomal trafficking and Golgi apparatus 
sorting; Vps35 results in α-synuclein accumulation in endosomes due to disruption of 
cathepsin D trafficking; RME-8 and GAK results in PD-like neurodegeneration [178, 
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181]. Interestingly, the majority of the mutations seem to result in accumulation of α-
synuclein, which in turn lead to further impairment of the endo-lysosomal system. 
Mitophagy 
Mitophagy, a special form of autophagy, maintains mitochondrial homeostasis by the 
selective degradation of damaged and dysfunctional mitochondria [190, 191]. Defective 
mitophagy result in the accumulation of impaired mitochondria that leads to oxidative 
stress, mitochondrial calcium overload and cell death via cytochrome c release – aspects 
that contribute to mitochondrial dysfunction. Two autosomal PD genes, parkin and Pink1 
mediates mitophagy and constitute a mitochondrial quality control function, Pink1 is the 
mitochondrial sensor [181, 190, 191].  
In normal mitochondria, Pink1 is rapidly imported through the TOM complex of the 
OMM and into the TIM complex of IMM where it is cleaved by the mitochondrial 
processing peptidase (MPP). Pink1 is further cleaved by the rhomboid protease PARL, 
this cleavage releases an N-terminal deleted Pink1 into the cytosol where it is identified 
by the N-degron type 2 E3 ubiquitin ligases that target it to the proteasome [191]. In a 
defective mitochondrion (mitochondria) Pink1 is unable to translocate to the IMM 
through the disruption of the TIM complex by depolarizing agents, MPP and PARL are 
unable to cleave it and thus it accumulates in the OMM bound to the TOM complex [190, 
191]. The presence of Pink1 on the OMM serve to recruit and phosphorylate parkin, a 
ubiquitin E3 ligase, which activates its ligase activity. In addition, Pink1 phosphorylates 
ubiquitin, which activates parkin, this potentiates the activation of parkin which can bind 
to ubiquitin or to chains of ubiquitin [55]. Once parkin is activated, it methodically 
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ubiquitinates at least 36 substrates of the OMM, that extracts them from the OMM and 
targets them to the proteasome [191]. In addition, this ubiquitination forms dense poly-
ubiquitination chains that target the mitochondria to the forming autophagosome. 
Other PD-associated gene products are implicated in mitophagy by disruption of the 
Pink1/ Parkin pathway, this include Fbxo7 that directly interacts with Pink1 and parkin to 
contribute to mitophagy [192]. DJ-1 translocate to depolarized mitochondria and induces 
mitophagy, its loss of function is associated with mitochondrial dysfunction [179]. The 
importance of mitophagy is mitochondrial homeostasis, by clearing damaged and 
dysfunctional mitochondria. 
The ubiquitin-proteasome system 
This is one of the two quality control systems for removal of misfolded proteins, the 
ubiquitin-proteasome system (UPS), is a proteolytic system that involves the conjugation 
of polyubiquitin chains to specific substrates to induce a selective ATP-dependent 
degradation [179, 193]. Briefly, the ubiquitination process is highly regulated and allow 
for the binding of a single or multiple ubiquitin (Ub) molecules to a lysine residue of the 
substrate or target protein, this is initiated through the ATP-dependent action of ubiquitin 
activating enzymes (E1) binding to a ubiquitin molecule [193, 194]. This ubiquitin is then 
transferred to a ubiquitin conjugating enzyme (E2), the E2 enzyme transfers the ubiquitin 
molecule to the target protein in cooperation with a ubiquitin ligase (E3), which is 
thought to confer substrate specificity. This last step is complex and involves a multitude 
of proteins depending on the E3 recruited that may include adaptor proteins, cofactors and 
scaffolding proteins, the marked substrate is then targeted to the proteasome for 
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degradation by the help of chaperone proteins that recognize and bind to poly-ubiquitin 
molecules [193]. Disease states can result from a failure of any of this steps including 
proteasome dysfunction, as such two mechanisms can be implicated, the UPS and the 
ubiquitin signalling system. 
The presence of accumulated α-synuclein in Lewy bodies has been attributed to the 
breakdown of the UPS, and has been observed in the brains of patients with PD, 
furthermore, the inhibition of UPS causes protein inclusions and degeneration of the DA 
neurons [193, 195]. The expression of mutated α-synuclein induces the formation of 
filaments that directly interact with the 20S core of the proteasome to decrease its 
proteolytic function [196, 197]. More evidence for the involvement of the UPS in the 
pathology of PD is from mutations in parkin, which encodes a ubiquitin E3 ligase, that is 
thought to regulate the ubiquitination of α-synuclein [198, 199]. Several parkin substrates 
have significant functions in neurons, that include Pael-R, a G-protein-coupled 
transmembrane protein that appears to induce ER stress and cell death [200]; PARIS, a 
transcriptional repressor of the mitochondrial co-activator PGC-1α that is involved in 
mitochondrial biogenesis [201]. The association between parkin and Pink-1 is important 
in degradation and turnover of mitochondria [61]. Ubiquitination can be reversed by de-
ubiquitination enzyme (DUB), UCH-L1, an early onset PD susceptibility gene that is 
involved in regulation of substrates that are implicated in a myriad of functions such as 
mRNA transcription, protein translation, cell survival and neuronal plasticity [193]. The 
self-dimerization of UCH-L1 results in an E3 ligase function, that ubiquitinates α-
synuclein, resulting in PD pathology [202], and loss of DUB function leads to α-synuclein 
accumulation at the pre-synapse [203]. Another PD risk associated gene FBXO7, is 
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implicated in autosomal recessive PD when mutated [22]. It encodes an F-box protein, 
that constitutes one of the four subunits of the Skp1-Cullin-F-box (SCF) Ubiquitin ligase 
complex that is implicated in the UPS pathway [204]. Fbxo7 has been detected in Lewy 
bodies in brains of patients suffering from PD [205]. The number of PD genes involved in 
the UPS pathway probably shows the importance of this system in the pathology of PD. 
Oxidative stress 
Oxidative stress is one of the main molecular mechanisms underlying dopaminergic 
neurotoxicity and neuronal degeneration in PD  [198]. Neuronal and glial sources are 
implicated in the generation of oxidative stress, with the main contributor being increased 
radical formation from mitochondria and ER. Neurons are particularly sensitive to 
oxidative stress due to their high oxygen consumption, high generation of reactive oxygen 
and nitrogen species from neurochemical reactions and the deposition of metal ions in the 
brain that comes with ageing [206]. Overall, oxidative stress in PD results from 1) 
changes in dopamine synthesis that results from high concentration of dopamine and 
intermediates from its catabolism, general metabolic failure in the SNpc, and low 
mitochondrial reserve of midbrain DA neurons, 2) oxygen metabolism in the brain that 
fluctuates in normal neurons to produce ROS, high consumption of oxygen, exposure to 
environmental toxins, low levels of antioxidants, and low levels of free radical 
scavenging enzymes, 3) changes in metal concentration such as increase in iron and 
copper, 4) calcium homeostasis with fluxes that overstimulate DA neurons due to 
pacemaker functions of L-type calcium channels and excitotoxicity by glutamate 
receptors, and 5) aberrant mutations in PD-linked genes that alter mitochondrial and the 
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endosomal-lysosomal system functions [207]. Oxidative stress results from the excessive 
accumulation of ROS and RNS and has a detrimental effect on DA neurons and PD. ROS 
result from the univalent metabolic reduction of oxygen to form short-lived chemically 
reactive and toxic species [206, 208]. Free radicals that are formed include superoxide 
anion radical, hydroxyl radical, hydroperoxyl radical, peroxyl radicals as well as non-
radical species such as hydrogen peroxide, hypochlorous acid and peroxynitrite [209, 
210]. Peroxynitrite results from the reaction between nitric oxide and superoxide, to form 
reactive nitrogen species (RNS) that also include nitrogen dioxide, dinitrogen trioxide and 
dinitrogen tetroxide [206].  Cellular sources of ROS formation can either be exogenous; 
from radiation, chemicals, drugs, environmental toxins and pollutants or endogenous; 
mainly from mitochondria electron transport chain (METC), ER, lysosomes and 
peroxisomes [206, 208-210]. Evidence for oxidative stress in PD is demonstrated by 
enhanced lipid peroxidation, protein oxidation, and DNA oxidation present in the SNpc 
[198]. The main mechanisms involved in oxidative stress in DA neurons are briefly 
discussed. 
Dopamine synthesis 
Dopamine is an important neurotransmitter and its synthesis has been implicated in the 
selective degeneration of DA neurons as it contributes to oxidative stress, mitochondrial 
dysfunction, defects in the proteasomal and lysosomal systems, and formation and 
stabilization of neurotoxic protofibrils of α-synuclein [38]. Dopamine is initially 
synthesized from tyrosine by tyrosine hydroxylase (TH) to L-dihydroxyphenylalanine (L-
dopa) and requires oxygen, L-dopa is then decarboxylated to dopamine by aromatic 
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amino acid decarboxylase (AADC) that generate carbon dioxide. TH and AADC are 
coupled to the vesicular monoaminergic transporter 2 (VMAT-2), thus dopamine is not 
released into the cytosol but gets incorporated into monoaminergic synaptic vesicles that 
release it at the synaptic space [38, 208]. The oxidation of cytosolic dopamine results in 
ROS by formation of dopamine o-quinone, aminochrome and 5,6-indolequinone, excess 
cytosolic dopamine is degraded by monoamine oxidase (MAO) - found at the outer 
mitochondria membranes - by oxidative deamination to form 3,4-
dihydroxyphenylacetaldehyde, ammonia and hydrogen peroxide [38, 208]. MAO is 
implicated in DA degeneration by the production of hydrogen peroxide, a key step in the 
formation of hydroxyl radicals. 
Dopamine oxidation alters mitochondrial respiration and MPTP, the quinones formed 
through auto-oxidation can; modify PD-associated proteins by formation of adducts that 
include α-synuclein, parkin, DJ-1, SOD-2, and UCH-L1; inactivate dopamine transporter 
and TH enzyme; bring about mitochondria dysfunction of Complex I, III and V [38, 208]. 
The dopamine quinones can be oxidized to aminochrome, which generate superoxide 
radical and depletes NADPH, and forms neuromelanin that is found accumulated in the 
SNpc [38, 211]. Several factors can bring about dopamine oxidation, such as, manganese 
(III), copper (II), iron (III), xanthine oxidase, cytochrome P450, prostaglandin H 
synthase, lactoperoxidase and dopamine β-monooxygenase [38]. Neuromelanin appears 
to be associated with the development of PD, and accumulates in the SNpc and locus 
coeruleus, parts of the mid brain heavily affected by DA neurodegeneration [211]. As 
neurons die, they release the insoluble NM to the extra-cellular matrix, where it results in 
neuroinflammation and neuronal death. 
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Mitochondrial ROS generation 
The mitochondria are the major intracellular source of ROS production via the respiratory 
chain complexes in the process of oxidative phosphorylation (Figure 1) to produce energy 
in the form of ATP [212]. The mitochondria electron transport chain (METC) is 
composed of five multi-subunit complexes; NADH: ubiquinone (UQ) oxidoreductase or 
NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II), cytochrome 
bc1 complex (Complex III), cytochrome c oxidase (Complex IV), and ATP synthase 
(Complex V) [208, 212]. Mitochondrial Complex I and III are the main producers of 
ROS; Complex I produces superoxide in the matrix and Complex III in both the matrix 
and the intermembrane space. Briefly, mitochondria Complex I oxidizes NADH and 
reduces ubiquinone (UQ) to ubiquinol (UQH2) with translocation of protons from the 
matrix to the intermembrane space, during this process superoxide can be formed as a 
side process [212]. Complex II oxidizes succinate and reduces UQ to UQH2 and is 
additionally known to produce low levels of superoxide, Complex III funnels electrons 
from the UQ pool to cytochrome c and is a major site for generation of superoxide [213]. 
Other sites of superoxide production in the mitochondria associate with the UQ pool, and 
are as a result of reverse electron transport by Complex I. Mitochondria are the sites of 
nitric oxide generation by the nitric oxide synthases (NOS) during the breakdown of 
arginine to citrulline; and though this process remains unclear in mitochondria [212], the 
presence of nitric oxide in the mitochondria interferes with respiration, mitochondria 
biogenesis, and mitochondrial homeostasis. 
Defects of mitochondrial Complex I are observed in the SNpc of PD patients, in addition, 
α-ketoglutarate dehydrogenase; a Krebs cycle enzyme, is impaired [198]. Furthermore, 
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PD-linked gene mutations are associated with mitochondrial dysfunction that include 
altered protein localization, defects in mitochondrial morphology, and an impaired 
Complex I function [208-210, 212]. Pink1 and parkin are involved in mitochondrial 
turnover, and mutations in these genes result in increased oxidative stress as a result of 
defective mitochondrial function [209]. Moreover, mutations in DJ-1; a key oxidative 
stress sensor, decreases respiration and membrane potential that increases ROS [208]. 
Changes in antioxidant systems have been reported in PD; low levels of GSH, high iron 
levels that may increase ROS by interacting with hydrogen peroxide to produce hydroxyl 
radicals [210]. Oxidative stress as a result of ROS production by the mitochondria 
appears to be a key component of DA neurodegeneration leading to PD. 
Endoplasmic reticulum stress and ROS in PD 
The endoplasmic reticulum (ER) is the primary organelle for secretory pathways; 
secretory and transmembrane proteins enter in the unfolded state and exit either folded or 
misfolded, and are directed to other organelles or targeted for destruction [214-217]. The 
functions of the ER are numerous and include lipid biosynthesis, protein folding, 
translocation, and post-translational modifications such as glycosylation, disulfide bond 
formation, and chaperone-mediated protein folding processes [217], most of the protein 
modifications occur at the Golgi apparatus after which they are translocated to their target 
location . The ER lumen contains enzymes and chaperones that are involved in protein 
folding; misfolded protein aggregates are degraded by the ER-associated degradation 
(ERAD) system via the ubiquitin-proteasome system or by autophagy [214, 215, 217]. 
Protein aggregates trigger ER stress, to restore ER homeostasis, an ER stress response is 
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activated that is known as the “unfolded protein response (UPR)” [216, 217]. Broadly the 
ER stress response consists of decreased protein synthesis, increased transcription of ER 
chaperones such as GRP78/BiP and ERAD genes, and finally the initiation of apoptosis. 
Unfolded protein response pathway 
The three main signaling pathways in UPR are: inositol-requiring enzyme 1α (IRE1α), 
protein kinase RNA (PKR)-like kinase (PERK), and activating transcription factor 6 
(ATF6) [216-218] (Figure 4). These pathways work in parallel and employ unique signal 
transduction mechanisms to upregulate protein folding mechanisms and restore the ER 
balance. 
IRE1α is a type I transmembrane serine/threonine receptor protein kinase and 
endoribonuclease activities that is able to trans-autophosphorylate after homo-
oligomerization [216, 217]. Upon ER stress, IRE1α gets activated by homo-
oligomerization which aligns the serine/threonine kinase on the cytosolic carboxyl 
terminal for trans-autophosphorylation, this activates the endoribonuclease domain. In 
animals, the RNAse cleaves a preexisting mRNA X-box binding protein 1 (XBP1) to 
produce spliced XBP1 that codes for a transcription factor which activates UPR target 
genes and ERAD [216]. Prolonged activation of IRE1α can activate apoptotic signaling 
kinase-1 (ASK-1) to activate downstream pathways such as JNK and p38 MAPK that 
promote ER stress mediated apoptosis. In addition, regulated IRE1α-dependent 
degradation (RIDD) attenuates the unfolded proteins by targeting the misfolded mRNAs 
for degradation [218]. Proteins that appear to interact with IRE1α influence the 
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restoration of ER homeostasis and tips the balance towards survival: the ER resident anti-
apoptotic Bax inhibitor-1 (BI-1/TMBIM6) is known to block ER stress-induced cell death  
 
Figure 1.4 The unfolded protein response pathways 
Upon ER stress, the IRE1, ATF6 or the PERK pathways can be induced to regulate the 
unfolded protein response. The ultimate goal is the upregulation of UPR target genes. A 
protracted activation of UPR leads to an apoptotic response.  
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by the regulation of ER calcium homeostasis and ER-generated ROS accumulation [219]. 
In addition, BI-1 has been suggested to specifically inhibit the IRE1α-dependent branch 
of UPR, though other studies show it has a general ER stress regulation function by its 
influence on the three main UPR signaling pathways. Of interest to note is that the 
IRE1α-dependent UPR pathway is the most conserved ER stress response mechanism 
[217], and the TMBIM family of antiapoptotic molecules are more conserved than the 
Bcl-2 family [145]. This evolutionary conservation of an ancient pathway, and its 
regulatory components may highlight a conserved system across diverse species. 
PERK, a type I transmembrane serine/threonine kinase, is the translational arm of UPR 
that leads to the attenuation of mRNA translation under ER stress and thus preventing 
further protein synthesis and folding [216, 217]. Upon ER stress the cytosolic kinase 
domain trans-autophosphorylates and initiates translational arrest with phosphorylation of 
the eukaryotic initiation factor 2α (eIF2α) [218]. Phosphorylation of eIF2α stalls the 43S 
ternary complex and results in a general decline in translation of a majority of proteins, 
this reduces protein load on ER and causes cell cycle arrest and promotes survival [216]. 
Moreover, eIF2α causes the translational upregulation of transcription factors such as 
ATF4 and ATF5 that control many important genes involved in amino acid metabolism 
and transport, redox reactions, and ER stress-induced apoptosis. Under severe ER stress, 
ATF4 activates downstream UPR target genes; growth arrest and DNA damage-inducible 
34 (GADD34) encodes a regulatory subunit of the protein phosphatase PP1C that 
dephosphorylates eIF2α and reverses translational attenuation, and transcription factor 
C/EBP homologous protein (CHOP) activates apoptotic genes [218]. Thus, PERK 
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initially mediates a survival response and on protracted ER stress it favours a 
proapoptotic response. 
ATF6 is a type II transmembrane ER resident protein that is activated upon ER stress and 
translocate to the Golgi, where it undergoes sequential regulated intramembrane 
proteolysis (RIP) by the Golgi-resident site-1 and site-2 proteases (S1P and S2P) [216, 
218]. The cleaved product is a transcription factor that binds to ER stress response 
element and activates UPR targets such as GRP78, CHOP and XBP1. 
ER ROS production 
Under normal cellular conditions, cells have a basal level of ROS for signaling and 
normal function, but under conditions of stress, the levels exponentially increase [214]. 
Nonetheless cellular mechanisms for clearing the excess ROS exist that depend on; 
enzymes such as SOD, glutathione peroxidase, catalase, and thioredoxin reductase as well 
as non-enzymatic molecules such as vitamins. The redox status within the lumen of the 
ER affects the proper folding and formation of disulfide bonds [217]. The ER lumen has a 
highly oxidized environment that facilitates disulfide bond formation with a high ratio of 
reduced glutathione to oxidized glutathione GSH/GSSG [214]. This oxidized 
environment prevents aggregation and accumulation of unfolded proteins. 
In chaperone assisted protein oxidation, electron transfer from protein disulphide 
isomerase (PDI) to molecular oxygen and ER oxidorectin-1 (ERO1) depends on a FAD-
dependent reaction [217]. This is suggested as the main generator of ROS in the ER, and 
especially proteins with multiple disulphide bonds are more vulnerable to high ROS 
production. Since the protein thiols are repaired by utilizing GSH, ROS can be generated 
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when GSH is depleted, additionally, accumulated unfolded proteins can elicit calcium 
leak from the ER to the cytosol thus increasing ROS production in the mitochondria [214, 
217]. In addition, protein folding and refolding in the ER lumen are highly energy-
dependent processes, the depletion of ATP can stimulate mitochondrial OXPHOS to 
increase ATP and consequently increase mitochondrial ROS generation. Nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase 4 (Nox4) is implicated in ER ROS 
generation, due to its C-terminal special characteristics, electrons are constitutively 
transferred from NADPH to FAD [217]. Nox4-linked ROS generation is increased under 
conditions of stress and is known to trigger autophagic cell death. The microsomal 
monooxygenase (MMO) system is another major source of ROS in the ER and produces 
superoxide anion radicals and hydrogen peroxide; it oxygenates exogenous and 
endogenous substrates that are electron-accepting partners of NADPH-p450 reductase 
(NPR) [217]. The electron leakage between the coupling of NADPH to p450, and 
activation of p450 2E1 is a significant source of ROS in the ER. The previously discussed 
family of antiapoptotic molecules, TMBIM, of which BI-1 belongs regulates ER stress-
mediated ROS accumulation by decreasing p450 2E1 activity and protein expression 
[219]. It is suggested that BI-1 decreases electron uncoupling between NPR and p450 2E1 
by binding to one of them which reduces ER stress-initiated ROS production and cell 
death signaling. 
ER stress link to PD 
One of the main pieces of evidence linking ER stress to PD is the observation of 
upregulation of the ER stress sensors PERK and eIF2α in DA neurons of PD patients 
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[179, 216], and that several mutated PD-linked genes are involved in the regulation of 
ERS. Of the PD-associated genes, α-synuclein appears to be the main cause of ERS: it has 
a high propensity to misfold, aggregate, accumulate and induce normal folded species to 
misfold [179]. Wild type and mutated α-synuclein are able to elicit ERS and the 
upregulation of BiP/GRP78, XBP1, CHOP and ATF4 to induce cell death. Several 
studies implicate α-synuclein in the inhibition of the ER/Golgi transport, that leads to 
accumulation of immature proteins at the ER, or later steps in the biosynthetic secretory 
pathway that result in ER overload and ERS [39]. This appears to occur when α-synuclein 
enters the ER lumen, possibly through uptake by endocytosis followed by retrograde 
vesicular transport to the ER. In addition, α-synuclein has been reported to block ERAD 
which causes the buildup of excess unfolded proteins. 
There is altered regulation of parkin, an E3 ubiquitin ligase, where ATF4 causes an 
upregulation and CHOP downregulates it, possibly as a mitochondrial protective response 
induced by ER stress [216]. Mutations in parkin may be responsible for a dysfunctional 
ERAD which relies on the UPS to degrade misfolded proteins. Moreover, mutations in 
parkin are implicated in the misfolding and accumulation of Pael-R that results in 
apoptosis through activation of CHOP. Lrrk2 is found localized in the ER lumen of DA 
neurons from PD patients [179], other PD-linked genes have been reported to abrogate 
the normal function of the ER, that leads to ERS. 
ER-Mitochondrial interaction and calcium homeostasis 
Cellular organelles exist in an intricate relationship with interaction and cooperation that 
facilitates rapid and efficient biological functions, such interactions are between the 
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nucleus and the ER and the ER and the mitochondria [214, 217]. The physical interaction 
between the mitochondria and the ER occurs at mitochondria-associated ER membranes 
(MAM) and bring the two organelles into close proximity [220]. Different protein 
interactions tether the ER and the mitochondria, such as the interaction between 
VDAC/Porin and the IP3 receptor, or the enrichment of Mitofusin 2 (MFN2) at the ER-
mitochondrion interface where it can interact with another MFN2 or MFN1. This close 
interaction is the site for mitochondrial division, lipid transfer and metabolism, calcium 
exchange and signaling and the initiation of apoptosis [179, 220]. The ER is the main 
cellular calcium store, upon release, cytosolic calcium levels are restored by the 
mitochondria which takes up the calcium and utilizes it in oxidative phosphorylation in 
ATP production. A mitochondrial calcium overload is detrimental to cell survival and as 
such MAM allow for the exchange of calcium in a regulated manner [179]. 
DA neurons are maintained in an autonomously active state by the pacemaker action of 
voltage-dependent L-type calcium channels that elevate cytosolic calcium levels, this 
makes DA neurons vulnerable to mitochondria dysfunction as a result of the huge 
calcium buffer action [220]. Another consequence of calcium overload in the 
mitochondria is the opening of the mPTP that through the release of apoptogenic factors 
initiates cell death. The increase in mitochondria calcium uptake, that occurs during ER 
stress leads to an increase in oxidative phosphorylation, that in tandem increases ROS and 
when unchecked leads to cell death [214, 217]. This is a positive feedback as the ER 
continuously feeds the mitochondria more calcium which results in more ROS and leads 
to oxidative stress. 
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ER-induced oxidative stress and ROS production causes release of calcium through the 
IP3R that leads to the opening of the mPTP and accelerates mitochondrial ROS 
generation [214]. Early stages of ERS cause the release of calcium from ER, this calcium 
is mopped up by the mitochondria that results in elevated metabolism and increased ROS 
generation [217]. High mitochondrial calcium activates NOS that forms nitric oxide, NO 
can then interfere with both Complex I and IV and further enhance the production of 
ROS. Molecules that modulate ER calcium release influence cell survival, Bax inhibitor-1 
and other members of the TMBIM family have been implicated in pro-survival signaling 
in the ER after ERS; BI-1 is proposed to alter ER calcium homeostasis by either, 1) 
possession of calcium channel properties, 2) sensitization of IP3R or 3) its Ca2+ /H+ 
antiporter action [145]. Therefore, the ER-mitochondrial calcium cycle is important for 
both ER-induced stress and ROS production in the mitochondria. 
The presence of α-synuclein in the cytosol, the ER, the mitochondria and in the MAM 
implicates it in the regulation of calcium signaling and the ER-mitochondria tethering 
[179]. Mutant α-synuclein blocks protein localization at the ER-mitochondria interface 
that decreases the degree of tethering and impairs the integrity of the mitochondrial 
network. DJ-1 which is a PD-associated gene modulates mitochondrial calcium levels by 
promoting ER-mitochondria tethering [220]. Pink1, GBA, and Lrrk2 are also implicated 
in altered ER-mitochondria by changes in calcium homeostasis and the representative 
neurodegeneration. 
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ER-Golgi axis and Golgi stress in PD 
The Golgi complex is important in the secretory pathway and is responsible for the 
modification of proteins and lipids as well as correct delivery of target molecules to their 
destination [221]. The Golgi complex is closely positioned to the nucleus and is at the 
heart of the endomembrane trafficking system; it receives newly synthesized proteins 
from the ER; modifies them by glycosylation, sulfation, phosphorylation and proteolytic 
cleavage; and finally exports them to their target location. The disruption of this pathway 
is known to be causative factor for several disease states including PD. 
Golgi fragmentation is observed in PD though it is yet unclear as to the functional and 
pathological significance of this disruption in disease aetiology [39]. The altered 
expression of Rab1, Rab2, Rab8 and Syntaxin-5, early secretory machinery molecules, is 
implicated in PD-induced Golgi fragmentation [221]. The disruption of the ER-Golgi 
trafficking pathway is one of the mechanisms suggested for α-synuclein-induced 
neurotoxicity and may be through post ER budding when it interferes with Rab and 
SNARE-dependent COPII vesicle tethering and/or fusion [39]. The importance of this 
pathway is exemplified by the observation that α-synuclein toxicity blocks simultaneous 
steps of the biosynthetic secretory pathway. 
Goals of study 
The role of Bcl-2 proteins in Drosophila melanogaster is not well understood compared 
to their function in humans, and the involvement of mitochondrial dysfunction in the 
pathogenesis of PD and in cell death led us to investigate the effects of altered expression 
of Bcl-2 homologues in Parkinson disease models, and in particular those that have a 
  
49 
 
strong association to the mitochondria. Thus, we sought to investigate the protective and 
detrimental effects of the suppression and overexpression of Buffy, the sole pro-survival 
Bcl-2 homologue in Drosophila (Chapter 2), and Debcl, the sole pro-death homologue in 
the α-synuclein-induced Drosophila model of PD (Chapter 3). Moreover, we sought to 
investigate the pro-survival roles of Buffy in different established models of PD that 
includes parkin, Pink1 (Appendix 2), and HtrA2 (Chapter 5), all which are strongly 
associated with mitochondrial dysfunction in the pathogenesis of PD and PD-like 
symptoms in Drosophila. We also characterized the phenotypes of loss of Pdxk, an 
increased risk to PD gene, in Drosophila DA neurons and attempted to rescue the Pdxk-
induced phenotypes by overexpression of Buffy (Chapter 7). To further investigate the 
role of autophagy in PD, we suppressed Atg6 also known as Beclin-1, and Pi3K59F also 
known as Vps34 in DA neurons, and subsequently attempted to rescue the resultant 
phenotypes by overexpression of the pro-survival Bcl-2 homologue Buffy (Chapter 4). 
To evaluate the role of the highly conserved anti-apoptotic family of TMBIM (Chapter 6), 
we suppressed CG3814, the Drosophila homologue of Lifeguard/TMBIM2 in DA neurons 
and attempted to rescue its phenotypes with the pro-survival Buffy. We inhibited CG2076, 
the Drosophila homologue of GHITM/TMBIM5 in DA neurons and additionally 
attempted to rescue the induced phenotypes through overexpression of Buffy. The last 
member of this family we investigated BI-1/TMBIM6 that ties in the role of ER in stress-
induced cell death, and additionally analysed the effects of the inhibition of BI-1 along 
with expression of α-synuclein and the overexpression of Buffy. Interestingly the 
inhibition of these three members appeared to model PD in Drosophila. To further 
evaluate the role of the mitochondria in DA neurons, we inhibited porin – a mitochondrial 
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voltage-dependent anion channel (VDAC) protein (Chapter 8), and MICU1 – a 
mitochondrial calcium uptake channel protein (Appendix 3). The protective role of Buffy 
was evaluated in DA neurons with well-established PD models and the novel models. 
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Abstract  
In contrast to the complexity found in mammals, only two Bcl-2 family genes have been 
found in Drosophila melanogaster including the pro-cell survival, human Bok-related 
orthologue, Buffy. The directed expression of α-synuclein, the first gene identified to 
contribute to inherited forms of Parkinson disease (PD), in the dopaminergic neurons 
(DA) of flies has provided a robust and well-studied Drosophila model of PD complete 
with the loss of neurons and accompanying motor defects.  To more fully understand the 
biological basis of Bcl-2 genes in Parkinson disease (PD), we altered the expression of 
Buffy in the dopamine neurons with and without the expression of α-synuclein, and in the 
developing neuron-rich eye.  
To alter the expression of Buffy in the dopaminergic neurons of Drosophila, the Ddc-Gal4 
transgene was used. The directed expression of Buffy in the dopamine producing neurons 
resulted in flies with increased climbing ability and enhanced survival, while the 
inhibition of Buffy in the dopaminergic neurons reduced climbing ability over time 
prematurely, similar to the phenotype observed in the α-synuclein-induced Drosophila 
model of PD. Subsequently, the expression of Buffy was altered in the α-synuclein-
induced Drosophila model of PD. Analysis revealed that Buffy acted to rescue the 
associated loss of locomotor ability observed in the α-synuclein-induced model of PD, 
while Buffy RNA interference resulted in an enhanced α-synuclein-induced loss of 
climbing ability. In complementary experiments the overexpression of Buffy in the 
developing eye suppressed the mild rough eye phenotype that results from Gal4 
expression and from α-synuclein expression. When Buffy is inhibited the roughened eye 
phenotype is enhanced. 
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The inhibition of Buffy in DA neurons produces a novel model of PD in Drosophila. The 
directed expression of Buffy in DA neurons provide protection and counteracts the α-
synuclein-induced Parkinson disease-like phenotypes. Taken all together this 
demonstrates a role for Buffy, a Bcl-2 pro-cell survival gene, in neuroprotection. 
Background  
Parkinson disease (PD) is the most common human movement disorder and the second 
most common neurodegenerative disease; afflicting about 1 to 2% of the population over 
50 years of age [1, 2]. PD is strongly associated with the selective and profound loss of 
dopaminergic (DA) neurons to result in marked clinical features which include muscle 
rigidity, resting tremors, postural instability, bradykinesia as well as non-motoric 
symptoms like autonomic, cognitive and psychiatric problems [2]. The neuropathological 
hallmarks exhibited by PD patients include the presence of Lewy Bodies (LB) and Lewy 
Neurites (LN) in surviving neurons. This is due to the loss of DA neurons in the 
substantia nigra pars compacta (SNpc) region of the brain, coupled with the presence of 
eosinophilic, intracytoplasmic proteinaceous inclusions comprised of the α-synuclein and 
ubiquitin proteins, among others [2-4]. This unusual protein accumulation is believed to 
lead to cellular toxicity and, eventually, the PD pathogenesis. Other associated 
pathological mechanisms include aberrant protein aggregation and mitochondrial damage 
[5-7]. Although the majority of PD cases are considered to be sporadic, familial forms 
have been documented and much has been discovered through study of the associated 
gene loci in model organisms [8-10]. PARK1/4 was the first gene associated with PD to 
be identified [3], and it encodes for a small soluble protein of unknown function 
predominantly found in neural tissues [3, 8, 11]. The first Drosophila model of PD 
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utilized a human α-synuclein transgene to induce the PD-like symptoms [12]. The success 
of this model is its ability to recapitulate features of human PD such as 1) age-dependent 
loss in locomotor function 2) LB-like inclusions and 3) age-dependent loss of DA 
neurons; and therefore, has found wide use for studying the molecular basis of α-
synuclein-induced neurodegeneration [12-19]. The utilization of the UAS/GAL4 spatio-
temporal expression system [20], and the availability of a plethora of promoters or 
enhancers of which TH-Gal4, elav-Gal4 and Ddc-Gal4 are employed in modelling PD in 
flies, makes Drosophila a powerful model organism [12-19]. Mitochondrial dysfunction 
due to the accumulation of α-synuclein has been implicated as one of the mechanisms 
leading to PD [21-24]. The association of α-synuclein with components of the 
mitochondria is thought to lead to oxidative stress, apoptosis, autophagy and the eventual 
neurodegeneration. 
The Bcl-2 family of genes are key regulators of cell death and survival in animals and are 
functionally composed of proapoptotic and pro-cell survival (antiapoptotic) members [25-
28]. The pro-survival proteins protect the mitochondria in part, from disruption by the 
proapoptotic proteins [26, 29-32]. In mammals, the antiapoptotic members possess four 
Bcl-2 homology (BH) domains - BH1, BH2, BH3 and BH4 – and include Bcl-2, BclXL, 
Mcl-1 among others. The proapoptotic members, Bax, Bak and Bok, have three BH 
domains: BH1, BH2 and BH3. A BH3-only domain class of proapoptotic proteins is 
present and includes Bid, Bim, Bad, Bik, Hrk, Noxa and Puma [33-35]. The multi-domain 
proapoptotic proteins are required for mitochondrial outer membrane (MOM) 
permeabilization and the subsequent release of apoptogenic factors into the cytosol [36-
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39]. As thus, the antiapoptotic members guard the mitochondria and stop the release of a 
plethora of death causing molecules that initiate apoptosis. 
The Bcl-2 family of proteins are thought to be the “guardians” of the mitochondria, 
involved in the life and death decisions at the cellular level by initiating mitochondrial 
remodelling, mitochondrial outer membrane permeabilization and the release of apoptotic 
factors from the mitochondria [40]. This delicate balance is maintained by the activity of 
the pro-survival and anti-survival members of the protein family. Many of the apoptotic 
pathway proteins that participate in the intrinsic and extrinsic cell death pathways have 
been identified in Drosophila [41-43]. The Bcl-2 family member homologues in 
Drosophila are limited to the single pro-cell survival Buffy and the sole pro-cell death 
Debcl [44-48]. These two proteins share a strong similarity within their domains and with 
the mammalian pore-forming proapoptotic member Bok/Mtd.  
In previous studies, the overexpression of Buffy has been shown to suppress Pink1 mutant 
phenotypes [49] and suggest a role for this protein 1) in interacting with the Pink1 protein 
and other mitochondrial proteins or 2) in a pathway that regulates mitochondrial function 
and integrity. Studies show that Buffy has little involvement in cell death during 
development [50], though it has a role in regulating cell death that occurs in response to 
external stimuli and a role in the mitochondrial pathway for the activation of cell death 
during Drosophila oogenesis [51], all which point to an important role for this protein in 
aspects of cell death. Indeed, early studies have demonstrated that Buffy plays roles in 
both anti- and pro-survival [52, 53] depending upon the stimuli. 
A direct role for the Bcl-2 proteins in mitochondrial dynamics has been shown in the 
activation of cell death in Drosophila melanogaster during mid-oogenesis [51] and in the 
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Pink1 loss-of-function Parkinson disease model [49]. The predicted role of the 
mitochondria in PD pathogenesis makes the α-synuclein-induced model of PD [12] a very 
attractive model for the investigation of the role of Bcl-2 proteins. First, we examine the 
effects of increasing and decreasing Buffy activity in DA neurons and, secondly, we 
investigate the potential suppression of the α-synuclein-induced PD phenotypes by the 
overexpression of the pro-survival Bcl-2 homologue Buffy. 
Materials and Methods 
Drosophila media and culture 
Stocks and crosses were maintained on a standard medium containing cornmeal, 
molasses, yeast, agar, water and treated with propionic acid and methylparaben. Seven 
millilitre aliquots of media was poured into vials, allowed to solidify, and refrigerated at 
4°C to 6°C. Stocks were maintained on solid media for two to three weeks before transfer 
onto new media to re-culture. Stocks were kept at room temperature (22°C ± 2°C) while 
crosses and experiments were carried out at 25°C and 29°C. 
Drosophila stocks and derivative lines 
UAS-Buffy [52] was generously provided by Dr. Leonie Quinn (University of 
Melbourne), UAS-α-synuclein [12] was provided by Dr. M. Feany of Harvard Medical 
School and Dr. J. Hirsch (University of Virginia) provided Ddc-Gal4 flies [54]. UAS-
Buffy-RNAi (w[*]; P{w[+mC]=UAS-Buffy.RNAi}3), GMR-Gal4 [55] and UAS-lacZ flies 
were obtained from the Bloomington Drosophila Stock Center at Indiana University. The 
UAS-α-synuclein/CyO; Ddc-Gal4/TM3 was generated using standard homologous 
recombination methods and was used to overexpress α-synuclein in the dopaminergic 
neurons using the dopa decarboxylase (Ddc) transgene. The UAS-α-synuclein/CyO; 
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GMR-Gal4 line was used to overexpress α-synuclein in the developing eye using the 
Glass Multiple Reporter (GMR) elements. PCR reactions and gel electrophoresis were 
used for analysis of recombination events. 
Ageing assay 
Several single vial matings of five females and three males of each genotype were made 
and a cohort of critical class male flies were collected upon eclosion. At least two 
hundred flies were aged per genotype at a density of 20 flies or fewer per vial on fresh 
media which was replenished every other day to avoid crowding. Flies were observed and 
scored every two days for the presence of deceased adults. Flies were considered dead 
when they did not display any movement upon agitation [56]. Longevity data was 
analysed using the GraphPad Prism version 5.04 and survival curves were compared 
using the log-rank (Mantel-Cox) test. Significance was determined at 95%, at a P-value 
less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
A cohort of critical class male flies was collected upon eclosion and scored for their 
ability to climb over their lifetime [57, 58]. Every 7 days, 50 males from every genotype 
were assayed for their ability to climb 10 centimetres in 10 seconds in a clean climbing 
apparatus in ten repetitions. Analysis was performed using the GraphPad Prism version 
5.04 and climbing curves were fitted using non-linear regression and compared using 
95% confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the drosophila eye 
Several single vial matings were made at 29°C and a cohort of adult male flies collected 
upon eclosion and aged for three days before being frozen at -80°C. Whole flies were 
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mounted on scanning electron microscope stubs, desiccated overnight and photographed 
with a FEI Mineral Liberation Analyzer 650F scanning electron microscope. For each 
cross at least 10 eye images were analysed using the National Institutes of Health (NIH) 
ImageJ software [59] and biometric analysis performed using GraphPad Prism version 
5.04. The percent area of eye disruption was calculated as previously described [60]. But 
briefly, the ratio of disrupted eye area was calculated by dividing the total area of the eye 
with the total disrupted area of the eye. The total disrupted area of the eye was the sum of 
any two or more ommatidia that were fused together. 
Results  
Buffy is closely related to the human proapoptotic Bok 
Bioinformatic analysis of the protein sequences encoded by the Buffy and Bok genes 
reveal 33% identity. The Buffy protein consists of 299 amino acids and reveals the 
presence of the BH1, BH2, BH3, BH4 and TM domains (Figure 1). The Eukaryotic 
Linear Motif (ELM) resource search for functional sites indicates the presence of a 
monopartite variant of a basically charged NLS between amino acids 101 and 106. There 
is a number of BH3-homology region binding sites in the central region of the protein. 
Bok has 212 amino acids and similarly shows the presence of the BH1, BH2, BH3, and  
BH4 domains. Although, the two proteins are determined to be antiapoptotic and 
proapoptotic respectively, both show the presence of a BH4 domain, the homology 
domain that is associated with pro-survival proteins. 
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Figure 2.1 Buffy is closely related to human Bcl-2 ovarian killer (Bok) 
When Buffy protein is aligned with human Bok, the Bcl-2 homology (BH) domains show 
strong conservation. Clustal Omega multiple sequence alignment [61, 62] of Drosophila 
melanogaster Buffy protein (Drosophila melanogaster NP_523702.1) with the human 
Bok (Homo sapiens NP_115904.1) showing the highlighted conserved BH domains, the 
BH3-homology region binding site, and the TM (trans-membrane) helices. Buffy 
possesses a monopartite basically charged nuclear localisation signal (NLS) region. The 
domains were identified using NCBI Conserved Domain Database Search (CDD) [63]. 
"*" indicate the residues that are identical, ":" indicate the conserved substitutions, "." 
indicate the semi-conserved substitutions. Colours show the chemical nature of amino 
acids: red is small hydrophobic (including aromatic), blue is acidic, magenta is basic, and 
green is basic with hydroxyl or amine groups. 
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Loss of Buffy decreases lifespan and climbing ability 
When Buffy is inhibited in the DA neurons by RNA interference, the resulting flies have a 
shortened lifespan and impaired climbing ability. The median lifespan for these flies is 58 
days compared to 64 days for the controls (Figure 2A). The nonlinear fitting of the 
climbing curves resulted in a slope gradient that was significantly different at 95% 
confidence interval (Figure 2B). This suggests that Buffy is required for the normal 
functioning of DA neurons and inhibition in DA neurons confers a disadvantage by 
reducing lifespan and impairing the locomotor ability of these flies. 
Buffy increases lifespan and climbing ability when overexpressed in DA neurons 
When Buffy is overexpressed in DA neurons, the survival parameters of these flies differ 
slightly (Figure 2A), with Buffy-overexpressing flies having a median lifespan of 68 days 
compared to 64 days for the controls. The overexpression of Buffy in DA  
neurons led to an increased climbing ability as indicated by the nonlinear fitting of the 
curve with 95% CI (Figure 2B). This suggests that Buffy improves longevity and 
markedly improves climbing ability in Drosophila when expressed in DA neurons to 
improve the general “healthspan” of these flies. 
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Figure 2.2 Buffy alters lifespan and climbing ability when mis-expressed in DA 
neurons 
A) Directed expression of UAS-Buffy in the DA neurons driven by Ddc-Gal4 results in 
increased survival compared to the controls overexpressing UAS-lacZ, while inhibition 
via Buffy-RNAi results in reduced survival. The genotypes are UAS-lacZ/ Ddc-Gal4; 
UAS-Buffy/ Ddc-Gal4; and UAS-Buffy-RNAi/ Ddc-Gal4. Longevity is shown as percent 
survival (P < 0.01, determined by log-rank and n≥200). B) Directed expression of UAS-
Buffy results in increased climbing ability as determined by non-linear fitting of the 
climbing curves and comparing at 95% confidence intervals. Inhibition by Buffy-RNAi 
decreased the locomotor ability when expressed in dopaminergic neurons. The genotypes 
are UAS-lacZ/ Ddc-Gal4; UAS-Buffy/ Ddc-Gal4; and UAS-Buffy-RNAi/ Ddc-Gal4. Error 
bars indicate the standard error of the mean (SEM) and n=50. 
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Inhibition of Buffy enhances the α–synuclein-induced phenotypes 
The inhibition of Buffy by RNA interference when co-expressed with α-synuclein, under 
the directions of Ddc-Gal4, results in short-lived flies with strongly impaired locomotor 
function. The median lifespan of the α-synuclein-expressing control flies was 60 days, 
while that of those co-expressing the Buffy-RNAi inhibitory transgene along with α-
synuclein was 50 days (Figure 3A). The climbing ability of these flies was more impaired 
than those expressing α-synuclein alone, as indicated by the nonlinear fitting of the 
climbing curves (Figure 3B). 
Overexpression of Buffy in DA neurons rescues the α–synuclein-induced loss of 
climbing ability 
The overexpression of Buffy in DA neurons expressing α-synuclein results in an increased 
median lifespan of 68 days, compared to 60 days for the control flies (Figure 3A). The 
climbing curves indicate that there was a significant improvement in the climbing ability 
of the flies when Buffy was overexpressed (Figure 3B) and thus, suppressing the 
phenotypes observed when α-synuclein is expressed in DA neurons. This suggests that the 
overexpression of Buffy confers protection to DA neurons, as a result of the expression of 
α-synuclein. 
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Figure 2.3 Buffy rescues the α-synuclein-induced phenotypes of decreased lifespan 
and climbing ability 
A) Directed overexpression of Buffy in the DA neurons increase longevity whereas flies 
with Buffy loss-of-function show a decline in lifespan. Genotypes are UAS-α-synuclein, 
Ddc-Gal4/UAS-lacZ; UAS-α-synuclein, Ddc-Gal4/ UAS-Buffy; and UAS-α-synuclein, 
Ddc-Gal4/ UAS-Buffy-RNAi. Longevity is shown as percent survival (P < 0.01, 
determined by log-rank and n≥200). B) The co-expression of Buffy in the α-synuclein 
model of PD rescued the age-dependent loss in climbing ability. The directed 
overexpression of Buffy in the DA neurons remarkably increased the climbing ability over 
time compared to the control, while the suppression of Buffy resulted in flies that climbed 
similar to the control. The genotypes are UAS-α-synuclein; Ddc-Gal4/UAS-lacZ, UAS-α-
synuclein; Ddc-Gal4/ UAS-Buffy, and UAS-α-synuclein; Ddc-Gal4/ UAS-Buffy-RNAi. 
Analysis of the climbing curves and significance was determined by comparing the 95% 
confidence intervals. Error bars indicate the SEM and n=50. 
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Overexpression of Buffy suppresses the α-synuclein-induced developmental defects 
in the eye 
The expression of α-synuclein in the developing eye results in developmental defects. 
When Buffy is overexpressed in the developing eye, developmental defects resulting  
from GMR-Gal4 (Figure 4B, I) and from GMR-Gal4 and α-synuclein expression (Figure 
4B, IV) are suppressed. The disruption of the ommatidial array is restored to control 
levels in both cases (Figure 4B). These results suggest that overexpression of Buffy can 
counteract the toxic effects of α-synuclein in the developing eye in addition to the effects 
of GMR-Gal4. 
Discussion 
The recapitulation of PD-like symptoms in Drosophila melanogaster and especially the 
age-dependent loss of climbing ability led to the investigation of gene products that could 
suppress this phenotype [12, 13, 64]. Mitochondrial dysfunction as a result of α-synuclein 
accumulation has been implicated in PD pathogenesis and, thus, we have investigated the 
consequences of the overexpression of the Drosophila Bcl-2 homologue Buffy. The 
analysis of climbing over the lifespan of the flies has been applied to determine the role of 
the various gene products in rescuing the α-synuclein-induced phenotypes [12, 57, 64, 
65]. This assay allows for scoring of flies based on their loss of climbing ability and is a 
key indicator of the effect the overexpressed gene has on the phenotype. 
The α-synuclein-expressing models of PD in Drosophila show little difference in lifespan 
between the control and wild type, A53T and A30P α-synuclein flies [12]. In our study, 
when Buffy is overexpressed in the DA neurons under the control of the Ddc-Gal4 driver,   
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Figure 2.4 Buffy suppresses the α-synuclein-induced developmental defects in the eye 
A) Scanning electron micrographs when Buffy is overexpressed or inhibited in the eye 
with the eye-specific GMR-Gal4 transgene; (I) GMR-Gal4/ UAS-lacZ; (II) GMR-Gal4/ 
UAS-Buffy; (III) GMR-Gal4/ UAS-Buffy-RNAi and when co-expressed with α-synuclein; 
(IV) UAS-α-synuclein; GMR-Gal4 / UAS-lacZ; V) UAS- α-synuclein; GMR-Gal4/ UAS-
Buffy; and VI) UAS-α-synuclein; GMR-Gal4/ UAS-Buffy-RNAi. B) Biometric analysis 
showed a significant difference in the disrupted area of the eye when Buffy was inhibited 
in the developing eye (I-III). Biometric analysis shows a marked difference when Buffy is 
inhibited in an α-synuclein expressing background (IV-VI) with decreased ommatidia 
number and highly degenerated ommatidial array whereas when Buffy is overexpressed in 
the α-synuclein background, there is a rescue of the α-synuclein-induced phenotypes as 
determined by one-way ANOVA and Dunnett's multiple comparison test (P<0.05 and 
95% CI), error bars indicate the SEM, asterisks (*) represents statistical significance.  
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there is a significant increase in their longevity. This may be partly due to defects in 
mitochondrial Complex I function, the pro-survival Buffy likely plays a mitochondrial 
protective role to increase longevity. This was not verified experimentally and as such is 
one of our potential future investigations into the mechanistic properties of Buffy. The 
inhibition of Buffy in the DA neurons resulted in a marked decrease in survival. This 
inhibition of Buffy is sufficient to negate its protective role and thus promote cell death as 
has recently been shown by Clavier and colleagues [66]. Thus, the pro-survival properties 
of Buffy are evident. 
Locomotor dysfunction is one of the associated symptoms of PD, the α-synuclein-
expressing model demonstrated a clear age-dependent loss in climbing ability [12]. When 
we overexpressed Buffy in the DA neurons under the control of Ddc-Gal4, the flies 
produced a climbing index significantly different from that of control flies. The Buffy flies 
lost the climbing ability later than the control flies and is likely due to the protective role 
that Buffy confers to the mitochondria. In contrast, the inhibition of Buffy results in a 
highly-compromised climbing ability when compared to the controls. The degree of 
locomotor dysfunction seemed to be like that observed when α-synuclein is overexpressed 
in DA neurons. Taken together, these results would indicate an early protective role for 
Buffy in the DA neurons even in the absence of induced cellular stress. 
The inhibition of Buffy in the DA neurons of the α-synuclein-induced PD model 
significantly decreased lifespan, indicating that low levels of Buffy compromise the 
health of DA neurons. When Buffy was overexpressed along with α-synuclein, there was a 
marked improvement in the climbing ability of these flies. These results suggest that 
overexpressing Buffy in the DA neurons counteracts the α-synuclein-induced phenotype 
  
80 
 
of locomotor dysfunction over their lifespan. The Buffy loss-of-function flies displayed a 
reduced climbing ability compared to the control flies. Therefore, expression of the pro-
survival Buffy can rescue the α-synuclein-dependent model of PD from climbing 
dysfunction. 
Directed overexpression of Buffy in the developing eye rescues the roughened eye 
phenotypes caused by Gal4 and α-synuclein expression, whereas the inhibition of Buffy 
results in a more disrupted ommatidial array. This indicates that elevated levels of Buffy 
in the developing eye offers protection from toxic protein insults to normalize cellular 
differentiation, neurogenesis and cell survival. 
Conclusions  
Buffy inhibition results in shortened lifespan and impaired locomotor function and 
represents a novel model of PD in Drosophila melanogaster. The overexpression of Buffy 
improves healthspan and counteracts the effects of α-synuclein expression to demonstrate 
its protective function. Further studies are required to fully elucidate how Buffy may 
interact with the other PD genes, and how these interactions fit into the regulation of 
mitochondrial integrity by the Bcl-2 proteins. 
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Abstract 
Parkinson disease (PD) is a debilitating movement disorder that afflicts 1 to 2% of the 
population over 50 years of age. The common hallmark for both sporadic and familial 
forms of PD is mitochondrial dysfunction. Mammals have at least twenty proapoptotic 
and antiapoptotic Bcl-2 family members, in contrast, only two Bcl-2 family genes have 
been identified in Drosophila melanogaster, the proapoptotic mitochondrial localized 
Debcl and the antiapoptotic Buffy. The expression of α-synuclein, the first gene identified 
to contribute to inherited forms of PD, in the dopaminergic neurons (DA) of flies has 
provided a robust and well-studied Drosophila model of PD complete with the loss of 
neurons and accompanying motor defects. The altered expression of Debcl in the DA 
neurons and neuron-rich eye along with the expression of α-synuclein offers an 
opportunity to highlight the role of Debcl in mitochondrial-dependent neuronal 
degeneration and death. The directed overexpression of Debcl using the Ddc-Gal4 
transgene in the dopaminergic neurons of Drosophila resulted in flies with severely 
decreased survival and a premature age-dependent loss in climbing ability, phenotypes 
that are strongly associated with models of PD in Drosophila. The inhibition of Debcl 
resulted in enhanced survival and improved climbing ability whereas the overexpression 
of Debcl in the α-synuclein-induced Drosophila model of PD resulted in more severe 
phenotypes. In addition, the co-expression of Debcl along with Buffy partially counteracts 
the Debcl-induced phenotypes, to improve the lifespan and the associated loss of 
locomotor ability observed. In complementary experiments, the overexpression of Debcl 
along with the expression of α-synuclein in the eye enhanced the eye ablation that results 
from the overexpression of Debcl. The co-expression of Buffy along with Debcl 
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overexpression results in the rescue of the moderate developmental eye defects. The co-
expression of Buffy along with inhibition of Debcl partially restores the eye to a 
roughened eye phenotype. Taken all together these results suggest a role for Debcl in 
neurodegenerative disorders. 
Introduction 
Parkinson disease (PD) is a human movement disorder that is strongly associated with the 
selective and profound degeneration and loss of dopaminergic (DA) neurons to result in a 
set of marked clinical features [1]. The neuropathological hallmarks exhibited by PD 
patients include the presence of Lewy Bodies (LB) which are intracytoplasmic 
proteinaceous inclusions composed of α-synuclein and ubiquitin among other proteins [1-
3]. This atypical protein aggregation and accumulation is believed to lead to cellular 
toxicity and contribute to the pathogenesis of PD. Additional pathological mechanisms 
that are associated with PD include aberrant protein aggregation and mitochondrial 
damage [4-6]. Familial forms of PD have highlighted the genetic basis of PD and the 
study of the associated gene loci in model organisms offers great understanding of the 
disease aetiology and pathology [7-9]. The gene encoding α-synuclein, a small soluble 
protein of largely unknown function predominantly found in neural tissues, was first to be 
identified as responsible for inherited PD [3]. Mitochondrial dysfunction due to the 
accumulation of α-synuclein has been implicated as one of the mechanisms leading to PD 
[10-13]. The association of α-synuclein with components of the mitochondria is thought 
to lead to oxidative stress, apoptosis, autophagy and eventually, neurodegeneration. The 
first Drosophila model of PD utilized a human α-synuclein transgene to induce the PD-
like symptoms [14]. This model system is very successful and widely applied, as it 
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displays the age-dependent loss of locomotor function, the degeneration of DA neurons 
and LB-like inclusions, features that are present in human PD [14-21]. Drosophila has 
available tissue specific gene enhancers such as TH-Gal4, elav-Gal4 and Ddc-Gal4, 
which are used to model PD in flies in combination with the powerful bipartite UAS/Gal4 
[22] system. Of importance is the correlation between DA neuron loss and the age-
dependent loss of locomotor function [21, 23] which validates the implication that age-
dependent loss of locomotor function is as a result of DA neuron degeneration. 
The Bcl-2 family of genes are crucial controllers of apoptosis in animals and are 
functionally composed of proapoptotic and antiapoptotic members [24-27]. In mammals, 
this multigene family has about 20 members, the antiapoptotic proteins protect the 
mitochondria from disruption by the proapoptotic proteins [25, 28-31]. The antiapoptotic 
members possess four Bcl-2 homology (BH) domains while the proapoptotic members 
have three to four BH domains. The proapoptotic proteins initiate apoptosis by the 
permeabilization of the outer mitochondrial membrane which results in the release of 
apoptogenic factors into the cytosol [32-35]. The antiapoptotic members protect the 
mitochondria from permeabilization by the proapoptotic members and block the release 
of apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF) among 
others from being released from the inner mitochondrial membrane into the cytosol. 
Drosophila melanogaster possesses many of the apoptotic pathway proteins that 
participate in the intrinsic and extrinsic cell death pathways [36, 37]. The Bcl-2 family 
member homologues in Drosophila are limited to the single antiapoptotic Buffy [38], and 
the sole proapoptotic Death executioner Bcl-2 homologue, Debcl [38-42]. Debcl has a 
  
89 
 
strong similarity with the mammalian mitochondria outer membrane permeabilization 
protein Bok/Mtd.  
The importance of Debcl is perhaps demonstrated by the presence of 5’ nuclear 
transcription factor Y (NF-Y) promoter region which has been shown to be important for 
gene promoter activity [43]. The tumour suppressor gene Retinoblastoma (Rbf1 in 
Drosophila) induces a Debcl-and Drp1-dependent mitochondrial cell death [44]. Rbf1 
induces cell death by reducing the expression of the sole Debcl antagonist Buffy [45]. The 
Rbf1-induced apoptosis is dependent on Debcl-dependent mitochondrial ROS production 
and essentially Debcl is required downstream of Buffy for apoptosis to occur. The Debcl-
induced ROS production appears to be through Glycerophosphate oxidase 1 participation 
to increase mitochondria ROS accumulation [46]. The organic solute carrier partner 1/ 
oxidored nitrodomain-containing protein 1 (OSCP1/NOR1), a known tumour suppressor 
induces apoptosis by the down-regulation of the Buffy gene and the up-regulation of the 
Debcl gene [47]. Debcl is not required for most developmental cell death, but has been 
shown to play a role in embryonic cell death [48] and stress-induced apoptosis [49]. 
Antiapoptotic Buffy antagonizes Debcl-induced apoptosis by physical interaction [38], 
probably at the mitochondria where Debcl localizes [50]. The presence of a mitochondrial 
outer membrane (MOM)-targeting motif in Debcl indicates it possibly has a role in 
mitochondrial cell death pathway. 
The role of the mitochondria in PD pathogenesis makes the α-synuclein-induced model of 
PD [14] a very attractive model for the investigation of the role of Bcl-2 proteins. Here, 
we investigate the potential enhancement or suppression of the α-synuclein-induced PD 
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phenotypes by the inhibition and overexpression of the pro-apoptotic Bcl-2 homologue 
Debcl. 
Materials & methods 
Drosophila media and culture 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben. Stocks were sustained on solid media for 
two to three weeks before being transferred onto new media to re-culture. Stocks were 
kept at room temperature (22°C ± 2C) while crosses and experiments were carried out at 
25C and 29C. 
Drosophila stocks and derivative lines 
UAS-Buffy [38] was a gift from Dr. Leonie Quinn of University of Melbourne, UAS-α-
synuclein [14] by Dr. M. Feany of Harvard Medical School and Ddc-Gal4 [51] by Dr. J. 
Hirsch of University of Virginia. y1 v1; P{y[+t7.7] v[+t1.8]=TRiP.JF02429}attP2 hereby 
referred to as Debcl-RNAi, GMR-Gal4 [52] and UAS-lacZ were sourced from the 
Bloomington Drosophila Stock Center at Indiana University. The UAS-α-synuclein/CyO; 
Ddc-Gal4/TM3; UAS-α-synuclein/CyO; GMR-Gal4; UAS-Buffy/CyO; Ddc-Gal4 and 
UAS-Buffy/CyO; GMR-Gal4 derivative lines were generated using standard homologous 
recombination methods and were used for overexpression of either α-synuclein or Buffy in 
DA neurons using the Ddc-Gal4 transgene or in the developing eye using the GMR 
response elements. PCR reaction was used to determine the amplification of DNA 
products from primers designed from the Homo sapiens synuclein, alpha (non A4 
component of amyloid precursor) (SNCA), transcript variant 1 mRNA, NCBI reference 
sequence: NM_000345.3 using the NCBI primer design tool. The 5’ to 3’ sequence of the 
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forward primer was GTGCCCAGTCATGACATTT, while that of the reverse primer was 
CCACAAAATCCACAGCACAC and were ordered from Invitrogen. The Drosophila 
melanogaster Buffy mRNA, NCBI reference sequence: NM_078978.2, was used to 
design a set of Buffy primers that would target both the endogenous and the 
overexpression transcripts. The 5’ to 3’ sequence of the forward primers were 
CACAGCGTTTATCCTGCTGA and CGGGTGGTGAGTTCCATACT, while that of the 
reverse primers were TCGCAGTGTGAAGATTCAGG and 
TTAATCCACGGAACCAGCTC, and were ordered from Eurofins MWG Operon. Gel 
electrophoresis was used for confirmation of recombination events via presence of the 
PCR product. 
Ageing assay 
Several single vial matings were made and a cohort of critical class male flies was 
collected upon eclosion. At least two hundred flies were aged per genotype at a density of 
20 or fewer flies per vial to avoid crowding on fresh media which was replenished every 
other day. Flies were observed and scored every two days for the presence of deceased 
adults. Flies were considered dead when they did not display movement upon agitation 
[53]. Longevity data was analysed using the GraphPad Prism version 5.04 and survival 
curves were compared using the log-rank (Mantel-Cox) test. Significance was determined 
at 95%, at a P-value less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
A batch of male flies was collected upon eclosion and scored for their ability to climb 
[54]. Every 7 days, 50 males from every genotype were assayed for their ability to climb 
10 centimetres in 10 seconds in a clean climbing apparatus in 10 repetitions. Analysis was 
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performed using GraphPad Prism version 5.04 and climbing curves were fitted using non-
linear regression and compared using 95% confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the Drosophila eye 
Several single vial crosses were made at 29°C and adult male flies collected upon 
eclosion and aged for three days before being frozen at -80°C. Whole flies were mounted 
on scanning electron microscope stubs, desiccated overnight and photographed with a FEI 
Mineral Liberation Analyzer 650F scanning electron microscope. For each cross at least 
10 eye images were analyzed using the National Institutes of Health (NIH) ImageJ 
software [55] and biometric analysis performed using GraphPad Prism version 5.04. The 
percent area of eye disruption was calculated as previously described [56]. Briefly, the 
ratio of disrupted eye area was calculated by dividing the total area of the eye with the 
total disrupted area of the eye which was the sum of any two or more ommatidia that 
were fused together. Comparisons for statistical analysis were performed using one-way 
ANOVA and Dunnett's multiple comparison test. Significance was determined at p<0.05. 
Results  
Debcl is similar to the human proapoptotic Bcl-2 ovarian killer (Bok) 
Bioinformatic analysis of the protein sequences encoded by the Debcl and Bok genes 
reveal 37% identity and 55% similarity. The Debcl protein consists of 300 amino acids 
and indicates the existence of the BH1, BH2, BH3, BH4 and TM domains, similar to the 
212 amino acids human Bok (Figure 1). An ELM resource search for functional sites [57] 
indicates the presence of a transmembrane domain (membrane anchor region), an 
inhibitor of apoptosis binding motif (IBM) at amino acids 1 to 5, a PDZ domain at amino 
acids 295 to 300, an ER retention motif at amino acids 109 to 115 and between amino 
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acids 258 to 262, an Atg8 binding motif at amino acids 36 to 42, a nuclear receptor box 
motif at amino acids 295 to 300, and a ubiquitination motif of the SPOP-binding 
consensus at amino acids 2 to 6 and another one at position 74 to 79. There is a number of 
BH3-homology region binding sites in the central region of the protein as determined by 
an NCBI conserved domain search [58]. Although the two proteins Bok and Debcl have 
been determined to be antiapoptotic, both show the presence of a BH4 domain, the 
homology domain that is most often associated with pro-survival proteins. 
Directed misexpression of Debcl in DA neurons alters lifespan and locomotor ability 
The inhibition of Debcl in the DA neurons by RNA interference results in a lifespan with 
a median survival of 64 days that is similar to 62 days for the controls expressing the 
benign lacZ transgene as determined by a Log-rank (Mantel-Cox) test (Figure 2A). The 
locomotor ability showed a slight improvement when nonlinear fitting of the climbing 
curves was performed with significant differences at 95% CI (Figure 2B). This suggests 
that the inhibition of the proapoptotic Debcl confers a small advantage for the normal 
functioning of DA neurons. When Debcl is overexpressed in DA neurons, the survival 
criteria of these flies differ greatly (Figure 2A), with Debcl-overexpressing flies having a 
median lifespan of 48 days compared to 62 days for the controls expressing the benign 
lacZ transgene as indicated by a Log-rank (Mantel-Cox) test. The overexpression of 
Debcl in DA neurons severely impairs climbing ability as determined by the nonlinear 
fitting of the curve with 95% CI (Figure 2B). This suggests that the overexpression of 
Debcl in DA neurons interferes with the normal functioning of these flies and results in 
compromised “healthspan”. 
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Figure 3.1 Debcl is related to human Bcl-2 ovarian killer (Bok) 
(A). When Debcl protein is aligned with human Bok the Bcl-2 homology (BH) domains 
show strong conservation. Clustal Omega multiple sequence alignment [59, 60] of 
Drosophila melanogaster Debcl protein (Dmel is Drosophila melanogaster 
NP_788278.1) with the human Bok (Hsap is Homo sapiens NP_115904.1), mouse Bok 
(Mmus is Mus musculus NP_058058.1) and mosquito Bok (Agam is Anopheles gambiae 
NP_309956.4) showing the highlighted conserved BH domains and the TM helices. The 
domains were identified using NCBI Conserved Domain Database Search (CDD) [58] 
and ELM resource search for functional sites [57]. "*" indicate the residues that are 
identical, ":" indicate the conserved substitutions, "." indicate the semi-conserved 
substitutions. Colours show the chemical nature of amino acids. Red is small hydrophobic 
(including aromatic), Blue is acidic, Magenta is basic, and Green is basic with hydroxyl 
or amine groups.  
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Figure 3.2 Debcl alters lifespan and climbing ability when expressed in DA neurons 
A) The directed inhibition of Debcl in the DA neurons driven by Ddc-Gal4 results in a 
slightly increased median survival compared to the control flies overexpressing UAS-
lacZ, while the overexpression of Debcl results in severely reduced survival. The 
genotypes are UAS-lacZ/ Ddc-Gal4; UAS-Debcl-RNAi/ Ddc-Gal4 and UAS-Debcl/ Ddc-
Gal4. Longevity is shown as percent survival (P < 0.01, determined by log-rank and 
n≥200). B) The inhibition of Debcl results in improved climbing ability whereas the 
overexpression of Debcl results in a highly compromised climbing ability as determined 
by non-linear fitting of the climbing curves and comparing at 95% confidence intervals. 
The genotypes are UAS-lacZ/ Ddc-Gal4; UAS-Debcl-RNAi/ Ddc-Gal4 and UAS-Debcl/ 
Ddc-Gal4. Error bars indicate the standard error of the mean (SEM) and n=50. 
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Altered expression of Debcl influences the α–synuclein-induced phenotypes 
The inhibition of Debcl by RNAi along with the expression of α-synuclein under the 
direction of the Ddc-Gal4 transgene results in increased lifespan and healthier climbing 
ability compared to the control (Figure 3). The Debcl-RNAi along with α-synuclein-
expressing flies had a median lifespan of 67 days, while that of α-synuclein-expressing 
controls was 60 days as determined by a Log-rank (Mantel-Cox) test (Figure 3A). The 
climbing ability of these flies was slightly improved than of the α-synuclein-expressing 
controls as indicated by the nonlinear fitting of the climbing curves and compared the 
95% CI (Figure 3B). These results show that the inhibition of the proapoptotic Debcl 
confers a significant advantage to flies under the influence of the neurotoxic effects of the 
human transgene α-synuclein. The overexpression of Debcl along with α-synuclein in DA 
neurons results in decreased median lifespan of 44 days, compared to 60 days for the 
control flies as determined by a Log-rank (Mantel-Cox) test (Figure 3A). The climbing 
curves indicate that there was a significant reduction in the climbing ability of the flies 
with overexpression of Debcl (Figure 3B) and thus, enhancing the phenotypes observed 
when α-synuclein is expressed in DA neurons. This suggests that the overexpression of 
Debcl further increases the toxic effects of the expression of α-synuclein. 
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Figure 3.3 Overexpression of Debcl enhances the α-synuclein-induced phenotypes of 
decreased lifespan and climbing ability 
A) Directed overexpression of Debcl in the DA neurons severely decreases longevity 
whereas its inhibition shows an incline in lifespan. Genotypes are UAS-α-synuclein; Ddc-
Gal4/UAS-lacZ; UAS-α-synuclein; Ddc-Gal4/ UAS-Debcl-RNAi; and UAS-α-synuclein; 
Ddc-Gal4/ UAS-Debcl. Longevity is shown as percent survival (P < 0.01, determined by 
log-rank and n≥200). B) The co-expression of Debcl in the α-synuclein model of PD 
enhanced the age-dependent loss in climbing ability. The directed inhibition of Debcl in 
the DA neurons improved the climbing ability over time compared to the control. The 
genotypes are UAS-α-synuclein; Ddc-Gal4/UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ UAS-
Debcl-RNAi, and UAS-α-synuclein; Ddc-Gal4/ UAS-Debcl. Analysis of the climbing 
curves and significance was determined by comparing the 95% confidence intervals. 
Error bars indicate the SEM and n=50. 
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The overexpression of the pro-survival Buffy rescues the Debcl-induced phenotypes 
The overexpression of Buffy and Debcl in DA neurons results in a longer lifespan and 
improved locomotor ability (Figure 4). The median lifespan of these flies was 62 days 
when compared to Buffy and lacZ overexpressing controls at 68 days. The median 
survival of Debcl-RNAi flies was 68 days as determined by a Log-rank (Mantel-Cox) test 
(Figure 4A). The climbing ability of these flies was also much improved as determined by 
comparing the climbing indices at 95% CI (Figure 4B). Taken together these results 
suggest that Buffy antagonizes the Debcl-induced phenotypes of shortened lifespan and 
poor climbing ability to markedly improve “healthspan”. 
Overexpression of Debcl enhances the α-synuclein-induced developmental eye 
defects 
The overexpression of Debcl in the Drosophila eye results in severe ablation of the eye 
due to apoptosis [40, 41] while expression of α-synuclein in the eye results in 
developmental defects (Figure 5A, IV). When Debcl is overexpressed in the eye, 
developmental defects resulting from Gal4 [61] (Figure 5A, I and 5B), inhibition of 
Debcl (Figure 5A, II and 4B), and overexpression of Debcl (Figure 5A, III and 5B) are 
enhanced. Biometric analysis of the ommatidia number and the percentage of eye 
disruption showed significant differences in the compared genotypes to the control that 
express the benign lacZ transgene (Figure 5B). The inhibition of Debcl along with α-
synuclein expression (Figure 5A, V and 5C) and the co-expression of Debcl and α-
synuclein (Figure 5A, VI and 5C) result in enhanced phenotypes. The disruption of the 
ommatidial array due to fusion of the ommatidia and smaller eye is severely enhanced by 
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Figure 3.4 Overexpression of Buffy partially rescues the Debcl-induced phenotypes 
A) The overexpression of Buffy along with the overexpression of Debcl or Debcl-RNAi 
restores lifespan and B) significantly improves the climbing ability of these flies. The 
genotypes are UAS-Buffy; Ddc-Gal4/ UAS-lacZ, UAS-Buffy; Ddc-Gal4/ UAS-Debcl-RNAi 
and UAS-Buffy; Ddc-Gal4/ UAS-Debcl. Longevity was determined by log-rank (Mantel-
Cox) test and n≥200 while climbing ability curves were fitted non-linearly and compared 
with 95% CI. 
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Figure 3.5 Buffy partially rescues the Debcl-induced developmental eye defects 
A) Scanning electron micrographs when Debcl is overexpressed or inhibited in the eye 
with the eye-specific GMR-Gal4 transgene; (I) GMR-Gal4/ UAS-lacZ; (II) GMR-Gal4/ 
UAS-Debcl-RNAi; (III) GMR-Gal4/ UAS-Debcl, when co-expressed with α-synuclein; 
(IV) UAS-α-synuclein; GMR-Gal4 / UAS-lacZ; V) UAS-α-synuclein; GMR-Gal4 / UAS-
Debcl-RNAi VI) UAS- α-synuclein; GMR-Gal4/ UAS-Debcl; and when co-expressed with 
Buffy VII) UAS-Buffy; GMR-Gal4/ UAS-lacZ VIII) UAS-Buffy; GMR-Gal4/ UAS-Debcl-
RNAi and IX) UAS-Buffy; GMR-Gal4/ UAS-Debcl. B) Biometric analysis showed a 
significant difference in the disrupted area of the eye when Debcl was inhibited in the 
developing eye and the depressed ommatidia number and high levels of disruption when 
Debcl is overexpressed. C) Biometric analysis shows a marked difference when Debcl is 
inhibited in an α-synuclein expressing background with increased ommatidia number and 
a less disrupted ommatidial array, whereas when Debcl is overexpressed along with the 
expression of α-synuclein, there is a dramatic decrease in ommatidia number coupled with 
severe disruption of the ommatidial array. D) The biometric analysis reveals the 
restoration of Debcl-induced phenotypes by overexpression of Buffy. The inhibition and 
overexpression of Debcl along with overexpression of Buffy results in increased 
ommatidia number together with improved disruption of the ommatidial array as 
determined by one-way ANOVA and Dunnett's multiple comparison test (P<0.05 and 
95% CI), error bars indicate the SEM, asterisks (*) represents statistically significant 
result and n=10. 
  
102 
 
the overexpression of Debcl together with α-synuclein (Figure 4A, VI and 4C). The 
analysis of the ommatidia number and disruption of the eye revealed significant 
differences, the inhibition of Debcl yielded “healthier” eyes and its overexpression 
resulted in worsened phenotypes (Figure 5C). The ommatidial disarray that results from 
inhibition of Debcl are completely rescued by overexpression of the pro-survival Buffy 
(Figure 5A, VIII and 5D), while the ablated eye that result from Debcl overexpression is 
partially rescued upon Buffy overexpression, restoring the ablation to a mildly severe 
rough eye phenotype (Figure 5A, IX and 5D). Biometric analysis showed recouped 
ommatidia number and a lessened disruption of the eye, though they still were 
significantly different from the control (Figure 5D).  These results suggest that 
overexpression of Debcl along with expression of α-synuclein enhances the Debcl-
induced eye ablation, while the overexpression of Debcl together with Buffy partially 
rescues the eye phenotype. 
Discussion 
Since mitochondrial dysfunction is central to the pathology of both sporadic and familial 
forms of PD [62], it was important to highlight the role and consequences of the altered 
expression of the proapoptotic mitochondrial gene Debcl in this process. The 
overexpression of Debcl in Drosophila and other systems, including mammalian, has 
been demonstrated to lead to apoptosis [39-42, 48, 49, 63]. The recapitulation of PD-like 
symptoms in Drosophila melanogaster, especially the age-dependent loss of climbing 
ability, has led to investigation of genes that could suppress these phenotypes [14, 15, 64]. 
Our results show that the overexpression of Debcl results in a severely shortened lifespan 
followed by premature loss in climbing ability; phenotypes that are reminiscent of PD-
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like symptoms in model organisms. Thus, our work shows the intricate balance between 
life and death decisions in the sensitive dopamine producing neurons. It seems that excess 
amounts of Debcl protein are sufficient to upset the survival mechanisms and lead to 
degeneration and death of DA neurons. The importance of Debcl-induced apoptosis is 
exhibited by the strict control in its gene product by the tumour suppressors Rbf1 [44], 
OSCP1/NOR1 [47], and NF-Y [43]. Furthermore, it has a motif for ubiquitination, 
probably by the TrCP homologue slimb that targets it for destruction by the proteasome 
[65]. The inhibition of Debcl had a converse result, with flies that had a longer lifespan 
and healthy climbing ability. It is possible that the suppression of Debcl tips the balance 
towards the survival pathways controlled by the antiapoptotic Buffy. Our results indicate 
that overexpression of Debcl appears to be a novel model of PD as a result of neuronal 
apoptosis. 
The α-synuclein-induced model of PD in Drosophila shows little difference in lifespan 
between the control and wild type, A53T and A30P α-synuclein flies [14]. In our study, 
the overexpression of Debcl in the DA neurons resulted in a marked decrease in lifespan. 
This is in part due to toxic effects as a result of the expression of α-synuclein, and 
additionally, due to Debcl-induced apoptosis. The Debcl-induced apoptosis is mediated 
by other factors including; the mitochondrial fission protein Drp1 [44] that interacts with 
Debcl to induce mitochondrial fragmentation; Glycerophosphate oxidase-1 [46] that 
increases mitochondrial ROS accumulation; and possibly through the initiation of 
autophagy, since both α-synuclein expression [66] and Debcl [67] overexpression are 
implicated in this process. This worsening of phenotypes was also observed when Debcl 
was overexpressed with α-synuclein in the eye. The inhibition of Debcl in the DA neurons 
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resulted in a marked increase in survival and improved locomotor ability. This inhibition 
of Debcl is sufficient to negate its apoptotic role and thus promote cell survival through 
the opposing antiapoptotic Buffy. 
Locomotor dysfunction is one of the major symptoms of PD. The demonstration of an 
age-dependent loss of climbing ability is pivotal to highlighting the effects of 
degeneration and death of DA neurons, ultimately as a consequence of altered gene 
expression as opposed to cellular senescence [68]. The overexpression of Debcl in the DA 
neurons produced a climbing index significantly different from that of control flies with 
the loss of climbing ability in an age-dependent manner and likely due to Debcl-induced 
neuronal degeneration. The degree of locomotor dysfunction seemed to be similar to that 
observed when α-synuclein is overexpressed in DA neurons. Taken together, these results 
would indicate a detrimental effect in overexpression of Debcl in DA neurons that result 
in a novel model of PD in flies. 
In contrast, the inhibition of Debcl in the same neurons results in a remarkable 
improvement in climbing ability when compared to the controls. The inhibition of Debcl 
in the DA neurons of the α-synuclein-induced PD model significantly increased lifespan 
and climbing ability, indicating that reduced levels of Debcl are sufficient to alter the 
healthspan of DA neurons. The Debcl-induced apoptosis relies on downstream effectors 
that either induces ROS accumulation [46] or the fragmentation of the mitochondria [44]. 
As the down-regulation of Buffy or up-regulation of Debcl results in apoptosis [47], the 
cellular advantage of Debcl inhibition may be indirect through the de-repression of the 
Buffy gene product that confers survival advantages. The directed expression of Buffy 
along with Debcl results in an improved “healthspan” compared to the Debcl-induced 
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phenotypes and corroborate other studies that show the overexpression of the pro-survival 
Buffy confers survival advantages through increased survival and improved climbing 
ability under conditions of stress [69]. Our study suggests that the overexpression of Buffy 
is similar to an up-regulation that ultimately blocks Debcl-induced apoptosis, similar to 
results obtained when its regulation by Rbf1 or dE2F2 is altered to repress it 
transcriptionally [44, 45]. This suppression of Buffy is sufficient to induce Debcl-
dependent apoptosis, in addition to the promotion of Debcl activity by dNF-Y [43]. The 
co-overexpression of Debcl and Buffy in the eye resulted in a partial rescue of the Debcl-
induced phenotypes. Therefore, overexpression of the pro-survival Buffy suppresses the 
Debcl-dependent phenotypes. 
Conclusions  
Directed inhibition of Debcl results in improved survivorship and extended climbing 
ability whereas the directed overexpression of Debcl results in reduced lifespan and 
impaired locomotor function. These phenotypes are rescued upon co-expression with the 
pro-survival Buffy. The overexpression of Debcl enhances the effects of α-synuclein 
expression. Buffy counteracts Debcl-induced phenotypes, and represents a potential target 
to enhance neuronal survival in response to the detrimental effects of Debcl-induced 
apoptosis. 
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Chapter 4 - The Inhibition of Atg6 and Pi3K59F autophagy genes in 
dopaminergic neurons decreases lifespan and locomotor ability in 
Drosophila melanogaster 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Genetics and Molecular Research 15(4): 
gmr15048953. DOI: 10.4238/gmr15048953 (M’Angale and Staveley, 2016). 
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Abstract 
Autophagy is a cellular mechanism implicated in the pathology of Parkinson’s disease. 
The proteins Atg6 (Beclin 1) and Pi3K59F are involved in autophagosome formation, a 
key step in the initiation of autophagy. We first used the GMR-Gal4 driver to determine 
the effect of reducing the expression of the genes encoding these proteins on the 
developing Drosophila melanogaster eye. Subsequently, we inhibited their expression in 
D. melanogaster neurons under the direction of a Dopa decarboxylase (Ddc) transgene, 
and examined the effects on longevity and motor function. Decreased longevity coupled 
with an age-dependent loss of climbing ability was observed. In addition, we investigated 
the roles of these genes in the well-studied α-synuclein-induced Drosophila model of 
Parkinson’s disease. In this context, lowered expression of Atg6 or Pi3K59F in Ddc-
Gal4-expressing neurons results in decreased longevity and associated age-dependent loss 
of locomotor ability. Inhibition of Atg6 or Pi3K59F together with overexpression of the 
sole pro-survival Bcl-2 Drosophila homolog Buffy in Ddc-Gal4-expressing neurons 
resulted in further decrease in the survival and climbing ability of Atg6-RNAi flies, 
whereas these measures were ameliorated in Pi3K59F-RNAi flies. 
Introduction  
Parkinson disease is the second most common human neurodegenerative disease and is 
characterized by the progressive degeneration and loss of the dopamine-producing 
neurons in the centrally located substantia nigra pars compacta (SNpc) region of the 
brain. PD is marked by severe locomotor dysfunction as well as non-motoric symptoms 
such as autonomic, cognitive and psychiatric deficiencies [1, 2]. Although the majority of 
PD cases are sporadic, familial forms with a genetic link have been identified and studied 
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extensively in model organisms [3, 4]. The first gene to be identified associated with 
familial forms of PD encodes α-synuclein, a small soluble protein predominantly found in 
neural tissues [5-7]. The association of α-synuclein with components of the mitochondria 
is thought to lead to oxidative stress, apoptosis, autophagy and the eventual 
neurodegeneration [8-10]. The link between autophagic dysfunction and aberrant α-
synuclein in the pathogenesis of both sporadic and familial forms of PD has been 
established [11]. The pathogenesis of PD must therefore involve several failed cellular 
mechanisms and the disruption of autophagic homeostasis contributes to the development 
of this neurodegenerative disorder. 
Autophagy is a tightly regulated catabolic mechanism used by eukaryotic cells to degrade 
long-lived proteins and organelles. It is a multi-step pathway with key regulators TOR 
kinase, AMP-activated protein kinase, Bcl-2/Bcl-XL inhibition of the Beclin1/class III 
PI3K complex, p53 tumour suppressor protein among others that respond to the absence 
or presence of nutrients, growth factors, and energy levels [12, 13]. The formation of the 
phagophore marks the initiation of autophagy and the ULK1-Atg13-FIP200 complex is 
pivotal. The nucleation phase of initial phagophore formation requires the interaction of 
the ULK1 complex with the Atg6-interacting complex, composed of Atg6, class III PI3K, 
Vps15 and Atg14L. Stimulation of this complex generates phosphatidylinositol-3-
phosphate that promotes autophagosomal membrane nucleation [12, 14, 15]. This is 
followed by autophagosomal elongation and maturation. The final step is the fusion of the 
autophagosome to the acidic lysosome. 
The Atg6-interacting complex acts in a regulatory step, with Atg6-binding proteins like 
AMBRA1, UVRAG and Bif-1 promoting autophagy and Rubicon and Bcl-2/Bcl-XL 
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inhibiting autophagy. The inhibition of Atg6-dependent autophagy by the anti-apoptotic 
Bcl-2 proteins point to a regulatory role by this important protein family [16]. One way 
this inhibition is thought to occur is when anti-apoptotic Bcl-2 proteins bind to the Bcl-2 
homology 3 (BH3) domain of Atg6 and thus interfering with the initiation of autophagy. 
Another group suggest Bcl-2 proteins affects autophagy only indirectly by the inhibition 
of the pro-apoptotic Bcl-2 proteins Bax and Bak [17]. The sequestration of Atg6 by Bcl-2 
proteins can be reversed by phosphorylation of the Atg6 BH3 domain by the Death 
associated protein (DAP) kinase [18]. Atg6 binds class III PI3K within its Apg6 domain 
to effect its role in vacuolar protein sorting and autophagy [19]. Autophagy is highly 
conserved, with single orthologues of many of the components involved in this 
mechanism present in Drosophila [20, 21]. For example, the Atg6-interaction complex 
seems to be well conserved and is central to autophagy [22, 23]. Orthologues of Atg14L, 
UVRAG, Rubicon and Bcl-2 are present in the fly and may play the same role they do in 
mammals by forming different autophagy regulatory complexes. 
PD is one of the diseases where the breakdown in autophagy has been implicated in the 
pathogenesis. The vesicular nature of Lewy Bodies, the dominant pathological features 
present in surviving neurons of PD patients, has led to the suggestion that the autophagic-
lysosomal pathway contributes to the formation or dissolution of LBs [24, 25]. The 
implication of autophagy in human disease and especially in neurodegenerative disorders 
makes Drosophila an attractive model to study the consequences of altering gene products 
of the autophagy molecules, Atg6 and the class III PI3K or Pi3K59F. The first fly model 
of PD utilized a human transgene of α-synuclein to induce the PD-like symptoms [26] and 
has become one of the most successful model systems to study PD due to recapitulation 
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of the degeneration and loss of DA neurons, age-dependent loss of locomotor ability, 
presence of LB-like inclusions and compromised survival [4]. We determined the effect 
of directed inhibition of Atg6 or Pi3K59F via directed expression of RNAi transgenes in 
the DA neurons of Drosophila. Further Atg6 or Pi3K59F inhibitory transgenes were co-
expressed with α-synuclein to investigate their role in the first Drosophila model of PD. 
As well, loss of function of the autophagy genes were evaluated along with the only pro-
survival Bcl-2 homologue in Drosophila, Buffy. 
Materials and Methods 
Bioinformatic analysis 
The protein sequences were sourced from National Center for Biotechnology Information 
(NCBI) (http://www.ncbi.nlm.nih.gov/protein/) and the domains were identified using the 
NCBI Conserved Domain Database (CDD) (Marchler-Bauer et al. 2015) 
(http://www.ncbi.nlm.nih.gov/cdd) and the Eukaryotic Linear Motif (Dinkel et al. 2016) 
(http://elm.eu.org/) which focuses on annotation and detection of eukaryotic linear motifs 
(ELMs), also known as short linear motifs (SLiMs). A Clustal Omega multiple sequence 
alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/) (Goujon et al. 2010; Sievers et al. 
2011) was used to align sequences and show conservation of the domains in the selected 
organisms. The nuclear export signal (NES) was predicted using the NetNES 1.1 server 
(http://www.cbs.dtu.dk/services/NetNES/) (la Cour et al. 2004). 
Drosophila media and culture 
Stocks and crosses were maintained on a standard medium containing cornmeal, 
molasses, yeast, agar, and water and treated with propionic acid and methylparaben.  
Stocks were maintained on solid media for two to three weeks before transfer onto new 
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media to re-culture.  Stocks were kept at room temperature (22°C ± 2C) while crosses 
and experiments were carried out at 25C and 29C. 
Drosophila stocks and derivative lines 
UAS-α-synuclein [26] was generously provided by Dr. M. Feany of Harvard Medical 
School, UAS-Buffy [27] by Dr. Leonie Quinn of University of Melbourne, and Ddc-Gal4 
[28] by Dr. J. Hirsch of University of Virginia. Atg6-RNAi (w1118; P{GD11647}v22122), 
and Pi3K59F-RNAi (P{KK107602}VIE-260B) were obtained from Vienna Drosophila 
Resource Center. GMR-Gal4 [29] and UAS-lacZ flies were obtained from the 
Bloomington Drosophila Stock Center at Indiana University. The UAS-α-synuclein/CyO; 
Ddc-Gal4/TM3 and UAS-α-synuclein/CyO; GMR-Gal4 were generated using standard 
homologous recombination methods and were used to overexpress α-synuclein in the DA 
neurons or developing eye under the direction of Ddc-Gal4 or GMR-Gal4. The UAS-
Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; GMR-Gal4 lines were used to overexpress 
Buffy in the DA neurons and in the developing eye respectively. PCR reaction was used to 
determine the amplification of DNA products from primers designed from the Homo 
sapiens synuclein, alpha (non A4 component of amyloid precursor) (SNCA), transcript 
variant 1 mRNA, NCBI reference sequence: NM_000345.3 using the NCBI primer 
design tool. The 5’ to 3’ sequence of the forward primer was 
GTGCCCAGTCATGACATTT, while that of the reverse primer was 
CCACAAAATCCACAGCACAC and were ordered from Invitrogen. The Drosophila 
melanogaster Buffy mRNA, NCBI reference sequence: NM_078978.2, was used to 
design a set of Buffy primers that would target both the endogenous and the 
overexpression transcripts. The 5’ to 3’ sequence of the forward primers were 
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CACAGCGTTTATCCTGCTGA and CGGGTGGTGAGTTCCATACT, while that of the 
reverse primers were TCGCAGTGTGAAGATTCAGG and 
TTAATCCACGGAACCAGCTC and were ordered from Eurofins MWG Operon. Gel 
electrophoresis was used for confirmation of recombination events via presence of the 
corresponding PCR product. 
Ageing assay 
Several crosses between five females and three males were made of each genotype and a 
cohort of each adult critical class male flies was collected upon eclosion. At least two 
hundred flies were aged per genotype, at a density of ≤ 20 flies per vial to avoid 
overcrowding. Flies were observed and scored every two days for presence of deceased 
adults [30] and survivors transferred to fresh media.  Longevity data was analysed using 
GraphPad Prism version 5.04 and survival curves were compared using the log-rank 
(Mantel-Cox) test.  Significance was determined at 95%, at a P-value less than or equal to 
0.05 with Bonferroni correction. 
Climbing assay 
A cohort of the adult critical class male flies from each genotype was collected upon 
eclosion and scored for their ability to climb over time [31, 32]. Climbing analysis was 
performed using GraphPad Prism version 5.04, climbing curves were fitted using non-
linear regression and compared using 95% confidence intervals at a 0.05 P-value. 
Scanning electron microscopy of the drosophila eye 
Several single vial matings of five females and three males were made of each genotype 
at 29°C and a group of adult male flies collected upon eclosion and aged for three days 
before being frozen at -80°C. Whole flies were mounted on scanning electron microscope 
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stubs, desiccated overnight and photographed with a FEI Mineral Liberation Analyzer 
650F scanning electron microscope. For each cross at least 10 eye images were analysed 
using the National Institutes of Health (NIH) ImageJ software [33] and biometric analysis 
performed using GraphPad Prism version 5.04. The ratio of disruption of the eye was 
calculated as previously described [34]. Comparisons for statistical analysis were 
performed using one-way ANOVA and Dunnett's multiple comparison test. Significance 
was determined at p<0.05. But briefly, the ratio of disrupted eye area was calculated by 
dividing the total area of the eye with the total disrupted area of the eye. The total 
disrupted area of the eye was the sum of any two or more ommatidia that were fused 
together. 
Results 
Both Atg6 and Pi3K59F are evolutionarily conserved 
Bioinformatic analysis of the protein sequences of Atg6 (also known as Beclin 1) and 
Pi3K59F revealed domains that are remarkably conserved among diverse species, 
signifying the importance of these two autophagy proteins (Figure 1). The Drosophila 
Atg6 protein is comprised of 422 amino acids, and when aligned with human Beclin 1 
which is composed of 450 amino acids, it has 50% identity and 67% similarity and the 
APG6/Vps30 domain is conserved as well as a NES (Figure 1A). A putative non-
canonical BH3 domain is possibly present in Drosophila that could function in inhibiting 
Atg6 as occurs in mammals through sequestration by the pro-survival Bcl-2 proteins 
(Figure 1B). A multiple sequence alignment of the Drosophila Pi3K59F protein with the 
human homologue shows evolutionary conservation in the class III PI3K genes with a 
64% identity and 79% similarity (Figure 1C), with both members possessing the C2, PIK  
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Figure 4.1 The autophagy proteins Atg6 and Pi3K59F are evolutionarily conserved 
(A). Multiple alignment of the Drosophila melanogaster homologue and the human Atg6 
shows conservation of the APG6/Vps30 domain that is important for the initiation of 
autophagy and presence of a NES (Hsap is Homo sapiens NP_003757.1 and Dmel is 
Drosophila melanogaster NP_523702.1). (B) Drosophila possess a putative BH3 domain 
which is conserved with a few amino acid substitutions as Clustal Omega multiple 
sequence alignment [43, 44] of Drosophila Atg6 protein with that of mammalian and 
insect homologues shows (H.sapiens is Homo sapiens NP_003757.1, P.troglodytes is Pan 
troglodytes XP_511522.2, M.musculus is Mus musculus NP_062530.2, R.norvegicus is 
Rattus norvegicus NP_001029289.1, C.quinquefasciatus is Culex quinquefacsiatus 
XP_001861442.1, D.melanogaster is Drosophila melanogaster NP_523702.1 and 
M.domestica is Musca domestica XP_005189450.1). (C) Pi3K59F is highly conserved, 
with both organisms containing the C2, the PIK accessory domain and the kinase catalytic 
domains (Hsap is Homo sapiens NP_002638.2 and Dmel is Drosophila melanogaster 
NP_477133.1). The domains were identified using the NCBI Conserved Domain 
Database Search (CDD) [45]. "*" indicate the residues that are identical, ":" indicate the 
conserved substitutions, "." indicate the semi-conserved substitutions. Colours show the 
chemical nature of amino acids. Red is small hydrophobic (including aromatic), Blue is 
acidic, Magenta is basic, and Green is basic with hydroxyl or amine groups.   
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and the kinase catalytic domains. The Drosophila sequence shows the presence of a NES, 
NLS, several Atg8 binding motifs and a di-Arginine ER retention motif as determined by 
the ELM database [35]. 
The conditional expression of Atg6 or Pi3K59F in the Drosophila developing eye 
results in differing eye phenotypes 
The directed inhibition of Atg6 or Pi3K59F in the developing eye results in a significant 
disruption of the ommatidial array and while the inhibition of Atg6 results in a higher 
mean ommatidia number, that of Pi3K59F result in a lower mean ommatidia number 
(Figure 2A, I-III). The suppression of these two autophagy genes in the developing eye 
result in highly disrupted ommatidia (Figure 2B) and points to a role of these autophagy 
proteins in the normal development of the eye.  
The co-expression of Atg6-RNAi or Pi3K59F-RNAi with α-synuclein-expression in the 
developing eye enhanced the developmental eye defects (Figure 2A, IV-VI). The 
disruption of the ommatidial array is pronounced and the mean number of ommatidia is 
reduced (Figure 2C). These results suggest that the inhibition of Atg6 or Pi3K59F coupled  
with the toxic effects of α-synuclein in the developing eye enhances the developmental 
eye defects. 
Similarly, the co-expression of Atg6 or Pi3K59F with Buffy in the developing eye results 
in a slight increase in the number of ommatidia and a marked decrease in the disruption of 
the ommatidial array (Figure 2A, VII-IX and 2D). 
Inhibition of Atg6 or Pi3K59F in the DA neurons phenocopies PD phenotypes 
The inhibition of Atg6 or Pi3K59F in DA neurons by RNA interference under the control 
of Ddc-Gal4 results in flies with decreased survival (Figure 3A). The median lifespan of
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Figure 4.2 The conditional expression of Atg6 or Pi3K59F in the Drosophila 
developing eye results in differing eye phenotypes 
A) Scanning electron micrographs when Atg6 or Pi3K59F are suppressed in the 
developing eye; (I) GMR-GAL4/ UAS-lacZ, (II) GMR-GAL4/ Atg6-RNAi and (III) GMR-
GAL4/ Pi3K59F-RNAi, or when inhibited along with α-synuclein-expression; IV) UAS-α-
synuclein; GMR-Gal4/ UAS-lacZ, V) UAS-α-synuclein; GMR-Gal4/ Atg6-RNAi, and VI) 
UAS-α-synuclein; GMR-Gal4/ Pi3K59F-RNAi, and when co-expressed with Buffy; VII) 
UAS-Buffy; GMR-Gal4/ UAS-lacZ, VIII) UAS-Buffy; GMR-Gal4/ Atg6-RNAi and IX) 
UAS-Buffy; GMR-Gal4/ Pi3K59F-RNAi. B) Biometric analysis shows a significant 
difference in the number of ommatidia and percent disruption of the ommatidial array, 
with Atg6 flies having a higher mean number of ommatidia whereas Pi3K59F flies had a 
lower mean number of ommatidia compared to the control flies. C) The inhibition of Atg6 
or Pi3K59F with α-synuclein results in lower ommatidial count and a higher percentage 
of eye disruption than the control. D) When Buffy is co-expressed in the eye with Atg6 or 
Pi3K59F, there is an increase in the mean number of ommatidia and the percentage of 
disrupted area of the eye declines compared to the control. Comparisons were determined 
by one-way ANOVA and Dunnett's multiple comparison test (P<0.05), error bars are 
SEM, n=10 and asterisks (*) represent statistical significance.  
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Atg6-RNAi flies was 58 days and 64 days for Pi3K59F-RNAi flies compared to 73 days 
for the control. The directed inhibition of Atg6 or Pi3K59F in DA neurons resulted in 
impaired climbing ability as indicated by the comparison of the climbing curves at 95% 
CI (Figure 3B). This suggests that the inhibition of Atg6 or Pi3K59F decreases longevity 
and climbing ability in Drosophila when expressed in DA neurons and thus, normal levels 
of these proteins are required for the normal functioning of DA neurons. 
Inhibition of Atg6 or Pi3K59F in the α–synuclein-induced PD model alters survival 
and climbing ability 
The overexpression of α-synuclein in DA neurons results in flies that have impaired 
climbing ability and a shortened lifespan, the inhibition of Atg6 or Pi3K59F in DA 
neurons of flies expressing α-synuclein slightly altered lifespan and locomotor ability 
(Figure 4A and 4B). Atg6-RNAi flies had a median lifespan of 56 days same as Pi3K59F-
RNAi flies compared to the controls at 62 days. The nonlinear fitting of the curves with 
95% CI determined that the rate of climbing was not statistically different between the  
Atg6-RNAi or Pi3K59F-RNAi flies when compared to the control, though the climbing 
indices were slightly lower than the ones obtained from the controls. This suggests that  
inhibition of the autophagy genes appears to slightly modify the phenotypes present when 
α-synuclein is expressed in the DA neurons of Drosophila. 
Co-expression of Atg6 or Pi3K59F with Buffy suppresses the Pi3K59F–induced 
phenotypes 
The co-expression of Atg6-RNAi or Pi3K59F-RNAi with the pro-survival Bcl-2 
homologue in Drosophila, Buffy, results in an enhanced loss of Atg6-induced phenotypes 
and a suppression of the loss of Pi3K59F-induced phenotypes (Figure 5). The 
overexpression of Buffy with Atg6-RNAi resulted in reduced survival with a median
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Figure 4.3 Inhibition of Atg6 or Pi3K59F in the DA neurons phenocopies PD-like 
phenotypes 
A) Directed inhibition of Atg6 or Pi3K59F in the DA neurons directed by Ddc-Gal4 
results in a decrease in survival compared to the control flies overexpressing UAS-lacZ. 
The genotypes are Ddc-GAL4/ UAS-lacZ, Ddc-GAL4/ Atg6-RNAi and Ddc-GAL4/ 
Pi3K59F-RNAi. Longevity is shown as percent survival P < 0.05, determined by the log-
rank (Mantel-Cox) test and n≥200). B) The inhibition of Atg6 or Pi3K59F in the DA 
neurons resulted in a significant decrease in climbing ability as determined by non-linear 
fitting of the climbing curves and comparing 95% confidence intervals. The genotypes 
are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ Atg6-RNAi and Ddc-Gal4/Pi3K59F-RNAi. Error 
bars indicate SEM and n=50. 
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Figure 4.4 Inhibition of Atg6 or Pi3K59F in the α–synuclein-induced PD model does 
not alter impaired survival and climbing ability 
A) The inhibition of Atg6 or Pi3K59F along with α-synuclein-expression in the DA 
neurons did not alter median lifespan when compared to the controls. Genotypes are UAS-
α-synuclein; Ddc-Gal4/ UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ Atg6-RNAi and UAS-α-
synuclein; Ddc-Gal4/ Pi3K59F-RNAi. Longevity is shown as percent survival, P < 0.05, 
determined by log-rank (Mantel-Cox) test with n≤200. B) The co-expression of Atg6-
RNAi or Pi3K59F-RNAi in the α-synuclein-induced model of PD did not result in any 
significant age-dependent loss in climbing ability compared to the control. The genotypes 
are UAS-α-synuclein; Ddc-Gal4/ UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ Atg6-RNAi and 
UAS-α-synuclein; Ddc-Gal4/ Pi3K59F-RNAi. Error bars indicate SEM and n=50. 
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lifespan of 46 days compared to 66 days for the control (Figure 5A). The impaired 
climbing ability was enhanced in these flies as determined by the nonlinear fitting of the 
climbing curves and compared at 95% CI (Figure 5B). This is possibly due to the 
interaction of Buffy with the BH3 domain of Atg6 and further restricting the activity of 
Atg6 in the initiation of autophagy. Interestingly, the co-expression of Pi3K59F with 
Buffy results in a suppression of the phenotypes observed of reduced survival and 
climbing ability. The median lifespan of these flies was 66 days compared to 66 days in 
the controls (Figure 5A). The climbing ability of these flies improved to normal levels 
when the climbing curves were compared with the control (Figure 5B). 
Discussion 
The biometric analysis of the Drosophila eye when Atg6 or Pi3K59F was inhibited shows 
significant differences in the eye phenotypes. The inhibition of Atg6 results in a 
significant increase in the number of ommatidia and the disrupted area of the eye. 
Alternatively, when Pi3K59F is inhibited, there is a reduction in the number of 
ommatidia but with a high degree of degeneration of the ommatidial array. Though these 
two autophagy proteins are known to form the same complex, it is possible that when 
exclusively conditionally inhibited, they may have differing effects on the developing 
eye. Altered Atg6 or Pi3K59F expression in the α-synuclein-expressing developmental 
eye defects model resulted in an enhanced phenotype. Both genes resulted in a depressed 
ommatidia number and highly degenerated ommatidial array. It is interesting that the 
effect of inhibiting Atg6 or Pi3K59F in an α-synuclein background is the worsening of 
the phenotype in the developing eye, a trend that we did not observe in the DA neurons.   
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Figure 4.5 Co-expression of Atg6 or Pi3K59F with Buffy suppresses the loss of 
Pi3K59F-induced phenotypes and enhances the loss of Atg6-induced phenotypes 
A) The co-expression of Buffy with Atg6-RNAi enhanced the suppression of Atg6-induced 
decrease in survival whereas the co-expression of Buffy with Pi3K59F-RNAi resulted in 
suppression of reduced median survival. Genotypes are UAS-Buffy; Ddc-Gal4/UAS-lacZ, 
UAS-Buffy; Ddc-Gal4/ Atg6-RNAi, and UAS-Buffy; Ddc-Gal4/ Pi3K59F-RNAi. B) The 
co-expression of Atg6-RNAi with Buffy in the DA neurons result in an enhancement of the 
age-dependent loss in climbing ability. Alternatively, the co-expression of Pi3K59F-RNAi 
with Buffy result in the suppression of the age-dependent loss in climbing ability when 
compared to the control. The genotypes are UAS-Buffy; Ddc-Gal4/UAS-lacZ, UAS-Buffy; 
Ddc-Gal4/ Atg6-RNAi, and UAS-Buffy; Ddc-Gal4/ Pi3K59F-RNAi. Error bars indicate 
SEM and n=50.  
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The toxic effects of α-synuclein in the developing eye are well documented [26], and 
shows that the toxic effects of α-synuclein in the eye is additive with a worsening eye 
phenotype with additional assaults [34]. It seems therefore, that the inhibition of the 
autophagy genes Atg6 or Pi3K59F in tandem with α-synuclein expression produces 
severe eye degeneration. The co-expression of the Bcl-2 protein Buffy with Atg6-RNAi or 
Pi3K59F-RNAi resulted in increased ommatidia number and a reduction in disruption of 
the eye. Interestingly, the inhibition of Pi3K59F in the developing eye results in reduced 
ommatidia number, contrary to when co-expressed with Buffy, the number of ommatidia 
increases but the degeneration of the eye worsens tremendously. Similarly, the inhibition 
of Atg6 in the developing eye result in increased ommatidia number and co-expression 
with Buffy results in a similar ommatidia count and percent disruption of the eye. 
The conditional expression of Atg6 or Pi3K59F in the DA neurons of Drosophila 
melanogaster result in reduced survival and an age-dependent loss in climbing ability, 
phenotypes associated with Drosophila models of PD. The reduction of Atg6 and 
Pi3K59F activity in the dopamine producing neurons may be detrimental to the health of 
these flies that manifest PD-like symptoms. Atg6 and Pi3K59F are involved in the 
nucleation phase of autophagy in the formation of the autophagosome [12]. The inhibition 
of these two important autophagy proteins may lead to decreased autophagic activity and 
further degeneration of the DA neurons.  
When α-synuclein is overexpressed in the DA neurons, it leads to locomotor impaired 
flies. In previous studies, the accumulation of α-synuclein in Lewy Bodies and Lewy 
Neurites has been attributed to failure of the UPS degradation system [36] but recent 
studies show α-synuclein could be degraded by the lysosomal pathway and especially 
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autophagy and chaperone-mediated autophagy (CMA) [13, 15, 37]. The co-expression of 
Atg6 or Pi3K59F with α-synuclein does not alter longevity and climbing ability when 
compared to α-synuclein-expressing flies. The inhibition of autophagy leads to the 
accumulation of α-synuclein demonstrating an important role in normal α-synuclein 
turnover [38]. The post-translational modifications of α-synuclein interferes with its 
degradation by CMA, the degradation of other products by CMA [39] and inhibition of an 
early point in autophagosome formation [40]. The evidence obtained point to an already 
compromised autophagy system and as such the toxicity of α-synuclein and the α-
synuclein-induced phenotypes are not worsened by reducing the activity of the autophagy 
system. 
The Bcl-2 family of proteins bind Atg6, a BH3-only protein, in a multimeric complex that 
is involved in vesicle nucleation stage of the autophagosome formation. The discovery of 
the BH3 domain, a binding site for interaction between the antiapoptotic Bcl-2 proteins 
and required for inhibition, in Atg6 showed that not only do Bcl-2 proteins regulate 
apoptosis, but function as anti-autophagic proteins [41]. Bcl-2 proteins seem to play a 
crucial role in maintaining autophagic homeostasis since phosphorylation of Atg6 that 
weakens this interaction promote autophagy [18].  Atg6 has a binding site for Pi3K59F 
and it is this interaction that leads to the production of phosphoinositol-3-phosphate that 
is pivotal to the nucleation process [19]. The overexpression of the Bcl-2 homologue 
Buffy with Atg6-RNAi resulted in the worsening of survival and climbing ability in Atg6 
flies but interestingly rescues the inhibition of Pi3K59F-induced phenotypes. Taken 
together, these results suggest enhanced Atg6-induced phenotypes and suppression of the 
Pi3K59F-induced phenotypes by Buffy. Since Bcl-2 proteins have been shown to block 
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Atg6-dependent autophagy by inhibiting the formation of the Atg6/Pi3K59F complex 
[42], we are inclined to theorize that Buffy plays a similar role in Drosophila 
melanogaster. Excessive levels of autophagy lead to cell death, and as such Buffy may 
act to balance the levels of autophagy via the Atg6 pathway to remove dysfunctional 
mitochondria, counteracting the PD-like symptoms in Drosophila. The accumulation of α-
synuclein promotes excessive levels of autophagy leading to removal of mitochondria, 
and it is possible that once most neurons are depleted of mitochondria, synaptic function 
is interrupted. 
Conclusions 
The inhibition of either Atg6 or Pi3K59F result in reduced longevity and impaired 
locomotor function, possibly a novel model of PD. It will be important to establish the 
function of these proteins other than in autophagy so as to further understand their 
function. Buffy, like most pro-survival Bcl-2 proteins, shows anti-autophagic tendencies 
by worsening the phenotypes of the inhibition of Atg6 or Pi3K59F. It is yet unclear how 
Buffy effects this response, but it might interact with the putative BH3 domain of Atg6, 
disrupting the formation of the Atg6/Pi3K59F complex that is key to the initiation of 
autophagy. Further studies are required to elucidate the roles of Atg6, Pi3K59F, and 
Buffy in the autophagy–lysosome pathway. 
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Chapter 5 - The HtrA2 Drosophila model of Parkinson Disease is 
suppressed by the pro-survival Bcl-2 Buffy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Genome 60 (1): 1 – 7 DOI: 10.1139/gen-
2016-0069 (M’Angale and Staveley, 2017). 
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Abstract 
Mutations in High temperature requirement A2 (HtrA2), also designated PARK13, which 
lead to the loss of its protease activity have been associated with Parkinson disease (PD). 
HtrA2 is a mitochondrial protease that translocates to the cytosol upon the initiation of 
apoptosis where it participates in the abrogation of inhibitors of apoptosis (IAP) inhibition 
of caspases. Here we demonstrate that the loss of the HtrA2 function in the dopaminergic 
neurons of Drosophila melanogaster results in PD-like phenotypes and we attempt to 
restore the age-dependent loss in locomotor ability by co-expressing the sole pro-survival 
Bcl-2 homologue Buffy. The inhibition of HtrA2 in the dopaminergic neurons of 
Drosophila resulted in shortened lifespan and impaired climbing ability and the 
overexpression of Buffy rescued the reduction in lifespan and the age-dependent loss of 
locomotor ability. In supportive experiments, the inhibition of HtrA2 in the Drosophila 
eye results in eye defects, marked by reduction in ommatidia number and increased 
disruption of the ommatidial array; phenotypes that are suppressed by the overexpression 
of Buffy. 
Introduction 
Loss of function mutations in High temperature requirement A2 (HtrA2; also known as 
Omi), a mitochondrial localized serine protease, are linked to Parkinson disease (PD) [1]. 
HtrA2 encodes a nuclear protein with a mitochondrial targeting signal at the amino-
terminus, that appears to be related to the Drosophila Reaper, Hid and Grim pro-apoptotic 
proteins due to the presence of the inhibitor of apoptosis (IAP) inhibitory Reaper-like 
motif [2]. The HtrA2 protein is released into the cytosol from the mitochondria during 
  
137 
 
apoptosis to bind IAPs and thus block the inhibition of caspases [3]. The binding of 
HtrA2 to IAPs activates the protease function. 
A common facet of Parkinson disease (PD) is mitochondrial dysfunction and the loss of 
mitochondrial Complex I function in the midbrain of PD patients highlights the 
importance of the mitochondria in the pathology [4-6]. A role for HtrA2 in 
neurodegeneration has been established through an association with the autosomal 
dominant early onset Alzheimer disease gene presenilin [7]. As well, the amyloid β 
protein interacts with the HtrA2 protein [8].  The motor neuron degeneration (mnd2) 
disorder in mice is caused by a loss-of-function mutation in the protease-domain encoding 
region of HtrA2 [9]. Further studies in mice showed a link between altered expression of 
HtrA2 and PD-like neurodegeneration [10]. This protein seems to play an important role 
in cellular protection in response to stress. 
In Drosophila melanogaster, the HtrA2 serine protease has been shown to function in 
apoptosis through the cleavage of IAP1 in the vicinity of the mitochondria [11-13]. 
Modelling of PD in Drosophila is robust and has been insightful in understanding the role 
of several PD-linked genes in disease pathology [14-16]. The links between HtrA2 and 
other PD-linked genes has been demonstrated in both mammals and the fly, including the 
Pink1 kinase [17, 18] and the E3 ubiquitin ligase, parkin [18, 19]. The link between 
HtrA2 and the Pink1/Parkin pathway has been challenged by an in vivo study that relied 
on a loss of function [20]. Whether HtrA2 functions downstream of the Pink1/Parkin 
pathway or if it affects mitochondrial homeostasis, the loss of its protease activity is 
known to lead to neuronal degeneration. 
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We demonstrate that an age-dependent loss in locomotor function, accompanied by a 
reduction in lifespan, results when HtrA2 is inhibited in the DA neurons of Drosophila, 
which corroborates previous studies [19]. In addition, the overexpression of the anti-
apoptotic Bcl-2 homologue Buffy has been shown to restore healthspan in a disease model 
[21]. Here, we report inhibition of HtrA2 along with overexpression of the sole pro-
survival Bcl-2 homologue Buffy. 
Materials and methods 
Drosophila media and culture 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben. Stocks were maintained on solid media 
and kept at room temperature (22°C ± 2°C) while crosses and experiments were carried 
out at 25°C and 29°C. 
Drosophila stocks and derivative lines 
UAS-Buffy [22] was provided by Dr. Leonie Quinn (University of Melbourne) and Ddc-
Gal4 [23] by Dr. J. Hirsch of University of Virginia. w1118; P{GD13932}cv24104 referred 
to as HtrA2-RNAi was obtained from Vienna Drosophila Resource Center, GMR-Gal4 
[24] and UAS-lacZ flies were acquired from the Bloomington Drosophila Stock Center at 
Indiana University. The GMR-Gal4; UAS-Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; 
GMR-Gal4 were generated using standard homologous recombination methods and were 
used for overexpression of Buffy in DA neurons using the Ddc-Gal4 transgene or in the 
developing eye using the GMR response elements. PCR reactions and gel electrophoresis 
were used for analysis of recombination events. 
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Ageing assay 
Several single-vial matings were carried out to produce a cohort of critical class male flies 
that were collected upon eclosion. At least two hundred flies were aged per genotype at a 
density of 20 or fewer flies per vial to avoid crowding on fresh media replenished every 
other day. Flies were observed and scored every two days for the presence of deceased 
adults. Flies were considered dead when they did not display movement upon agitation 
[25]. Longevity data was analysed using the GraphPad Prism version 5.04 and survival 
curves were compared using the log-rank (Mantel-Cox) test. Significance was determined 
at 95%, at a P-value less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
Cohort of critical class male flies was collected upon eclosion and scored for their ability 
to climb during their lifetime [26, 27]. Every 7 days, 50 males from every genotype were 
assayed for their ability to climb 10 centimetres in 10 seconds in a clean climbing 
apparatus in ten repetitions. Analysis was performed using the GraphPad Prism version 
5.04 and climbing curves were fitted using non-linear regression and compared using 
95% confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the drosophila eye 
Several single-vial matings were made at 29o C, a cohort of adult male flies collected 
upon eclosion and aged for three days before being frozen at -80o C. Whole flies were 
mounted on scanning electron microscope stubs, desiccated overnight and photographed 
with a FEI Mineral Liberation Analyzer 650F scanning electron microscope. For each 
cross at least 10 eye images were analysed using the National Institutes of Health (NIH) 
ImageJ software [28] and biometric analysis performed using GraphPad Prism version 
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5.04. The percent area of eye disruption was calculated as previously described [29]. The 
ratio of disrupted eye area was calculated by dividing the total area of the eye with the 
total disrupted area of the eye. The total disrupted area of the eye was the sum of any two 
or more ommatidia that were fused together. Statistical analyses were performed using 
one-way ANOVA and Dunnett's multiple comparison test at p<0.05. 
Results 
The HtrA2 protease and PDZ domains are highly conserved 
The Drosophila and human protein sequences have a 52% identity and 70% similarity 
along their full length as determined by NCBI BLAST comparison, the two domains, 
Trypsin and PDZ are highly conserved as determined by an NCBI conserved domain 
search [30] (Figure 1). An ELM resource search for functional sites [31] indicates the 
presence of an inhibitor of apoptosis binding motif (IBM) that function in the abrogation 
of caspase inhibition by IAPs, three different di-Arginine ER retention motifs, an Atg8 
binding motif and a possible NLS. TargetP [32] shows a pre-sequence cleavage site at the 
17th amino acid in Drosophila and the 45th amino acid in the human version. 
Inhibition of HtrA2 results in an age-dependent loss in locomotor ability 
The inhibition of HtrA2 in the DA neurons results in shortened lifespan and impaired 
climbing ability with a median survival of 58 days compared to 75 days for the lacZ 
controls as determined by Log-rank (Mantel-Cox) test (Figure 2A). The directed 
inhibition of HtrA2 in the DA neurons produces flies with significantly impaired climbing 
ability as determined by the nonlinear fitting of the climbing curves (Figure 2B). These 
results suggest an important role for HtrA2 in the normal functioning of DA neurons in 
Drosophila. 
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Figure 5.1 The protease and PDZ domains are conserved in human and Drosophila 
HtrA2 
The Drosophila melanogaster HtrA2 isoform B gene encodes a protein comprised of 422 
amino acids and contains a presequence cleavage site, trypsin and PDZ domains. 
Domains are highly conserved in the organisms compared as determined by the NCBI 
Conserved Domain Database Search (CDD) [30] and the Eukaryotic Linear Motif 
resource search [33]. A Clustal Omega multiple sequence alignment [34, 35] show 
conservation of the trypsin and PDZ domains (Hsap is Homo sapiens NP_037379.1, 
Mmus is Mus musculus NP_062726.3, Dmel is Drosophila melanogaster 
NP_001262565.1 and Agam is Anopheles gambiae XP_310886.5). "*" indicate the 
residues that are identical, ":" indicate the conserved substitutions, "." indicate the semi-
conserved substitutions. Colours show the chemical nature of amino acids. Red is small 
hydrophobic (including aromatic), Blue is acidic, Magenta is basic, and Green is basic 
with hydroxyl or amine groups. 
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Figure 5.2 Loss of HtrA2 activity in DA neurons shortens lifespan and retards 
climbing ability 
A) The inhibition of HtrA2 in DA neurons using the Ddc-Gal4 transgene results in 
decreased median lifespan when compared to control flies expressing UAS-lacZ. The 
genotypes are Ddc-Gal4/ UAS-lacZ and Ddc-Gal4/ UAS-HtrA2-RNAi. Longevity is 
shown as percent survival (P < 0.05, determined by the log-rank (Mantel-Cox) test and 
n≥200). B) The inhibition of HtrA2 in the DA neurons resulted in a significant decline in 
climbing ability as determined by nonlinear fitting of the climbing curves and comparing 
95% CI. The genotypes are Ddc-Gal4/ UAS-lacZ and Ddc-Gal4/ UAS-HtrA2-RNAi. Error 
bars indicate SEM and n=50.   
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HtrA2 loss of function phenotypes are rescued by overexpression of pro-survival 
Buffy 
The overexpression of the pro-survival Bcl-2 homologue Buffy along with the suppression 
of HtrA2 result in increased lifespan and improved climbing ability (Figure 3A and 3B). 
The co-expression of Buffy with HtrA2-RNAi resulted in increased median survival of 68 
days when compared to Buffy control flies with median survival of 65 days as determined 
by Log-rank test (Figure 3A). The climbing ability of the HtrA2-RNAi flies was improved 
as determined by comparison of the climbing curves at 95% CI (Figure 3B). These results 
suggest a pro-survival role for Buffy; by increasing the general healthspan of HtrA2-RNAi 
flies. 
Inhibition of HtrA2 in the eye decreases ommatidia number and increases 
degeneration, phenotypes that are rescued upon Buffy overexpression 
The inhibition of HtrA2 in the eye under the control of the GMR-Gal4 transgene, results 
in decreased ommatidia number and significant disruption of the ommatidial array 
(Figure 4A, II and 4B, I) as determined by an unpaired T-test p<0.0001. The 
overexpression of Buffy along with the inhibition of HtrA2 restored the number of 
ommatidia and the percentage disruption to control levels as determined by an unpaired 
T-test, p>0.50 (Figure 4A, III and 4B, II). Taken together, these results suggest that loss 
of HtrA2 activity is detrimental to normal development of the Drosophila eye and that 
Buffy suppresses the developmental eye defects that result from this inhibition. 
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Figure 5.3 HtrA2 loss of function phenotypes are suppressed by overexpression of 
Buffy 
A) The co-expression of Buffy with HtrA2-RNAi result in the suppression of the observed 
phenotype of decreased survival when compared to the control. Genotypes are Ddc-Gal4 
UAS-Buffy/ UAS-lacZ and Ddc-Gal4 UAS-Buffy/ UAS-HtrA2-RNAi. Longevity is shown 
as percent survival (P < 0.05, determined by log-rank (Mantel-Cox) test with n≤200). B) 
The inhibition of HtrA2 along with the overexpression of Buffy in the DA neurons results 
in the suppression of the age-dependent loss in climbing ability. The genotypes are Ddc-
Gal4 UAS-Buffy/ UAS-lacZ and Ddc-Gal4 UAS-Buffy/ UAS-HtrA2-RNAi. Analysis was 
done by nonlinear fitting of the climbing curves and significance was determined by 
comparing the 95% CI. Error bars indicate SEM and n=50. 
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Figure 5.4 HtrA2-induced eye phenotypes are suppressed upon Buffy overexpression 
A) Scanning electron micrographs when HtrA2 is inhibited in the eye and co-expressed 
along with either α-synuclein or Buffy. The genotypes are (I) GMR-Gal4/ UAS-lacZ; (II) 
GMR-Gal4/ UAS-HtrA2-RNAi; and (III) UAS-Buffy; GMR-Gal4/ UAS-HtrA2-RNAi. B) 
Biometric analysis when I) HtrA2 is inhibited in the eye indicated decreased ommatidia 
number and higher percentage of ommatidial disruption when compared to the control. II) 
The overexpression of Buffy results in restoration of the number of ommatidia and degree 
of ommatidial disruption to control levels. The genotypes are UAS-Buffy; GMR-Gal4/ 
lacZ and UAS-Buffy; GMR-Gal4/ UAS-HtrA2-RNAi Comparisons were determined by 
unpaired two-tailed T-test (P<0.05), error bars are SEM, asterisks (*) represent statistical 
significance and n=10.  
  
146 
 
Discussion 
The loss of protease function [1] or mutations in the PDZ domain [36] of PARK13/ 
HtrA2 confers susceptibility to PD, and disruption of HtrA2 was found to cause 
neurodegeneration and PD-like phenotypes in mice [10]. In corroborative experiments 
[19], when we inhibited HtrA2 in DA neurons of Drosophila using the dopa 
decarboxylase transgene, it resulted in a marked decline in survival and led to premature 
loss in locomotor function. HtrA2 is involved in cell death, the deletion of this gene in 
mice did not alter cell death rates, instead, suffered loss of a population of neurons in the 
striatum leading to neurodegeneration [10]. Studies suggest that the primary role of 
HtrA2 in neurons is protection against stress [19, 36]. The inhibition of HtrA2 in DA 
neurons resulted in flies with poor healthspan, they had shortened lifespans and lost their 
climbing ability prematurely. HtrA2 seems to have a special neuroprotective function 
since loss in its protease or PDZ domain activity, or its deletion or inhibition seems to 
lead to neurodegeneration. Interestingly, the inhibition of HtrA2 in the eye resulted in 
fewer number of ommatidia and worsening of the rough eye phenotype. It seems the 
neuroprotective functions of this protein are not limited to DA neurons specifically, but 
general neuroprotection.  
The functional HtrA2 acts in the vicinity of the mitochondria in Drosophila [11], further 
showing the importance of the mitochondria in cell death and aetiology of PD. In 
mammals HtrA2 is involved in a p53-dependent cell death pathway [37], but its role in 
Drosophila is an elusive one. In our experiments, the overexpression of the sole  
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pro-survival Bcl-2 homologue in Drosophila, Buffy [22], along with the inhibition of 
HtrA2 counteracted the loss of HtrA2-induced phenotypes. These flies had an increase in 
lifespan that was augmented by improved locomotor ability suggesting a protective role 
for Buffy. The HtrA2 null mutants in Drosophila do not exhibit mitochondrial 
morphological defects [20], though this does not exclude mitochondrial dysfunction. The 
study also did not find DA neuronal loss or muscle degeneration. Though the loss of DA 
neurons in Drosophila has remained a contentious issue as regards models of Parkinson 
disease [14, 16], there is consensus on PD-like phenotypes such as loss in locomotor 
ability. A lack of loss in DA neurons does not exclude degeneration and the progression 
of PD-like phenotypes in Drosophila. We have previously shown that the overexpression 
of Buffy suppresses the α-synuclein-induced PD-like phenotypes [21]. Therefore, the 
alleviation of HtrA2-induced phenotypes by overexpression of the pro-survival Buffy may 
be a general survival pathway signal or may be a specific HtrA2-dependent response. We 
obtained similar results when Buffy was overexpressed in the eye along with HtrA2-RNAi, 
with restored ommatidia number and decreased disruption of the ommatidial array. It 
seems that this serine protease functions in survival since its inhibition results in 
compromised healthspan, and the overexpression of the pro-survival Buffy rescues the 
phenotypes. 
In conclusion, the overexpression of the pro-survival Bcl-2 homologue Buffy along with 
the inhibition of HtrA2 suppresses the HtrA2-induced phenotypes of shortened lifespan, 
locomotor dysfunction and small roughened eye. 
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Supplementary results 
The co-expression of HtrA2-RNAi along with α-synuclein shortens lifespan and 
slightly enhances loss in locomotor ability 
The suppression of HtrA2 along with the expression of α-synuclein in DA neurons results 
in shortened lifespan but does not worsen the compromised climbing ability observed 
(Figure 5). These flies had a median survival of 56 days when compared to the α-
synuclein expression controls at 60 days as determined by log-rank test (Figure 5A). A 
non-linear fit of the climbing curves indicates no significance difference when the CI are 
compared at 95% (Figure 5B). These results show that the combined effects of the pro-
apoptotic HtrA2 and the expression of α-synuclein in DA neurons compromises lifespan. 
The expression of α-synuclein along with the inhibition of HtrA2 enhances the eye 
phenotypes 
The expression of α-synuclein along with the inhibition of HtrA2 in the developing eye 
results in further depression of the eye phenotypes, with a reduction in ommatidia number 
and an increase in ommatidial disarray as determined by an unpaired T-test (Figure 6A 
and 6B). 
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Figure 5-5 The co-expression of HtrA2-RNAi along with α-synuclein shortens 
lifespan but does not worsen locomotor ability 
A) The directed inhibition of HtrA2 along with α-synuclein expression in the DA neurons 
shortened lifespan when compared to the control. Genotypes are UAS-α-synuclein; Ddc-
Gal4/ UAS-lacZ and UAS-α-synuclein; Ddc-Gal4/ UAS-HtrA2-RNAi. Longevity is shown 
as percent survival (P < 0.05, determined by log-rank (Mantel-Cox) test with n≤200). B) 
The co-expression of HtrA2-RNAi with α-synuclein resulted in a slight decrease in age-
dependent loss in climbing ability compared to the control. The genotypes are UAS-α-
synuclein; Ddc-Gal4/ UAS-lacZ and UAS-α-synuclein; Ddc-Gal4/ UAS-HtrA2-RNAi. 
Analysis was done by nonlinear fitting of the climbing curves and significance was 
determined by comparing the 95% CI. Error bars indicate SEM and n=50. 
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Figure 5-6 HtrA2-induced eye phenotypes are enhanced upon α-synuclein expression 
A) Scanning electron micrographs when HtrA2 is inhibited in the eye and co-expressed 
along with either α-synuclein or Buffy. The genotypes are (I) GMR-Gal4/ UAS-lacZ; and 
(II) UAS-α-synuclein; GMR-Gal4/ UAS-HtrA2-RNAi. B) Biometric analysis of the 
inhibition of HtrA2 along with α-synuclein expression result in worsened eye phenotypes 
when compared to controls. The genotypes are UAS-α-synuclein; GMR-Gal4/ UAS-lacZ 
and UAS-α-synuclein; GMR-Gal4/ UAS-HtrA2-RNAi. Comparisons were determined by 
unpaired two-tailed T-test (P<0.05), error bars are SEM, asterisks (*) represent statistical 
significance and n=10. 
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Chapter 6 - The anti-apoptotic Bax-inhibitor-1 family in Drosophila 
melanogaster  
Overview 
The Bax inhibitor-1 family or the transmembrane Bax inhibitor-1 motif containing 
(TMBIM) family members are key regulators of cell death. It consists of at least six 
members that are found in a wide range of organisms, from bacteria, yeast, plants and 
animals. They contain at least six membrane-spanning domains and are found in a variety 
of cellular organelles such as the ER membrane localized Bax inhibitor-1 (Chapter 6A), 
the integral membrane Lifeguard (Chapter 6B), and the mitochondrial localized Growth 
hormone-inducible transmembrane protein (GHITM) (Chapter 6C). We sought to 
determine the effect of the inhibition of these three Drosophila homologues in the 
dopaminergic and other neurons, and investigated whether the pro-survival Bcl-2 
homologue Buffy could counteract the induced phenotypes. In the case of Lifeguard and 
GHITM, we sought to additionally, via bioinformatics, to characterize the Drosophila 
homologues. Our findings are discussed in the following three subsections of the chapter. 
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Bax-inhibitor-1 knockdown phenotypes are suppressed by Buffy and 
exacerbate degeneration in a Drosophila model of Parkinson disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been accepted for publication in PeerJ (M’Angale and 
Staveley, 2016). 
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Abstract 
Bax inhibitor-1 (BI-1) is an integral transmembrane protein that acts as a suppressor of 
Bax-induced apoptosis by regulation of endoplasmic reticulum (ER) stress-induced cell 
death. The gene is evolutionarily conserved, being found in diverse organisms that 
include yeast, Arabidopsis, Drosophila, mouse and humans. BI-1 is implicated in the 
regulation of calcium levels, reactive oxygen species, apoptosis, autophagy and ER stress 
signalling pathways. BI-1 is cytoprotective and its dysregulation result in disruption of 
cellular homeostasis and disease. We inhibited BI-1 in the sensitive dopa decarboxylase 
(Ddc) expressing neurons of Drosophila melanogaster to investigate its neuroprotective 
functions. We used organismal assays to assess longevity of the flies to determine the 
effect of the altered expression of BI-1 in the Ddc-Gal4-expressing neurons by employing 
two RNAi transgenic fly lines. We measured the locomotor ability of these RNAi lines by 
computing the climbing indices of the climbing ability and compared them to a control 
line that expresses the lacZ transgene. Finally, we performed biometric analysis of the 
developing eye, where we counted the number of ommatidia and calculated the area of 
ommatidial disruption. The inhibition of BI-1 in these neurons was achieved under the 
direction of the Ddc-Gal4 transgene and resulted in shortened lifespan and precocious 
loss of locomotor ability, phenotypes that appear to be strongly associated with the 
degenerative loss of dopaminergic neurons. BI-1 interacts with anti-apoptotic Bcl-2 
family members and, co-expression of Buffy, which encodes the sole anti-apoptotic Bcl-2 
protein in Drosophila, with BI-1-RNAi results in suppression of the reduced lifespan and 
impaired climbing ability. Expression of human α-synuclein in Drosophila dopaminergic 
neurons results in neuronal degeneration, accompanied by the age-dependent loss in 
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climbing ability. We exploited this neurotoxic system to investigate possible BI-1 
neuroprotective function. The co-expression of α-synuclein with BI-1-RNAi results in a 
slight decrease in lifespan coupled with an impairment in climbing ability. In supportive 
experiments, we employed the neuron-rich Drosophila compound eye to investigate 
subtle phenotypes that result from altered gene expression. The inhibition of BI-1 in the 
Drosophila developing eye under the direction of the GMR-Gal4 transgene results in 
reduced ommatidia number and increased disruption of the ommatidial array. Similarly, 
the co-expression of BI-1-RNAi with Buffy results in the suppression of the eye 
phenotypes. The expression of α-synuclein along with the inhibition of BI-1 resulted in 
reduction of ommatidia number and a higher degree of disruption of the ommatidial array. 
Inhibition of BI-1 in the dopaminergic neurons of Drosophila results in a shortened 
lifespan and premature loss in climbing ability, phenotypes that appear to be strongly 
associated with models of Parkinson disease in Drosophila, and which are suppressed 
upon overexpression of Buffy and worsened by co-expression with α-synuclein. This 
suggests that BI-1 is neuroprotective and its inhibition can be counteracted by the 
overexpression of the pro-survival Bcl-2 homologue. 
Introduction 
Bax inhibitor-1 (BI-1) belongs to a diverse group of proteins, known as Transmembrane 
Bax Inhibitor-1 Motif-containing (TMBIM) family [1-4], that have been determined to be 
regulators of cell death. A different nomenclature categorizes these proteins into the LFG 
family, adopted from the family member Lifeguard [5], which consists of at least six 
highly conserved members in a wide range of organisms [2, 6, 7]. These regulators of cell 
death, accomplish this role by the regulation of the death receptor, modulation of the 
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endoplasmic reticulum (ER) calcium homeostasis, ER stress signalling pathways, 
autophagy, reactive oxygen species (ROS) production, cytosolic acidification and, other 
cellular activities [3, 4]. The founding member of this group is BI-1, or TMBIM6 also 
known as testis enhanced gene transcript (TEGT), and has been demonstrated to inhibit 
the effect of Bax-induced cell death [8, 9]. Members of this protein family possess a BI-1-
like domain with six to seven transmembrane-spanning regions that are strongly 
associated with the ER membranes [9-11]. BI-1 is highly conserved across diverse species 
with eukaryotic homologues of BI-1 able to block Bax-induced cell death when expressed 
in yeast [7], thus implying it regulates an evolutionarily conserved cytoprotective 
pathway.  
This protein though not structurally related to the B cell lymphoma 2 family of proteins, 
forms a complex with the pro-survival members Bcl-2 and Bcl-XL but not with Bax or 
Bak [9, 12]. Therefore, it is likely the anti-apoptotic activity of BI-1/TMBIM6 is mediated 
by interaction with pro-survival members of the Bcl-2 family and acts downstream of 
Bcl-XL [13]. BI-1 deficient cells, that include neurons, are more sensitive to apoptosis 
induced by ER stress and has been linked to the modulation of ER calcium homeostasis 
[10, 14]. This implicates BI-1 in a variety of human diseases that include numerous 
cancers, obesity, liver diseases, autoimmune response, and diabetes [3, 4, 15-17]. 
Neuroprotective roles include, protection from oxygen-glucose deprivation, promotion of 
neuronal proliferation and differentiation, and stress-induced protection [14, 18-20]. It 
regulates ROS production by; modulation of unfolded protein response (UPR) induction 
in the ER [21], suppression of mitochondria-mediated ROS production [22], reduction of 
cytochrome P450 2E1 activity and regulation of the ER membrane lipid peroxidation 
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[23]. BI-1 undoubtedly has significant cytoprotective roles and their abrogation lead to 
cellular homeostatic dysfunction and disease. 
Drosophila melanogaster appear to possess most of the TMBIM protein family 
homologues with TMBIM6/BI-1 represented by BI-1/CG7188 [4, 5, 24]. Drosophila has 
been used as a model organism in the study of gene expression and in human disease 
models, albeit with very promising results [25]. Several studies have used Drosophila to 
elucidate the importance of this protein in cellular homeostasis; including functional 
conservation of this protein in evolutionarily diverse organisms [7], BI-1 as a negative 
regulator of the ER stress sensor IRE1α and its role in the UPR [12], and its modulation 
of autophagy [26]. Expression in the Ddc-Gal4-expressing neurons is the focus of our 
studies as they are very sensitive to subtle differences in gene products and can be used to 
study ROS, ER stress, apoptosis, autophagy and many other cellular processes. This is 
mainly because they degenerate in an age-dependent manner and this degeneration 
manifests as deficiency in locomotor function [25, 27-29]. The key elements of the 
Drosophila model of Parkinson disease that utilizes the expression of a human α-
synuclein transgene to induce the PD-like symptoms [27]; is its ability to recapitulate 
some features of human PD that include, age-dependent loss of DA neurons that manifest 
in age-dependent loss in locomotor function [25, 27, 29-34]. The spatio-temporal 
UAS/GAL4 expression system [35], and the availability of a plethora of promoters or 
enhancers of which TH-Gal4, elav-Gal4 and Ddc-Gal4 are employed to model PD in flies 
[25, 27, 29-34].  
The Bcl-2 family member homologues in Drosophila are limited to the single anti-
apoptotic Buffy and the pro-apoptotic Debcl [36]. In previous studies, the overexpression 
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of Buffy has been shown to confer survival advantages specifically in response to external 
stimuli and in conditions of cellular stress [37-40]. This point to an important role for this 
protein in aspects of cell death. We investigated the outcome of the inhibition of BI-1 in 
Drosophila neurons, and further determined whether there is an interaction with the anti-
apoptotic Bcl-2 protein Buffy. We employed two different RNAi lines to determine the 
specificity of the effects of inhibition of this gene and compared them to a control line. 
We further co-expressed BI-1 in DA neurons along with α-synuclein to investigate 
whether it possesses neuroprotective functions. Lastly, in supportive experiments we 
attempted to establish a role for BI-1 in the Drosophila developing eye. 
Materials and Methods 
Bioinformatic analysis 
The protein sequences were obtained from the National Center for Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov/protein/) and the domains were 
identified using the NCBI Conserved Domain Database (CDD; 
http://www.ncbi.nlm.nih.gov/cdd) [41] and the Eukaryotic Linear Motif (ELM; 
http://elm.eu.org/) [42] which focuses on annotation and detection of eukaryotic linear 
motifs (ELMs), also known as short linear motifs (SLiMs). A multiple sequence 
alignment was done using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) [43, 
44] to show conservation of the domains in the selected organisms. The prediction of the 
nuclear export signal (NES) was by NetNES (http://www.cbs.dtu.dk/services/NetNES/) 
[45]. Further analysis of protein sequences was performed with Phyre2 [46], a web portal 
for protein modelling, prediction and analysis 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). The sub-cellular 
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localisation was performed by MultiLoc2 [47] (https://abi.inf.uni-
tuebingen.de/Services/MultiLoc2). Transmembrane domains were further investigated 
and identified using TMpred [48], a program based on statistical analysis of TMbase 
(http://www.ch.embnet.org/software/TMPRED_form.html). 
Drosophila media, stocks and derivative lines 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben to inhibit fungal growth. Stocks were kept 
at room temperature while crosses and experiments for analysis of ageing and climbing 
ability were carried out at 25C while those for the eye analysis were performed at 29C. 
The P{KK100983VIE-260B stock hereby referred to as UAS-BI-1-RNAi (1) 
(http://stockcenter.vdrc.at/control/product/~VIEW_INDEX=0/~VIEW_SIZE=100/~produ
ct_id=110358) and w1118; P{GD1660}v37108 hereby referred to as UAS-BI-1-RNAi (2) 
(http://stockcenter.vdrc.at/control/product/~VIEW_INDEX=0/~VIEW_SIZE=100/~produ
ct_id=37108) were obtained from Vienna Drosophila Resource Center. Additional 
information on the RNAi constructs http://www.flyrnai.org/up-
torr/GetSummaryByGene?organism=Fly. The UAS-Buffy [36] was provided by Dr. L. 
Quinn (University of Melbourne), Ddc-Gal4 flies [49] by Dr. J. Hirsch (University of 
Virginia) and UAS-α-synuclein [27] by Dr. M. Feany (Harvard Medical School). GMR-
Gal4 [50] and UAS-lacZ flies were obtained from the Bloomington Drosophila Stock 
Center.  
The UAS-α-synuclein/CyO; Ddc-Gal4/TM3; UAS-α-synuclein/CyO; GMR-Gal4; UAS-
Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; GMR-Gal4 complex lines were used to 
overexpress α-synuclein or Buffy in neurons and the developing eye and were produced 
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employing standard homologous recombination and marker selection methods as 
previously described [51, 52]. Gel electrophoresis was used to detect the presence of PCR 
products. 
Ageing assay 
Several single vial crosses of each genotype were performed and a cohort of male flies 
collected upon eclosion and assessed using a protocol previously described [40, 53]. For 
each genotype at least 200 flies were aged and scored every 2 days for the presence of 
deceased adults [54]. Survival data was analysed using GraphPad Prism version 5.04, and 
curves were compared using the Log-rank (Mantel-Cox) test with statistical significance 
determined at 95%, at a P ≤ 0.05 with application of a Bonferroni correction to the 
familywise P value. 
Climbing assay 
A cohort of the critical class male flies was collected upon eclosion and scored for their 
ability to climb using a method that was previously described [55]. Climbing analysis was 
performed using the GraphPad Prism version 5.04 and climbing curves were fitted using 
non-linear regression and compared using 95% confidence interval with a P-value of 0.05 
or less being statistically significant. 
Scanning electron microscopy of the Drosophila eye 
Male flies were collected upon eclosion and aged for up to five days and then prepared 
for scanning electron microscopy using a standard protocol as previously described [40]. 
For each cross at least 10 different eye images were analysed using the National Institutes 
of Health (NIH) ImageJ software [56] and biometric analysis performed using GraphPad 
Prism version 5.04. Disruption area of the eye was calculated as has been previously 
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described [57]. Statistical comparisons comprised one-way analyses of variance 
(ANOVA) and Dunnett's multiple comparison tests. P-values less than 0.05 were 
considered significant. 
Results 
Drosophila BI-1 is closely related to the human homologue 
The 245 amino acids Drosophila BI-1 isoform A has a 42% identity and 68% similarity to 
the 295 amino acids human isoform B. The Drosophila homologue has a BI-1 domain 
between amino acids 21 – 223 and the human version at 74 – 286 (Figure 1) as 
determined by the NCBI Conserved Domain Database [41]. An alignment of the protein 
sequences using Clustal Omega [43, 44] shows high conservation of the BI-1-like domain 
in the organisms analysed (Figure 1A). Six transmembrane (TM) domains in both 
Drosophila and human BI-1, that are numbered TM1 to TM6 (Figure 1A) were identified 
using both Eukaryotic linear motif (ELM) [58] and TMpred [48]. An analysis of 
membrane-spanning domains by Phyre2 [46] reveals seven TM domains (Figure 1B) in 
both sequences that are highly identical in the cytoplasmic to intracellular orientation. An 
inhibitor of apoptosis binding motif (IBM) at amino acids 1-5, an endoplasmic reticulum 
(ER) retention motif at position 221-224, and binding motifs for Atg8 at position 212-224 
and calmodulin at amino acids 226-242 were identified by ELM. The presence of nuclear 
export signal (NES) was detected in both Drosophila and human BI-1 using NetNES [45] 
and only in Drosophila using the ELM. The 3D modelling of these proteins using Phyre2 
(Figure 1C) shows a close similarity in the structure and the orientation of the 
transmembrane domains with the image coloured by rainbow from the N → C terminus. 
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Figure 6.1 Drosophila BI-1 has six TM domains that are evolutionarily conserved 
A) The Drosophila, human, mouse and mosquito homologues contain a BI-1 domain with 
the Drosophila version situated between amino acids 21 – 223 and the human version at 
74 – 286 as determined by the NCBI Conserved Domain Database [41]. They have six 
transmembrane-spanning regions as predicted by the Eukaryotic Linear Motif (ELM) [58] 
and TMpred [48]. It shows presence of a motif rich region, that contains a NES, ER 
retention motif, Atg8 and calmodulin binding motifs as identified using ELM. Sequence 
alignment was performed by Clustal Omega [43, 44] and showed high conservation of the 
Bax inhibitor-1 domain (Hsap is Homo sapiens NP_001092046.1, Mmus is Mus musculus 
NP_001164506.1, Dmel is Drosophila melanogaster NP_648205.1 and Agam is 
Anopheles gambiae XP_315790.3). "*" indicate the residues that are identical, ":" 
indicate the conserved substitutions, "." indicate the semi-conserved substitutions. 
Colours show the chemical nature of amino acids. Red is small hydrophobic (including 
aromatic), Blue is acidic, Magenta is basic, and Green is basic with hydroxyl or amine 
groups. B) Additional protein analysis performed using Phyre2 [46] revealed the presence 
of seven transmembrane domains in both the Drosophila and human sequences (Image 
cartoons are obtained from Phyre2). C) The 3D modelling of the Drosophila and human 
proteins using Phyre2 shows a close similarity in the structure and the orientation of the 
transmembrane domains with the image coloured by rainbow from the N → C terminus 
(Image cartoons are obtained from Phyre2). 
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Inhibition of BI-1 in DA neurons decreases lifespan and severely impairs locomotor 
function 
The expression of both BI-1-RNAi lines in the Ddc-Gal4-expressing neurons results in 
decreased lifespan and impaired locomotor function. The median lifespan for these flies 
was 54 days for BI-1-RNAi (1) and 46 days for BI-1-RNAi (2) when compared to 70 days 
for the controls that express the lacZ transgene as determined by the Log-rank (Mantel-
Cox) test (Figure 2A). When BI-1 is suppressed in these neurons, the flies develop an 
early onset impairment of locomotor ability as determined by the nonlinear fitting of the 
climbing curves (Figure 2B). The 95% CI for the slope were 0.033 to 0.050 and 0.0175 to 
0.0355 for the two RNAi lines respectively when compared to 0.070 to 0.0975 for the 
lacZ control flies. These results appear to suggest a role for BI-1 in the protection of 
neurons in Drosophila. 
Buffy suppresses the loss of BI-1-induced phenotypes 
The directed overexpression of the pro-survival Bcl-2 homologue Buffy results in 
increased lifespan and improved climbing ability. When Buffy is co-expressed with both 
BI-1-RNAi lines in the Ddc-Gal4-expressing neurons, the results indicate an increased 
median lifespan of 70 days and 72 days respectively when compared to 72 days for Buffy 
co-expressed with lacZ control flies, as determined by Log-rank test (Figure 3A). The 
climbing ability of the BI-1-RNAi flies was not significantly different from the Buffy co-
expressed with lacZ controls as determined by comparison of the BI-1-RNAi climbing 
curves (Figure 3B) with the control curve. The 95% CI for the slope of BI-1-RNAi (1) was 
0.0340 to 0.057 and that of BI-1-RNAi (2) was 0.040 to 0.061 when compared to 0.035 to 
0.050 for the controls. Taken together these results suggest a pro-survival role for BI-1; as  
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Figure 6.2 Loss of BI-1 activity decreases survival and impairs climbing ability 
A) The inhibition of BI-1 in the Ddc-Gal4-expressing neurons results in reduced lifespan 
when compared to control flies expressing UAS-lacZ. The genotypes are Ddc-Gal4/ UAS-
lacZ, Ddc-Gal4/ UAS-BI-1-RNAi (1) and Ddc-Gal4/ UAS-BI-1-RNAi (2). Longevity is 
shown as percent survival (P < 0.05, determined by the log-rank (Mantel-Cox) test and 
N≥200). B) The inhibition of BI-1 in these neurons resulted in a significant decrease in 
climbing ability as determined by nonlinear fitting of the climbing curves and comparing 
the 95% CI. The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-BI-1-RNAi (1) and 
Ddc-Gal4/ UAS-BI-1-RNAi (2). Error bars indicate standard error of the mean and N=50. 
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Figure 6.3 The BI-1-induced phenotypes can be suppressed by the overexpression of 
Buffy 
A) The co-expression of Buffy with BI-1-RNAi in the Ddc-Gal4-expressing neurons result 
in the rescue of the observed phenotype of decreased survival when compared to the 
control. Genotypes are UAS-Buffy; Ddc-Gal4/UAS-lacZ, UAS-Buffy; Ddc-Gal4/ UAS-BI-
1-RNAi (1), and UAS-Buffy; Ddc-Gal4/ UAS-BI-1-RNAi (2). Longevity is shown as 
percent survival (P < 0.05, determined by log-rank (Mantel-Cox) test with N≤200). B) 
The inhibition of BI-1 along with the overexpression of Buffy in these neurons results in 
the suppression of the age-dependent loss in climbing ability. The genotypes are UAS-
Buffy; Ddc-Gal4/UAS-lacZ, UAS-Buffy; Ddc-Gal4/ UAS-BI-1-RNAi (1), and UAS-Buffy; 
Ddc-Gal4/ UAS-BI-1-RNAi (2). Analysis was done by nonlinear fitting of the climbing 
curves and significance was determined by comparing the 95% CI. Error bars indicate 
standard error of the mean and N=50. 
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the phenotypes induced by its inhibition are significantly counteracted by the pro-survival 
Bcl-2 homologue Buffy. 
Inhibition of BI-1 with the expression of α-synuclein slightly alters phenotypes 
The expression of α-synuclein in dopaminergic neurons results in impaired locomotor 
function that is attributed to cellular toxicity. The co-expression of BI-1-RNAi along with 
α-synuclein in the Ddc-Gal4-expressing neurons, slightly exacerbated the reduced 
survival and the loss in climbing ability observed with the expression of α-synuclein. The 
median lifespan was 52 days and 54 days for flies that express BI-1-RNAi along with α-
synuclein compared to 58 days for controls that co-express α-synuclein along with the 
lacZ transgene (Figure 4A) as determined by Log rank test with p<0.001. A comparison 
of the climbing curves by nonlinear fitting at 95% CI revealed they were significantly 
different (Figure 4B), with a CI of 0.038 to 0.049 for BI-1-RNAi (1) and 0.025 to 0.033 
for BI-1-RNAi (2) co-expressed along with α-synuclein and compared to 0.052 to 0.069 
for the α-synuclein co-expressed with lacZ control flies. This implies that the inhibition of 
BI-1 in the Ddc-Gal4-expressing neurons abrogates its cytoprotective function and 
enhances the α-synuclein-induced phenotypes. 
Inhibition of BI-1 in the eye decreases ommatidia number and increases 
degeneration, phenotypes that are rescued upon Buffy overexpression 
The directed inhibition of BI-1 in the Drosophila developing eye using the GMR-Gal4 
transgene resulted in eyes with decreased number of ommatidia and a higher disruption of 
the ommatidial array in both the RNAi lines that were tested (Figure 4A – C and 4J) as 
determined by a one-way analysis of variance with a p value less than 0.0001. Co-
expression of both BI-1-RNAi lines with Buffy restored the mean number of ommatidia  
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Figure 6.4 Loss of BI-1 in neurons enhances the α-synuclein-induced phenotypes 
A) The directed inhibition of BI-1 along with α-synuclein expression in the Ddc-Gal4-
expressing neurons resulted in a shortened lifespan when compared to the control. 
Genotypes are UAS-α-synuclein; Ddc-Gal4/ UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ 
UAS-BI-1-RNAi (1) and UAS-α-synuclein; Ddc-Gal4/ UAS-BI-1-RNAi (2). Longevity is 
shown as percent survival (P < 0.05, determined by log-rank (Mantel-Cox) test with 
N≤200). B) The co-expression of BI-1-RNAi with α-synuclein resulted in a slight but 
significant decrease in the age-dependent loss in climbing ability when compared to the 
control. The genotypes are UAS-α-synuclein; Ddc-Gal4/ UAS-lacZ, UAS-α-synuclein; 
Ddc-Gal4/ UAS-BI-1-RNAi (1) and UAS-α-synuclein; Ddc-Gal4/ UAS-BI-1-RNAi (2). 
Analysis was done by nonlinear fitting of the climbing curves and significance was 
determined by comparing the 95% CI. Error bars indicate standard error of the mean and 
N=50. 
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Figure 6.5 Inhibition of BI-1 in the developing eye results in decreased ommatidia 
and increased degeneration of the ommatidial array 
Scanning electron micrographs when BI-1 is inhibited in the Drosophila developing eye; 
(A) GMR-GAL4/ UAS-lacZ, (B) GMR-GAL4/ UAS-BI-1-RNAi (1) and (C) GMR-GAL4/ 
UAS-BI-1-RNAi (2), when inhibited along with overexpression of Buffy; D) UAS-Buffy; 
GMR-Gal4/ UAS-lacZ, E) UAS-Buffy; GMR-Gal4/ UAS-BI-1-RNAi (1) and E) UAS-
Buffy; GMR-Gal4/ UAS-BI-1-RNAi (2) and when co-expressed with α-synuclein; G) UAS-
α-synuclein; GMR-Gal4/ UAS-lacZ, H) UAS-α-synuclein; GMR-Gal4/ UAS-BI-1-RNAi, 
and I) UAS-α-synuclein; GMR-Gal4/ UAS-BI-1-RNAi. J) Biometric analysis when BI-1 is 
inhibited in the eye indicated decreased ommatidia number and higher percentage of 
ommatidial disruption when compared to the control. K) The co-expression of Buffy with 
both BI-1-RNAi lines resulted in the suppression of the eye phenotypes, the ommatidia 
number and disruption of the eye were restored to control levels. L) The inhibition of BI-1 
along with α-synuclein expression resulted in worsened eye phenotypes, the number of 
ommatidia was lower and the degree of ommatidial disruption was higher than either the 
inhibition of both BI-1 lines or that of α-synuclein when compared to controls. 
Comparisons were determined by one-way analysis of variance (ANOVA) with a 
Dunnett's multiple comparison post-test (P<0.05), error bars are standard error of the 
mean, N=10 and asterisks represent statistical significance (* p<0.05, ** p<0.01 and *** 
p<0.001). 
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and the percentage disruption to control levels as determined by a one-way analysis of 
variance with p = 0.2439 and 0.2342 (Figure 4D – F and 4K). Taken together, these 
results suggest that BI-1 may play a pro-survival role in the development of the 
Drosophila eye and that Buffy suppresses the developmental eye defects that result from 
the inhibition of BI-1. The inhibition of BI-1 along with α-synuclein expression resulted 
in a significant decrease in the number of ommatidia or increase in percentage disruption 
of the eye as determined by a one-way analysis of variance with a p value less than 
0.0001 in both instances (Figure 4G – I and 4L). The number of ommatidia and 
percentage of disruption was worse than with either α-synuclein expression or BI-1 
inhibition. This indicates that the inhibition of BI-1 enhances the α-synuclein-induced eye 
defects. 
Discussion 
The inhibition of BI-1 via stable inducible RNAi in the Ddc-Gal4-expressing neurons of 
Drosophila results in decreased survival and impaired climbing ability over time. 
Although there is no known homologue of Bax in Drosophila, the only pro-apoptotic Bcl-
2 homologue is Debcl [59-62], and has been demonstrated to possess pro-apoptotic 
functions. The Drosophila BI-1 is able to block Bax-induced cell death in yeast [7], and 
loss of BI-1 function induces cell death [9]. These results suggest neuronal dysfunction 
may result from degeneration or death when the function of BI-1 is reduced in the Ddc-
Gal4-expressing neurons. The BI-1-induced cell death could occur through interaction 
with pro-survival Bcl-2 proteins at the ER membrane [9] and especially Bcl-2 and Bcl-XL 
in humans and possibly Buffy in Drosophila. BI-1 seems to be involved in cellular 
functions that are protective to ER stress-induced apoptosis [10]. It seems to do this by 
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the regulation of calcium ions [13, 17] and ROS [23, 63]. BI-1 regulates ER stress by 
controlling ER-generated ROS accumulation and stress linked to the unfolded protein 
response. Therefore, the inhibition of this important ER stress regulator in the DA 
neurons would result in neuronal degeneration and death. The only pro-survival Bcl-2 
homologue in Drosophila is Buffy [36] and the overexpression of Buffy is known to confer 
survival advantages to cells under normal conditions and under conditions of stress [36, 
37, 39, 40, 52, 64, 65]. The overexpression of Buffy along with the inhibition of BI-1 
resulted in the suppression of the BI-1-induced phenotypes. This Buffy action may be 
specific to its interaction with BI-1 or to its general pro-survival signalling pathways. The 
rescue of the BI-1-induced phenotypes in both the Ddc-Gal4-expressing neurons and in 
the developing eye may indicate a pro-survival role for BI-1 in Drosophila, as the pro-
survival action of Buffy can abrogate its phenotypes. 
The expression of human α-synuclein in DA neurons of Drosophila results in impaired 
climbing ability [27], similar to what is observed in BI-1 loss of function. The expression 
of α-synuclein along with the loss of BI-1 activity significantly altered the impaired 
locomotor ability observed. The age-dependent loss of climbing ability could be a result 
of BI-1-induced apoptosis coupled with neurotoxicity that result from α-synuclein 
accumulation and the subsequent dysfunction of cellular mechanisms. All the same, it 
appears the presence of both mechanisms, vis a vis BI-1-induced apoptosis or α-synuclein 
aggregation neurotoxicity, confers a great disadvantage to Ddc-Gal4-expressing neurons. 
The suppression of BI-1 in the Drosophila eye under the direction of the GMR-Gal4 
transgene results in a lower ommatidia number when compared to the control. BI-1 is an 
apoptosis suppressor gene and the down-regulation of its protein product results in 
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programmed cell death [3]. The reduction in the ommatidia number observed is mainly 
due to the fusion of ommatidia and the resulting ommatidia disarray. The inhibition of BI-
1 in the Drosophila eye seems to exacerbate the Gal4-induced apoptosis that manifests as 
roughened eye phenotype [66]. The co-expression of the Bcl-2 pro-cell survival 
homologue Buffy with BI-1-RNAi results in the suppression of the phenotype, with the 
number of ommatidia and the roughened eye restored to control levels. Buffy seems to 
ameliorate this phenotype and it is possibly via a general action on survival signals or an 
interaction with BI-1. 
The expression of α-synuclein in the Drosophila eye results in reduced ommatidia and a 
highly disrupted ommatidial array [27]. This α-synuclein-induced developmental eye 
defects model is a viable system to show the effects of altered gene expression and its role 
in neuroprotection. The co-expression of α-synuclein with BI-1-RNAi in the Drosophila 
eye resulted in decreased ommatidia number and a highly disrupted ommatidial array 
when compared to the control that expresses α-synuclein. The number of ommatidia 
decreased further when α-synuclein was co-expressed with BI-1-RNAi. Additionally, the 
degree of disruption of the ommatidial array was also increased. Though it did not appear 
to be additive in nature, it seems that the combination of the expression of the neurotoxic 
α-synuclein and the inhibition of the activity of the anti-apoptotic BI-1 results in a 
worsening of the roughened eye phenotype. The accumulation of α-synuclein has been 
implicated in breakdown of cellular homeostasis that include apoptosis, ROS production, 
and autophagy [67]. The inhibition of BI-1 disrupts regulation of similar mechanisms as 
those implicated in α-synuclein-induced neurotoxicity that include apoptosis, autophagy 
and ROS production [3]. It therefore, follows that the combined action of α-synuclein 
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expression and BI-1 inhibition worsened the phenotypes that result from either α-
synuclein expression or BI-1 inhibition. 
Conclusions 
The inhibition of BI-1 in the Ddc-Gal4-expressing neurons of Drosophila results in 
reduction in lifespan and an age-dependent loss in climbing ability, phenotypes that are 
strongly associated with the degeneration and loss of dopaminergic neurons. The co-
expression of the pro-survival Buffy with BI-1-RNAi results in the rescue of the 
phenotypes observed, it is possible that Buffy and BI-1 interact to promote anti-apoptosis. 
Finally, BI-1 appears to be neuroprotective as its inhibition along with α-synuclein 
expression result in enhanced phenotypes. 
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Abstract 
Lifeguard is an integral transmembrane protein that modulates FasL-mediated apoptosis 
by interfering with the activation of caspase 8. It is evolutionarily conserved, with 
homologues present in plants, nematodes, zebra fish, frog, chicken, mouse, monkey and 
human. The Lifeguard homologue in Drosophila CG3814 contains the Bax inhibitor-1 
family motif that is of unknown function. The downregulation of Lifeguard result in 
disruption of cellular homeostasis and disease due to sensitizing neurons to FasL-
mediated apoptosis. We identified through bioinformatic analysis CG3814, a putative 
homologue of Lifeguard and knocked down CG3814/LFG under the control of the Dopa 
decarboxylase transgene in neurons of Drosophila melanogaster to investigate whether it 
possesses neuroprotective functions that have been reported in the human homologue. 
The knockdown of CG3814/LFG in the Ddc-Gal4-expressing neurons results in 
shortened lifespan and a highly-impaired locomotor ability, phenotypes that are strongly 
associated with the degeneration and subsequent loss of dopaminergic neurons. Lifeguard 
interacts with anti-apoptotic Bcl-2 proteins and possibly with pro-apoptotic members to 
induce its neuroprotective function. The co-expression of Buffy, the sole anti-apoptotic 
Bcl-2 gene family member in Drosophila, along with CG3814/LFG by stable inducible 
RNA interference results in the suppression of the shortened lifespan and the premature 
age-dependent loss in climbing ability. The suppression of CG3814/LFG in the 
Drosophila eye under the direction of the GMR-Gal4 transgene results in a reduction in 
ommatidia number and an increase in the disruption of the ommatidial array. The 
overexpression of Buffy along with the knockdown of CG3814/LFG counteracts the eye 
phenotypes. The knockdown of CG3814/LFG in Ddc-Gal4-expressing neurons in 
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Drosophila diminishes its neuroprotective ability and results in shortened lifespan and 
loss in climbing ability, phenotypes that are improved upon overexpression of the pro-
survival Buffy. 
Introduction 
Lifeguard (LFG) or Fas apoptotic inhibitory molecule 2 (FAIM2), also known as 
Transmembrane Bcl-2 associated protein X (Bax) inhibitor motif 2 (TMBIM2),   belongs 
to a diverse membrane-spanning protein family [1, 2] and inhibits apoptosis mediated by 
the Fas/CD95/Apo-1 receptor but not the closely related TNFR [3]. LFG was first 
identified as neuronal membrane protein 35 (NMP35) when it was found to be 
differentially upregulated during rat postnatal development [4] and predominantly 
localised to the endoplasmic reticulum (ER). A different nomenclature categorizes this 
protein into a family referred to as LFG, which is adopted from Lifeguard [1], and 
particularly classifies LFG as LFG2. This protein consists of seven transmembrane 
domains and is conserved being found in plants, insects, amphibians, fish and mammals 
[5]. LFG regulates cell death by interfering with caspase 8 activation but not its 
recruitment to the death-inducing signalling complex (DISC) [3], a role that is essential 
for the survival of neurons during development. Expression of LFG has been shown to be 
dependent on PI3K/Akt and its knockdown sensitizes neurons to FasL-induced apoptosis 
[6]. This appears to be through its regulation by PI3K. Another mechanism for LFG 
regulation of apoptosis suggests that LFG interacts with Bcl-XL and Bcl-2 at the ER to 
inhibit calcium release [7]. This interaction with Bcl-XL is contrary to previous findings 
where LFG was shown to interact with Bax [5]. The dysregulation of LFG has been 
implicated in disruption of cellular homeostasis that include many cancers and neuronal 
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diseases [8, 9]. Nevertheless, the antiapoptotic role of LFG has been demonstrated in 
addition to its interaction with the Bcl-2 family of proteins. 
The Bcl-2 family of genes are key regulators of cell death and survival in animals and are 
functionally composed of anti-apoptotic and proapoptotic members [10]. They regulate 
life and death decisions at the cellular level by maintaining a delicate balance of the pro-
apoptotic and anti-apoptotic members. The Bcl-2 family member homologues in 
Drosophila melanogaster are limited to the single anti-apoptotic Buffy and the pro-
apoptotic Debcl [11]. In previous studies, the overexpression of Buffy has been shown to 
confer survival advantages in response to external stimuli and under conditions of stress 
[12-15]. A role for this gene in the mitochondrial pathway has been described during 
Drosophila oogenesis [13]. This point to an important role for this protein in aspects of 
cell death. 
The Drosophila homologue was initially reported to be NMDARA1 by Schweitzer et al, 
though previous work by Pellicena-Palle and Salz reported this transcript to be 
NMDARA1 and a homologue of the rat glutamate binding protein (GBP) [4, 16]. It was 
listed as CG3798 in FlyBase and is currently Nmda1, also known as NMDA receptor 
associated protein [5] and the protein sequence used in Bioinformatic comparisons in this 
study is Nmda1 polypeptide C (http://flybase.org/reports/FBpp0088816.html). The 
accession number of the protein sequence used by Reimers et al (NP_610824.1) [5], has 
since been updated in both FlyBase and NCBI and currently represents CG3814 isoform 
A (Polypeptide Dmel\CG3814-PA) (http://flybase.org/reports/FBpp0086927.html). 
Interestingly, CG3814 and Nmda1 are adjacent each other on chromosome 2 (2R: 
12,875,164 to 12,876,966) and (2R: 12,877,094 to 12,880,230) respectively and are 
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transcribed in the same direction. Recent bioinformatic studies make comparisons 
between Drosophila CG3814 and/or CG9722 with human LFG [1, 2]. The presence of 
homologues of this protein family implicated in the regulation of FasL-mediated 
apoptosis may underpin their evolutionary importance in cytoprotection. Drosophila is 
used as a model organism to study the alteration of gene expression and to model human 
diseases, and has produced very promising results [17]. We used Ddc-Gal4-expressing 
neurons in our studies since they are sensitive to subtle disruptions in gene expression and 
degenerate in an age-dependent manner which manifests as deficiency in locomotor 
function. Since these neurons are highly sensitive, measurements of survival and climbing 
ability are rapid assays to assess the organismal effects of altered gene expression and to 
identify genetic interaction. We investigated the outcome of the knockdown of CG3814 
alias LFG - which has a wider expression pattern compared to CG9722 which is only 
expressed in the testes [1] – under the control of the Dopa decarboxylase transgene in 
neurons of Drosophila, and further we determined whether there is interaction with Bcl-2 
proteins by the overexpression of the pro-survival Bcl-2 homologue Buffy. 
Materials and Methods 
Bioinformatic analysis 
The protein sequences for Drosophila melanogaster: NP_610824.1, Homo sapiens: 
NP_036438.2, Xenopus tropicalis: NP_001072357.1, and Mus musculus: NP_082500.2 
were sourced from National Center for Biotechnology Information (NCBI; 
http://www.ncbi.nlm.nih.gov/protein/). The functional domains were identified using the 
NCBI Conserved Domain Database (CDD; http://www.ncbi.nlm.nih.gov/cdd; [18] and 
the Eukaryotic Linear Motif (ELM) resource (http://elm.eu.org/) [19] which focuses on 
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annotation and detection of eukaryotic linear motifs (ELMs), also known as short linear 
motifs (SLiMs). A Clustal Omega multiple sequence alignment 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) [20, 21] was used to show conservation of the 
Bax inhibitor-1 domain. Additional analysis with Phyre2 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) [22], a web portal for 
protein modelling, prediction and analysis was performed. 
Drosophila media, culture and stocks 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben. Stocks were kept at room temperature 
while crosses and experiments were carried out at 25°C and 29°C. The CG3814/ 
P{KK104535}VIE-260B hereby referred to as UAS-LFG-RNAi (1) 
(http://stockcenter.vdrc.at/control/product/~VIEW_INDEX=0/~VIEW_SIZE=100/~produ
ct_id=100645) was obtained from Vienna Drosophila Resource Center (Vienna, Austria), 
and y1 sc* v1; P{y[+t7.7] v[+t1.8]=TRiP.HMS00225} attP2 hereby referred to as UAS-
LFG-RNAi (2) was developed at Harvard Medical School Transgenic RNAi project 
(http://www.flyrnai.org/up-torr/GetSummaryByGene?organism=Fly) and was obtained 
from Bloomington Drosophila Stock Center at Indiana University, IN, USA. Information 
about these constructs is available online. The GMR-Gal4 [23] and UAS-lacZ flies were 
obtained from the Bloomington Drosophila Stock Center. The UAS-Buffy flies [11] were 
a gift from Dr. L. Quinn (University of Melbourne), and Ddc-Gal4 flies [24] by Dr. J. 
Hirsch (University of Virginia). The UAS-Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; 
GMR-Gal4 complex lines were used to overexpress Buffy in neurons and the developing 
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eye and were produced employing standard homologous recombination and marker 
selection methods as previously described [25, 26]. 
Survival assay 
Several crosses of each genotype were performed and a cohort of male flies collected 
upon eclosion [15, 27]. For each genotype at least 200 flies were aged and scored every 2 
days for the presence of deceased adults [28]. Longevity data were analysed using 
GraphPad Prism version 5.04 (GraphPad Software Inc., La Jolla, CA, USA), and survival 
curves were compared by the Log-rank (Mantel-Cox) test. Significance was determined at 
a 95% confidence interval and family-wise P ≤ 0.05 with Bonferroni correction. 
Climbing assay 
The critical class males flies were assayed for their ability to climb using a method 
previously described [29]. Climbing analysis was performed and climbing indices 
analysed by GraphPad Prism version 5.04. The climbing curves were fitted using non-
linear regression and data compared using 95% confidence intervals with a P-value of 
0.05 or less being significant. 
Scanning electron microscopy of the Drosophila eye 
A cohort of the critical class male flies was collected upon eclosion and prepared for 
imaging using a standard protocol previously described [15]. 10 different scanning 
electron micrographs of each genotype were analysed using the National Institutes of 
Health (NIH) ImageJ software [30] and biometric analysis performed using GraphPad 
Prism version 5.04. The area of disruption of the ommatidial array was determined as 
detailed previously [31]. Statistical comparisons comprised one-way analyses of variance 
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(ANOVA) and Dunnett's multiple comparison tests. P-values less than 0.05 were 
considered significant. 
Results 
Human LFG is closely related to Drosophila CG3814 and has seven TMD 
To characterize the Drosophila melanogaster homologue of LFG, we performed 
bioinformatic analysis on CG3814 isoform A that is composed of 239 amino acids and 
has 45% identity and 65% similarity to the 316 amino acids human LFG. The Drosophila 
homologue has 7 transmembrane (TM) domains (Figure 6) and a tumour necrosis factor 
receptor-associated factors (TRAF2) binding consensus motif at amino acids 55 to 58 and 
208 to 211 that may be involved in TNFR signalling as determined by NCBI Conserved 
Domain Database (CDD) [18], Eukaryotic linear motif (ELM) resource [19] and Phyre2 
[22].  The alignment of protein sequences using Clustal Omega multiple sequence 
alignment [20, 21] shows high conservation of the Bax inhibitor-1-like domain. The 3D 
modelling of these proteins using Phyre2 [22] shows a close similarity in the structure and 
the orientation of the transmembrane domains. 
Knock down of CG3814/LFG decreases lifespan and prematurely retards climbing 
ability 
We investigated the neuroprotective role of CG3814/LFG in Drosophila, and the 
suppression of CG3814/LFG in the Ddc-Gal4-expressing neurons results in a decrease in 
lifespan and impairment of locomotor ability. We employed two different RNAi lines to 
determine the specificity of the effects of knockdown of this gene and compared them to 
a control line. The median lifespan of LFG-RNAi flies was 42 days and 46 days compared 
to 70 days for the lacZ controls as compared by Log-rank (Mantel-Cox) test with a  
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Figure 6.6 Drosophila CG3814 has seven TM domains that are evolutionarily 
conserved 
A) The seven membrane-spanning regions of Drosophila CG3814 and the human 
homologue LFG were generated by Phyre2 [22] and show the similarity between the 
transmembrane domain orientation. B) The Drosophila melanogaster CG3814 isoform A 
is composed of 239 amino acids and is 45% identical to human LFG. Domains were 
identified using the NCBI Conserved Domain Database (CDD) [18] and the Eukaryotic 
Linear Motif [19]. Clustal Omega multiple sequence alignment [20, 21] of Drosophila 
CG3814 protein (D.melanogaster = Drosophila melanogaster NP_610824.1) with the 
human (H.sapiens = Homo sapiens NP_036438.2), frog (X.tropicalis = Xenopus 
tropicalis NP_001072357.1), and mouse (M.musculus = Mus musculus NP_082500.2) 
homologues shows conservation of the Bax inhibitor-1 domain. The domains were 
identified using the NCBI CDD. "*" indicate the residues that are identical, ":" indicate 
the conserved substitutions, "." indicate the semi-conserved substitutions. Colours show 
the chemical nature of amino acids. Red is small hydrophobic (including aromatic), Blue 
is acidic, Magenta is basic, and Green is basic with hydroxyl or amine groups. C) The 3D 
protein modelling of human LFG and the Drosophila CG3814 show remarkable 
similarity in the structure and the orientation of the transmembrane domains with the 
image coloured by rainbow from the N → C terminus (Image cartoons were obtained 
from Phyre2). 
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p<0.0001 (Figure 7A). The knockdown of CG3814 in these neurons produces flies with 
significantly impaired climbing ability as determined by the nonlinear fitting of the 
climbing curves and comparing the CI at 95% (Figure 7B). The LFG-RNAi flies had CI of 
0.069 to 0.091 and 0.050 to 0.071 when compared to 0.030 to 0.048 for the controls that 
express the benign lacZ transgene. These results taken together suggest a neuroprotective 
role for CG3814/LFG in Drosophila. 
Suppression of CG3814/LFG-induced phenotypes are counteracted by 
overexpression of the pro-survival Buffy 
We determined the pro-survival role of Buffy and CG3814/LFG in Drosophila neurons. 
The co-expression of the pro-survival Bcl-2 homologue Buffy along with the knockdown 
of CG3814/LFG results in significant increase in lifespan and improved climbing ability. 
When Buffy is co-expressed with LFG-RNAi, the results indicate a median lifespan of 70 
days for both RNAi constructs when compared to Buffy control flies with a median 
lifespan of 74 days as determined by Log-rank test (Figure 8A). This is an increase in 
survival when compared to the flies in Figure 2A that had the expression of CG3814/LFG 
reduced by RNAi. The climbing ability of the LFG-RNAi flies were improved as 
determined by comparison of the climbing curves at 95% CI (Figure 8B). The LFG-RNAi 
constructs had a CI of 0.049 to 0.068 and 0.043 to 0.057 compared to the controls with 
0.035 to 0.050, that indicate the climbing curves were not significantly different. These 
results suggest a pro-survival role for CG3814/LFG in Drosophila neurons as phenotypes 
that result from its insufficient levels can be abrogated by the overexpression of the pro-
survival Buffy. 
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Figure 6.7 Loss of CG3814/LFG activity decreases survival and impairs climbing 
ability 
A) The knockdown of CG3814/\LFG in the neurons under the control of the Ddc-Gal4 
transgene results in reduced lifespan, with a median survival of 42 days and 46 days when 
compared to 70 days for control flies that expresses the benign lacZ transgene. The 
genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-LFG-RNAi (1) and Ddc-Gal4/ UAS-
LFG-RNAi (2). Longevity is shown as percent survival (P < 0.05, determined by the log-
rank (Mantel-Cox) test and N≥200). B) The directed suppression of CG3814/LFG in the 
Ddc-Gal4-expressing neurons resulted in premature loss in climbing ability as determined 
by nonlinear fitting of the climbing curves and comparing 95% CI. The genotypes are 
Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-LFG-RNAi (1) and Ddc-Gal4/ UAS-LFG-RNAi 
(2). Error bars indicate standard error of the mean and N=50.   
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Figure 6.8 Buffy overexpression can counteract the CG3814/LFG-induced 
phenotypes 
A) The overexpression of Buffy along with LFG-RNAi results in the suppression of 
decreased survival as indicated by a median survival of 70 days for both RNAi constructs 
when compared to 74 days for the control. Genotypes are Ddc-Gal4 UAS-Buffy/ UAS-
lacZ, Ddc-Gal4 UAS-Buffy/ UAS-LFG-RNAi (1) and Ddc-Gal4 UAS-Buffy/ UAS-LFG-
RNAi (2). Longevity is shown as percent survival (P < 0.05, determined by log-rank 
(Mantel-Cox) test with N≥200). B) The knockdown of CG3814/LFG along with the 
overexpression of Buffy in these neurons results in the suppression of the age-dependent 
loss in climbing ability. The genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ, Ddc-Gal4 
UAS-Buffy/ UAS-LFG-RNAi (1) and Ddc-Gal4 UAS-Buffy/ UAS-LFG-RNAi (2). Analysis 
was done by nonlinear fitting of the climbing curves and significance was determined by 
comparing the 95% CI. Error bars indicate standard error of the mean and N=50.  
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Knock down of CG3814 in the eye decreases ommatidia number and increases 
degeneration, phenotypes that are rescued upon Buffy overexpression 
The biometric analysis of the neuron rich Drosophila compound eye can shed light on 
subtle differences in phenotypes that result from altered gene expression. The directed  
suppression of CG3814/LFG in the developing eye using the GMR-Gal4 transgene results 
in eyes that have fewer ommatidia and a higher disruption of the ommatidial array (Figure 
9A and 9B) as determined by a one-way analysis of variance (ANOVA) at a p of less than 
0.050. The reduction in ommatidia number is largely from the high degree of ommatidial 
fusion. Co-expression of LFG-RNAi with Buffy restored the mean number of ommatidia 
and percentage of disruption to control levels as determined by a one-way analysis of 
variance (ANOVA), p>0.50 (Figure 9A and 9C). Taken together, these results suggest 
that CG3814/LFG may play a role in the development of the neuron-rich Drosophila eye 
and that Buffy suppresses the developmental eye defects that result from its knockdown. 
Discussion 
Bioinformatic analysis of protein sequences from our study shows that CG3814 is the 
strongest candidate for Drosophila LFG, with a sequence identity of 45% and similarity 
of 65%, but we do not exempt CG9722, the only consideration was that CG3814 was 
widely expressed when compared to CG9722 that is predominantly expressed in the testis 
[1]. Therefore, we propose that CG3814 is the putative Drosophila homologue of LFG. 
The conditional knockdown of CG3814 by stable inducible RNA interference in neurons 
of Drosophila under the direction of the Ddc-Gal4 transgene resulted in decreased 
median survival and severely impaired climbing ability, phenotypes that were 
consistently present in both RNAi lines tested. The “healthspan” of these flies was highly  
A. 
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Figure 6.9 Knockdown of CG3814/LFG in the developing eye results in phenotypes 
that are counteracted by Buffy overexpression 
A) Scanning electron micrographs when CG3814/LFG is suppressed in the eye and co-
expressed along with Buffy. The genotypes are GMR-Gal4/ UAS-lacZ; GMR-Gal4/ UAS-
LFG-RNAi (1); GMR-Gal4/ UAS-LFG-RNAi (2); UAS-Buffy; GMR-Gal4/ UAS-LFG-
RNAi (1) and UAS-Buffy; GMR-Gal4/ UAS-LFG-RNAi (2). B) Biometric analysis when 
CG3814/LFG is suppressed in the eye indicated decreased ommatidia number and higher 
percentage of ommatidial disruption when compared to the control. C) Co-expression of 
Buffy with LFG-RNAi resulted in the suppression of the eye phenotypes, ommatidia 
number and disruption of the eye were restored to control levels as determined by 
biometric analysis. Comparisons were determined by a one-way analysis of the variance 
(ANOVA), p<0.05, error bars are standard error of the mean, asterisks (*) represent 
statistical significance and N=10. 
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compromised as determined by their shortened lifespan and precocious loss in locomotor 
function. LFG is able to block FasL-induced cell death and has been demonstrated to be 
neuroprotective [4, 9, 32, 33], being highly expressed in the neurons, and its loss-of-
function induces cell death. The profound loss in climbing ability that results from 
knockdown of CG3814/LFG in Drosophila neurons appears to be as a result of neuronal 
loss, since when compared to control flies around the same age and time point, there is a 
significant difference in the climbing abilities. In our findings, we did not perform any 
cell death assays and as such our conclusions are mostly based on behavioural phenotypes 
that are compared to controls. This does not negate the strong evidence we obtained on 
the effects of knocking down CG3814/LFG. In addition, the use of RNAi does not 
exclude off targets in regions that share homology with other BI-1 containing motifs, 
though data from Vienna Drosophila Resource Centre shows there are no off targets for 
these RNAi lines but in fact target the various isoforms present. Taken together, these 
results suggest a strong neuroprotective role for CG3814 in Drosophila Ddc-Gal4-
expressing neurons. 
The observed CG3814-induced phenotypes may be through a different mechanism by its 
interaction with pro-survival Bcl-2 proteins at the ER membrane [7], to regulate the 
release of calcium from the ER. Therefore, the knockdown of CG3814/LFG in the 
neurons appears to result in neuronal degeneration and death. The only known pro-
survival Bcl-2 homologue in Drosophila is Buffy [11]. The overexpression of Buffy is 
known to confer survival advantages to cells under normal conditions and under 
conditions of stress [11, 12, 14, 15, 26, 34, 35], the overexpression of Buffy along with the 
knockdown of CG3814 resulted in the suppression of the CG3814-induced phenotypes 
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marked by significantly improved survival and locomotor function. This Buffy action to 
improve “healthspan” may be specific to an interaction with CG3814 or may be attributed 
to a general pro-survival signalling pathway that is initiated by Buffy in response to stress 
mediated by the loss in CG3814 function. This additionally indicates a strong pro-
survival role for CG3814/LFG since the phenotypes that result from its knockdown are 
rescued by the pro-survival Buffy. 
In supportive experiments, the directed knockdown of CG3814 in the neuron-rich 
developing Drosophila eye under the direction of the GMR response elements resulted in 
a depressed ommatidia number. The reduction in the ommatidia number was attributed to 
the high degree of fusion of the ommatidium and consequently resulted in ommatidia 
disarray. The knockdown of CG3814 in the Drosophila eye seems to exacerbate the 
Gal4-induced apoptosis that manifests as roughened eye phenotype [36]. The 
overexpression of Buffy along with the knockdown of CG3814 results in the suppression 
of the phenotype, with the number of ommatidia and the degree of roughened eye 
restored to control levels. Buffy seems to ameliorate this phenotype and it is possibly via 
a general action on survival signals or through a concerted function to rescue CG3814-
induced apoptosis. 
Conclusions  
The knockdown of CG3814/LFG in the Ddc-Gal4-expressing neurons of Drosophila 
results in a severely shortened lifespan and marked age-dependent loss in climbing 
ability, phenotypes that are strongly associated with the degeneration and loss of DA 
neurons. The overexpression of the pro-cell survival Buffy along with the knockdown of 
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CG3814/LFG results in the rescue of the observed phenotypes that indicate a strong pro-
survival and neuroprotective role for CG3814/LFG in Drosophila neurons. 
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The Inhibition of CG2076, the GHITM homologue in neurons of 
Drosophila melanogaster can be rescued by Buffy  
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Abstract 
Growth hormone-inducible transmembrane protein (GHITM) is an inner mitochondrial 
membrane protein that contains the Bax inhibitor-1 motif and is implicated in the 
regulation of mitochondrial morphology and especially cristae structure. The 
downregulation of GHITM results in fragmented mitochondria and the release of 
cytochrome c, while its upregulation delays the release of cytochrome c. We inhibited 
CG2076 the Drosophila GHITM homologue in the neurons using RNA interference and 
analysed the phenotypic consequences of this mitochondrial protein. The directed 
expression of GHITM-RNAi in neurons under the control of the Dopa decarboxylase 
(Ddc) transgene results in shortened lifespan and impaired climbing ability. The co-
expression of Buffy, the only anti-apoptotic B cell lymphoma 2 (Bcl-2) protein in 
Drosophila, along with GHITM-RNAi results in suppression of the shortened lifespan and 
premature age-dependent loss in climbing ability. The inhibition of GHITM in the 
Drosophila eye results in decreased ommatidia number and elevated disruption of the 
ommatidial array, phenotypes that are rescued upon overexpression of Buffy. The 
inhibition of the mitochondrial located GHITM in the Ddc-Gal4-expressing neurons of 
Drosophila results in shortened lifespan and loss in climbing ability, phenotypes that are 
manifest of degeneration and death of dopaminergic neurons, and are improved upon 
overexpression of the pro-survival Buffy. 
Introduction 
The transmembrane Bax inhibitor-1 motif containing (TMBIM) family consists of several 
antiapoptotic members that are evolutionarily conserved, being found in viruses, bacteria, 
protozoans, plants and animals [1, 2]. This group of proteins is so diversely conserved 
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that they are present in organisms where the Bcl-2 family of proteins have not yet been 
identified. Generally, 6 members or orthologues can be present in an organism, that 
include TMBIM1/RECS1, TMBIM2/LFG, TMBIM3/GRINA, TMBIM4/GAAP, 
TMBIM5/GHITM and TMBIM6/BI-1 [2]. The different members are localised to 
different cellular organelles, with TMBIM1/RECS1 predominantly found in the 
endosomal/lysosomal membranes; TMBIM2/LFG at the plasma and intracellular 
membranes of the Golgi and the endoplasmic reticulum (ER); TMBIM3/GRINA is 
primarily located at the ER and Golgi compartments; TMBIM4/GAAP to the Golgi 
apparatus and the ER; TMBIM5/GHITM to the mitochondrial inner membrane; and 
TMBIM6/BI-1 at the ER [1-4]. Growth hormone-inducible transmembrane protein 
(GHITM)/TMBIM5 also referred to as Mitochondrial morphology and cristae 1 (MICS1) 
is a mitochondrial inner membrane protein that is involved in mitochondria morphology 
and specifically the cristae and is implicated in the release of cytochrome c from the 
mitochondria [5]. It was named GHITM as it was found dysregulated in expression 
analysis of inter-capsular brown adipose tissue of mice that were expressing a growth 
hormone antagonist [6]. This protein consists of seven transmembrane domains with a 
presequence as shown by the presence of a cleavage site at the amino (N)-terminal and is 
ubiquitously expressed in mammals [7, 8]. GHITM/MICS1 regulates cell death by the 
regulation of mitochondria morphology, since the knock down of this gene results in 
mitochondrial fragmentation and cristae disorganization followed by the release of 
mitochondrial proapoptotic proteins that include the apoptogenic cytochrome c [5]. 
Overexpression of GHITM/MICS1 can directly block the release of cytochrome c from 
the inner mitochondria membrane independent of Bax-induced permeabilization though it 
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does not block apoptotic death. Its maintenance of mitochondrial morphology therefore, 
is distinct from its role in the apoptotic process. 
The Drosophila melanogaster homologue is predicted to be CG2076 and CG1287 [2], the 
two putative genes have 56% and 53% protein sequence identity to the human GHITM as 
determined by BLAST; CG2076 is more closely related to the human homologue. 
Bioinformatic studies establish that the two genes are very closely related, 67% identity 
and 82% similarity in their protein sequences. CG2076 has two annotated transcripts on 
FlyBase but only one is unique, while CG1287 has only one annotated transcript [9]. 
Drosophila has been used as a model organism to study the phenotypic consequences of 
differential gene expression and to model human diseases with very promising results 
[10]. DA neurons are sensitive to subtle differences in gene products and degenerate in an 
age-dependent manner which can be quantified by scoring climbing ability of the affected 
flies. We investigated the outcome of the inhibition of CG2076, the Drosophila 
melanogaster homologue of GHITM in the Ddc-GAL4-expressing neurons, and further 
determined whether the Bcl-2 proteins, known to be the “guardians” of the mitochondria 
can rescue the CG2076/GHITM-induced phenotypes by the overexpression of the sole 
pro-survival Bcl-2 homologue in Drosophila, Buffy. 
Materials and Methods 
Bioinformatic analysis 
The protein sequences for Drosophila melanogaster: NP_610824.1, Homo sapiens: 
NP_036438.2, Xenopus tropicalis: NP_001072357.1, and Mus musculus: NP_082500.2 
were sourced from National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/protein/). The functional domains were identified using the 
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NCBI Conserved Domain Database (CDD) [11] (http://www.ncbi.nlm.nih.gov/cdd) and 
the Eukaryotic Linear Motif  [12] (http://elm.eu.org/) which focuses on annotation and 
detection of eukaryotic linear motifs (ELMs). A Clustal Omega multiple sequence 
alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/) [13, 14] was used to show 
conservation of the Bax inhibitor-1 domain. Transmembrane domains were confirmed 
using TMpred [15], a program based on statistical analysis of TMbase that identifies 
membrane-spanning regions (http://www.ch.embnet.org/software/TMPRED_form.html). 
Protein modelling, prediction and analysis was performed with Phyre2 [16], 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). The sub-cellular and 
mitochondrial targeting signal was identified using TargetP [17] 
(http://www.cbs.dtu.dk/services/TargetP/) and MultiLoc2 [18] (https://abi.inf.uni-
tuebingen.de/Services/MultiLoc2). 
Drosophila media and stocks 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben. Aliquots of media were poured into 
plastic vials, allowed to solidify, and refrigerated at between 4C and 6C. Stocks were 
raised at room temperature while crosses and experiments for analysis of ageing and 
climbing ability were carried out at 25C while those for the eye analysis were performed 
at 29C. The CG2076 stock, w1118; P{GD3308}v5537 hereby referred to as UAS-
GHITM-RNAi was obtained from the Vienna Drosophila Resource Center. UAS-Buffy 
[19] was kindly provided by Dr. L. Quinn of University of Melbourne and Ddc-Gal4 flies 
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[20] by Dr. J. Hirsch of University of Virginia. GMR-Gal4 [21] and UAS-lacZ flies were 
obtained from the Bloomington Drosophila Stock Center. 
Drosophila derivative lines 
The UAS-Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; GMR-Gal4 complex lines were 
used to overexpress Buffy in neurons and the developing eye and were produced 
employing standard homologous recombination and marker selection methods as 
previously described [22, 23]. Gel electrophoresis was used to confirm recombination 
events via the presence of a PCR product. 
Ageing assay 
Flies were aged using a standard protocol as previously described [24, 25]. Briefly, more 
than two hundred flies were aged per genotype and scored every two days for presence of 
deceased adults [26]. Longevity data was analysed using GraphPad Prism version 5.04 
and survival curves were compared using the Log-rank (Mantel-Cox) test.  Significance 
was determined at 95%, at a P-value less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
The climbing assay was performed as previously described [27]. Climbing indices were 
computed and then analysed using GraphPad Prism version 5.04. The 5-climbing index is 
a model generated for graded climbing analysis using non-linear regression and 5 is the 
highest level the flies can climb. Confidence intervals were compared at 95% at a P-value 
of 0.05. 
Scanning electron microscopy of the drosophila eye 
Crosses for the analysis of the Drosophila eye were made of each genotype at 29o C and a 
batch of male flies collected and assessed using a standard protocol previously described 
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[25]. 10 different scanning electron micrographs of each genotype were analysed using 
the National Institutes of Health (NIH) ImageJ software [28] and biometric analysis 
performed using GraphPad Prism version 5.04. The area of disruption of the ommatidial 
array was determined as detailed previously [29]. Statistical comparisons were evaluated 
using unpaired student T-tests. P-values less than 0.05 were considered significant. 
Results 
Human GHITM/MICS1 is closely related to Drosophila CG2076 
The Drosophila CG2076, the human GHITM homologue contains the Growth hormone-
inducible transmembrane hormone domain that is closely related to the Bax inhibitor-1-
like superfamily as determined by NCBI Conserved Domain Database (CDD) [11]. 
CG2076 is composed of 341 amino acids and shows 56% identity and 73% similarity to 
the 345 amino acids human GHITM (Figure 10). The Drosophila homologue has eight 
TM domains (Figure 10A) and the human transcript has seven TM domains as 
determined by the Eukaryotic linear motif (ELM) resource search [12] and Phyre2 [16]. A 
prediction of membrane-spanning regions using TMpred [15], indicates that all the 
aligned sequences possesses eight TM domains, the first seven fall within the 
GHITM/Bax inhibitor-1-like domain and the eighth membrane-spanning region falls 
outside the protein family domain. A similar search using Phyre2 [16], gave similar 
results for CG2076 but returned seven TM domains for the human version. A multiple 
sequence alignment of protein sequences using Clustal Omega [13, 14] shows high 
conservation of the Bax inhibitor-1-like domain (Figure 10B). CG2076/GHITM is 
localised to the mitochondria and has a mitochondrial targeting peptide with a  
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Figure 6.10 Drosophila CG2076/GHITM has eight TM domains that are 
evolutionarily conserved 
A) The membrane-spanning regions and the location of the N-terminus signal peptide 
present in human GHITM and Drosophila CG2076 as generated by Phyre2 [16]. B) The 
GHITM/Bax inhibitor-1-like domain is highly conserved and was identified using the 
NCBI Conserved Domain Database (CDD) [11] and the Eukaryotic Linear Motif [12], 
additional membrane-spanning domains were identified using TMpred [15] and Phyre2 
[16]. Clustal Omega multiple sequence alignment [13, 14] of Drosophila 
CG2076/GHITM protein (Dmel is Drosophila melanogaster NP_572681.1) with the 
human (Hsap is Homo sapiens NP_055209.2), mouse (Mmus is Mus musculus 
NP_510963.1) and mosquito (Agam is Anopheles gambiae XP_553771.3) homologues 
shows conservation of the Bax inhibitor-1 domain. "*" indicate the residues that are 
identical, ":" indicate the conserved substitutions, "." indicate the semi-conserved 
substitutions. Colours show the chemical nature of amino acids. Red is small hydrophobic 
(including aromatic), Blue is acidic, Magenta is basic, and Green is basic with hydroxyl 
or amine groups. C) A 3D modeling of both proteins using Phyre2 [16]. 
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presequence cleavage site at amino acid 43 as predicted using TargetP [17] and MultiLoc 
[18]. A 3D modelling of both proteins using Phyre2 [16] is shown (Figure 10C). 
Inhibition of CG2076/GHITM in the Ddc-GAL4-expressing neurons shortens lifespan 
and impairs climbing ability 
The suppression of CG2076/GHITM in the DA neurons results in severely shortened 
lifespan and highly impaired climbing ability. The median survival of GHITM-RNAi flies 
was 42 days compared to 68 days for the controls that express the benign lacZ as  
determined by Log-rank (Mantel-Cox) test (Figure 11A). The directed inhibition of 
CG2076/GHITM in the Ddc-GAL4-expressing neurons produces flies with significantly 
impaired climbing ability as determined by a nonlinear fit of the climbing curves (Figure 
11B). The comparison of the confidence intervals (CI) at 95% indicate a significant 
difference between the GHITM-RNAi flies with 0.036 to 0.051 compared with 0.084 to 
0.112 for the controls. These results suggest that CG2076/GHITM is required for the 
normal function of these neurons in Drosophila. 
Buffy suppresses the loss of CG2076/GHITM-induced phenotypes 
The overexpression of the pro-survival Bcl-2 homologue Buffy along with the suppression 
of CG2076/GHITM in the Ddc-GAL4-expressing neurons results in a significant increase 
in lifespan and improved climbing ability. The co-expression of Buffy with GHITM-RNAi 
results in increased median survival of 68 days when compared to Buffy control flies with 
a median survival of 72 days as determined by Log-rank test (Figure 12A). The climbing 
ability of the GHITM-RNAi flies was improved as determined by comparison of the 
climbing curves at 95% CI with 0.039 to 0.052 compared with 0.039 to 0.051 which was 
not significant (Figure 12B). These results suggest a pro-survival role for Buffy; it  
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B. 
 
Figure 6.11 Inhibition of CG2076/GHITM shortens lifespan and severely impairs 
climbing ability 
A) The inhibition of CG2076/GHITM in the Ddc-GAL4-expressing neurons results in 
shortened lifespan when compared to control flies expressing UAS-lacZ. The genotypes 
are Ddc-Gal4/ UAS-lacZ and Ddc-Gal4/ UAS-GHITM-RNAi. Longevity is shown as 
percent survival (P < 0.0001, determined by the log-rank (Mantel-Cox) test and n=200). 
B) The directed inhibition of CG2076/GHITM in these neurons resulted in premature loss 
in climbing ability as determined by nonlinear fitting of the climbing curves and 
comparing 95% CI (0.036 to 0.051 compared with 0.084 to 0.112). The genotypes are 
Ddc-Gal4/ UAS-lacZ and Ddc-Gal4/ UAS-GHITM-RNAi. Error bars indicate standard 
error of the mean (SEM) and n=50. 
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Figure 6.12 Overexpression of the pro-survival Buffy suppresses the 
CG2076/GHITM-induced phenotypes 
A) The overexpression of Buffy along with GHITM-RNAi in the Ddc-GAL4-expressing 
neurons resulted in improved survival when compared to the control. Genotypes are Ddc-
Gal4 UAS-Buffy/ UAS-lacZ and Ddc-Gal4 UAS-Buffy/ UAS-GHITM-RNAi. Longevity is 
shown as percent survival (P = 0.4006, determined by log-rank (Mantel-Cox) test with 
n=200). B) The inhibition of CG2076/GHITM along with the overexpression of Buffy in 
the DA neurons resulted in the suppression of the age-dependent loss in climbing ability. 
The genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ and Ddc-Gal4 UAS-Buffy/ UAS-
GHITM-RNAi. Analysis was done by nonlinear fitting of the climbing curves and 
significance was determined by comparing the 95% CI (0.039 to 0.052 compared with 
0.039 to 0.051). Error bars indicate SEM and n=50. 
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increases the general “healthspan” of GHITM-RNAi flies as it improves survival and 
locomotor function when CG2076/ GHITM is inhibited in these neurons. 
Inhibition of CG2076/GHITM in the eye decreases ommatidia number and increases 
disruption, phenotypes that are rescued upon Buffy overexpression 
The inhibition of CG2076/GHITM in the eye under the direction of the GMR-Gal4 
transgene decreases ommatidia number and results in significant disruption of the 
ommatidial array (Figure 13A, II and 13B) as determined by an unpaired T-test p<0.0001. 
The overexpression of Buffy along with the inhibition of CG2076/GHITM restored the 
number of ommatidia and the percentage disruption to control levels as determined by an 
unpaired T-test, p>0.50 (Figure 13A, III and 13C). Taken together, these results suggest 
that CG2076/GHITM may play a developmental role in the Drosophila eye and that Buffy 
suppresses the developmental eye defects that result from its inhibition. 
Discussion 
The precise function of the BI-1 consensus motif (UPF0005) is not known, but it encodes 
six to seven transmembrane spanning domains that are highly conserved in many species 
and signifies an important biological function [8]. Bioinformatic analysis of protein 
sequences from previous work [2] and our own study showed CG2076 and CG1287 to be 
the strongest candidates for Drosophila GHITM; CG2076 appears to be the closest with a 
sequence identity of 56% and 73% similarity, though this does not exempt CG1287, our 
main consideration was the high degree of similarity to human GHITM as determined by 
BLAST. Therefore, we propose that CG2076 is the Drosophila homologue of 
GHITM/TMBIM5. 
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Figure 6.13 Inhibition of CG2076/GHITM in the eye results in decreased ommatidia 
and increased disruption of the ommatidial array 
A) Scanning electron micrographs when CG2076/GHITM is inhibited in the eye and co-
expressed along with Buffy. The genotypes are (I) GMR-Gal4/ UAS-lacZ; (II) GMR-Gal4/ 
UAS-GHITM-RNAi; and (III) UAS-Buffy; GMR-Gal4/ UAS-GHITM-RNAi. B) Biometric 
analysis when CG2076/GHITM is inhibited in the eye indicates decreased ommatidia 
number (P<0.0001) and higher percentage of ommatidial disruption (P<0.0001) when 
compared to the control. C) Co-expression of Buffy with GHITM-RNAi resulted in the 
suppression of the eye phenotypes, ommatidia number (P = 0.7302) and disruption of the 
eye (P = 0.1439) were restored to control levels (CI is UAS-Buffy; GMR-Gal4/ UAS-lacZ) 
as determined by biometric analysis. Comparisons were determined by unpaired two-
tailed T-test (P<0.05), error bars are SEM, n=10 and asterisks (*) represent statistical 
significance. 
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The inhibition of CG2076/GHITM using RNA interference under the direction of the 
Ddc-Gal4 transgene in the dopaminergic neurons of Drosophila resulted in decreased 
median survival and severely impaired climbing ability. The general wellbeing of these 
flies was highly compromised as demonstrated by the shortened lifespan and premature 
retardation in climbing ability. GHITM is a mitochondria inner membrane protein that 
possesses an N-terminal presequence that is important for its expression [7, 8]. The 
presence of a mitochondria targeting sequence firmly localizes it to the mitochondria, 
while the loss of GHITM function induces cell death [5]. This cell death has been 
attributed to the fragmentation of the mitochondria and the subsequent release of the 
apoptogenic factor cytochrome c. In addition, GHITM was reported to be physically 
associated with cytochrome c. Dopaminergic neurons are sensitive to energy 
requirements and mitochondrial dysfunction is the main culprit that leads to their 
degeneration and death [30]. The integrity of the mitochondria is vital to the survival of 
these important motor neurons and any disruption in their function is implicated in 
disease including Parkinson disease [30-32]. The results obtained suggest a strong role for 
CG2076/ GHITM in neuroprotection in Drosophila since the loss of function in the Ddc-
Gal4-expressing neurons results in shortened lifespan and impaired climbing ability. The 
observed GHITM-induced cell death is possibly through mitochondrial dysfunction. 
The pro-survival Bcl-2 family of proteins are known to protect the mitochondria from 
breach by the pro-apoptotic members and releasing a variety of apoptogenic molecules 
that include cytochrome c [33]. The sole pro-survival Bcl-2 homologue in Drosophila is 
Buffy [19], and the overexpression of Buffy along with the inhibition of CG2076/GHITM 
resulted in the suppression of the CG2076/GHITM-induced phenotypes. The 
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overexpression of GHITM partially blocks the release of cytochrome c during apoptosis 
[5], while its downregulation induced a failure to maintain normal mitochondrial network 
and disorganization of the cristae. We have previously shown that Buffy rescues Ddc-
GAL4-expressing neurons when co-expressed with the neurotoxic α-synuclein [25], or the 
pro-apoptotic Debcl [22],  or the Parkinson disease related High temperature requirement 
A2 (HtrA2) [34]. This Buffy protection may be induced by pro-survival pathways though 
it is possible that Buffy regulates mitochondrial cell death as the phenotypes that result 
from the inhibition of CG2076/GHITM are rescued by Buffy. This in addition highlights 
the protective role of CG2076/GHITM in the neurons as its phenotypes can be rescued by 
the overexpression of the pro-survival Buffy. 
The inhibition of CG2076/GHITM in the Drosophila eye under the direction of the GMR-
Gal4 transgene results in a depressed number of ommatidia, this was mostly due to the 
fusion of the ommatidia and the extensive ommatidial disarray. The inhibition of 
CG2076/GHITM in the Drosophila eye seems to exacerbate the Gal4-induced apoptosis 
that manifests as roughened eye phenotype [35]. The overexpression of Buffy along with 
the inhibition of CG2076/GHITM results in the suppression of the Gal4 and the Gal4 in 
addition to the GHITM-RNAi phenotypes, with the number of ommatidia and the degree 
of roughened eye restored to control levels. Buffy seems to ameliorate this phenotype 
possibly via a general action on survival signals through the mitochondria or through a 
concerted function to rescue GHITM-induced apoptosis at the mitochondria. 
Conclusions 
CG2076 appears to be the GHITM/TMBIM5 homologue in Drosophila based on sequence 
homology, the presence of a mitochondria targeting signal, and a 43 amino acids 
  
218 
 
presequence, features that it strongly shares with the human GHITM transcript. The 
inhibition of CG2076/GHITM in the Ddc-GAL4-expressing neurons of Drosophila results 
in a severely shortened lifespan and an age-dependent loss in climbing ability, phenotypes 
that are strongly associated with the degeneration and loss of DA neurons, and may as 
well point to a novel model of Parkinson disease. The overexpression of the pro-cell 
survival Buffy along with the inhibition of CG2076/ GHITM results in the rescue of the 
observed phenotypes. 
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Chapter 7 - A loss of Pdxk model of Parkinson Disease in Drosophila can 
be suppressed by Buffy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been submitted to BMC Research Notes (M’Angale and 
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Abstract  
The identification of a DNA variant in pyridoxal kinase (Pdxk) associated with increased 
risk to Parkinson disease (PD) gene led us to study the inhibition of this gene in the 
dopaminergic (DA) neurons of the well-studied model organism Drosophila 
melanogaster. The multitude of biological functions attributable to the vitamers catalysed 
by this kinase reveal an overabundance of possible links to PD, that include dopamine 
synthesis, antioxidant activity and mitochondrial function. Drosophila possesses a single 
homologue of Pdxk and we used RNA interference to inhibit the activity of this kinase in 
the DA neurons. The directed inhibition of Pdxk resulted in reduced lifespan and impaired 
locomotor ability. We investigated any association between this enhanced disease risk 
gene with the established PD model induced by expression of α-synuclein in the DA 
neurons. The results showed the observed decreased lifespan and impaired climbing 
ability were not supplemented by the inhibition of Pdxk. Interestingly, when we co-
expressed Pdxk-RNAi with the anti-apoptotic Bcl-2 homologue Buffy, we saw a 
suppression of the phenotypes. To drive the expression of Pdxk RNA interference in DA 
neurons of Drosophila we used Ddc-Gal4 which resulted in decreased longevity and 
compromised climbing ability, phenotypes that are strongly associated with Drosophila 
models of PD. The inhibition of Pdxk in the α-synuclein-induced Drosophila model of PD 
did not alter longevity and climbing ability of these flies. It has been previously shown 
that deficiency in vitamers lead to mitochondrial dysfunction and neuronal decay, 
therefore, co-expression of Pdxk-RNAi with the sole pro-survival Bcl-2 homologue Buffy 
in the DA neurons, resulted in increased survival and a restored climbing ability. In a 
similar manner, when we inhibited Pdxk in the developing eye using GMR-Gal4, we 
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found that there was a decrease in the number of ommatidia and the disruption of the 
ommatidial array was more pronounced. When Pdxk was inhibited with the α-synuclein-
induced developmental eye defects, the eye phenotypes were unaltered. Interestingly co-
expression with Buffy restored ommatidia number and decreased the severity of 
disruption of the ommatidial array. Though Pdxk is not a confirmed Parkinson disease 
gene, the inhibition of this kinase recapitulated the PD-like symptoms of decreased 
lifespan and loss of locomotor function, possibly producing a new model of PD. 
Background  
Parkinson disease (PD), the second most common human neurodegenerative disorder, 
after Alzheimer disease, afflicts about 1 % of the population over the age of 50 years of 
age [1]. The clinical disorders associated with PD are a variable combination of 
bradykinesia, postural instability, tremor, and rigidity, with a typical positive response to 
Levodopa [2]. Non-motor symptoms that include autonomic dysfunction, cognitive 
decline and psychiatric problems can also present [3]. These end-points are mainly 
attributed to the loss of dopaminergic (DA) neurons of the substantia nigra with the 
degeneration of the nigrostriatal dopaminergic system. However, the neuropathology of 
PD is known to be more widespread, with many non-dopaminergic nuclei affected, 
including the locus coeruleus, the brain stem, raphe nucleus, dorsal motor nucleus of the 
vagus, basal nucleus of the Meynert, amygdala, and hippocampus [4]. PD is characterized 
by the presence of neuronal inclusions composed of abnormal α-synuclein and generally 
referred to as Lewy-related pathology [2, 5]. This atypical protein accumulation is 
believed to lead to cellular toxicity and, eventually, the PD pathogenesis. A majority of 
PD cases are idiopathic but the emergence of familial cases led to the identification and 
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study of genes that are highly associated with PD [6, 7]. The understanding and 
exploitation of the genetic basis of PD has revealed over 20 genes that are implicated in 
PD pathogenesis[8], and highlighted the complexity of this neurodegenerative disease.  
The link between vitamin B6 and PD incidence has been explored for years, with some 
studies associating dietary vitamin B6 with reduced effectiveness of Levodopa [9]. Other 
studies have shown the advantages of a higher dietary vitamin B6 and the reduced risk of 
PD [10] or reported low dietary intake of vitamin B6 with increased risk to PD [11], either 
via its antioxidant abilities or through dopamine biosynthesis. Vitamin B6 is comprised of 
three pyridine derivatives or vitamers – which are chemical compounds that have a 
similar molecular structure and possess similar vitamin activity - known as pyridoxine 
(PN), pyridoxamine (PM), pyridoxal (PL) and their phosphorylated products pyridoxine-
5’-phosphate (PNP), pyridoxamine-5’-phosphate (PMP) and pyridoxal-5’-phosphate 
(PLP) (See Appendix 6) [12, 13]. PLP is the most metabolically active form and 
responsible for more than 100 enzymatic reactions [12], predominantly in amino acid 
metabolism, and is implicated in nervous system function (neurotransmitter synthesis), 
red blood cell formation (heme biosynthesis), vitamin formation, one-carbon metabolism 
(nucleic acid synthesis) and as a potent antioxidant [14]. In neuronal function, PLP plays 
a key role in the metabolism of neurotransmitters, including dopamine, serotonin, glycine, 
GABA, glutamate, D-serine and histamine [12]. The deficiency of vitamin B6 has been 
implicated in increased risk of cancer, neural decay and accelerated ageing. 
Mitochondrial oxidative decay is a major contributor to ageing [15, 16]. Mitochondrial 
function is more dependent on PLP than any other organelle as PLP function as a 
coenzyme for transaminases that are involved in the catabolism of all amino acids by the 
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urea cycle of the mitochondria [16]. PLP is involved in diverse biochemically important 
roles in the mitochondria including maintaining energy pathways, homocysteine and 
glutathione (an antioxidant) biosynthesis. The heme biosynthesis occurs predominantly in 
the mitochondria and depends on PLP as a coenzyme. The inadequate synthesis of heme 
can cause mitochondrial decay and oxidative DNA damage [15], whereas its inhibition 
can cause oxidant leakage, that increases cellular endogenous ROS formation. Vitamin B6 
has a direct antioxidant activity by preventing superoxide radical formation, glycated 
haemoglobin formation and erythrocyte lipid peroxidation [17]. The inter-conversion of 
the pyridines to the biologically active phosphate derivative PLP require the action of 
pyridoxal kinase, thus, the activation of vitamin B6 to its active form, PLP, requires 
pyridoxal kinase. 
Pyridoxal kinase (Pdxk) belongs to the phosphotransferase family of proteins that are 
involved in the phosphorylation of vitamin B6 to pyridoxal-5-phosphate an important co-
factor in intermediary metabolism [18, 19]. They contain a ribokinase/pyridoxal domain 
and are highly conserved, being found in yeast, plants and animals. The association of the 
gene coding for Pdxk with Parkinson disease was through whole-genome expression 
profiling of human dopaminergic (DA) neurons, combined with association analysis in 
differentially regulated genes [20]. A DNA variant, single nucleotide polymorphism, in 
the Pdxk gene has been associated with an increased risk to PD [20], though other studies 
ruled out the association of the variant rs2010795 with PD in a cohort of patients [21]. 
The study did not rule out the existence of other Pdxk variants that may increase the risk 
for PD. The development of model systems to study potential therapies is important, and 
as such Drosophila melanogaster is a good model organism to study the pathophysiology 
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of movement disorders [22]. The first Drosophila model of PD utilized a human α-
synuclein transgene to induce the PD-like symptoms [23]. The success of this model is its 
ability to recapitulate features of human PD such as 1) age-dependent loss in locomotor 
function 2) LB-like inclusions and 3) age-dependent loss of DA neurons; and therefore 
has found wide use for studying the molecular basis of α-synuclein-induced 
neurodegeneration [22-29]. The utilization of the UAS/GAL4 spatio-temporal expression 
system [30], and the availability of a plethora of promoters or enhancers of which TH-
Gal4, elav-Gal4 and Ddc-Gal4 are employed in modelling PD in flies, makes Drosophila 
a powerful model organism [22-29]. We have previously shown the pro-survival 
advantages of Buffy, the sole anti-apoptotic Bcl-2 homologue in Drosophila by its rescue 
of the α-synuclein-induced phenotypes [31], we extended this study to investigate 
whether Buffy would rescue the loss of Pdxk-induced phenotypes in Drosophila. The 
development of PD models in Drosophila has therefore, many advantages that include 
extensive genetic resources including a bipartite expression system, and a genome with 
over 70% conservation of human disease genes. 
Materials and Methods 
Drosophila media and culture 
Stocks and crosses were maintained on a standard medium prepared from cornmeal, 
molasses, yeast, agar, water and treated with propionic acid and methylparaben. Aliquots 
of media were poured into plastic vials, allowed to solidify, and refrigerated at 4C until 
used. Stocks are kept at room temperature while crosses and experiments were carried out 
at 25C and 29C. 
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Drosophila stocks and derivative lines 
UAS-Buffy [36] was generously supplied by Dr. Leonie Quinn (University of Melbourne), 
UAS-α-synuclein [23] by Dr. Mel Feany of Harvard Medical School, and Ddc-Gal4 [38] 
by Dr. Jay Hirsch (University of Virginia). UAS-Pdxk-RNAi (P{KK108240}VIE-260B) 
was obtained from Vienna Drosophila Resource Center while GMR-Gal4 [39] and UAS-
lacZ flies were obtained from the Bloomington Drosophila Stock Center at Indiana 
University. The UAS-α-synuclein/CyO; Ddc-Gal4/TM3; UAS-α-synuclein/CyO; GMR-
Gal4; UAS-Buffy/CyO; Ddc-Gal4; and UAS-Buffy/CyO; GMR-Gal4 derivative lines were 
generated using standard recombination methods and used to overexpress either α-
synuclein or Buffy in the DA neurons using the Ddc-Gal4 transgene or in the developing 
eye using the GMR-Gal4 transgene. PCR reactions and gel electrophoresis were used for 
analysis of recombination events. 
Ageing assay 
Several crosses of five females and three males were made and a cohort of males 
collected upon eclosion. At least two hundred flies were aged per genotype at a density of 
≤ 20 flies per vial on fresh media, replenished every other day, to avoid crowding. Flies 
were observed and scored every two days for presence of deceased adults. As a rule, flies 
were considered dead when they did not display movement upon agitation [40]. 
Longevity data was analysed using the GraphPad Prism version 5.04. Survival curves 
were compared using the Log-rank (Mantel-Cox) test and significance was determined at 
95%, at a P ≤ 0.05 with Bonferroni correction. 
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Climbing assay 
A cohort of male flies was collected upon eclosion and scored for their ability to climb 
according to a standard protocol [41, 42]. Every 7 days, 50 or fewer males of each 
genotype were assayed for their climbing ability. Climbing analysis was performed using 
the GraphPad Prism version 5.04 and climbing curves were fitted using non-linear 
regression and compared using 95% confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the drosophila eye 
Crosses between five females and three males were made of each genotype at 29o C and a 
cohort of adult male flies collected upon eclosion and aged for three days before being 
frozen at -80o C. Whole flies were mounted on scanning electron microscope stubs, 
desiccated overnight and photographed with a FEI Mineral Liberation Analyzer 650F 
scanning electron microscope. For each cross ten eye images were analysed using the 
National Institutes of Health (NIH) ImageJ software [43] and biometric analysis 
performed using GraphPad Prism version 5.04. The percentage disruption of the eye was 
calculated as previously described [44]. 
Results  
Pdxk is evolutionarily conserved across diverse species 
The bioinformatic analysis of protein sequences encoded by the human, mouse, mosquito 
and fruit fly Pdxk gene revealed a highly conserved ribokinase/pyridoxal kinase domain 
(Figure 1). Comparison of the human and the Drosophila homologues reveal a 46% 
identity and a 64% similarity. The predicted Drosophila protein seems to possess active 
sites and motifs, including the ATP binding, a weak nuclear export signal (NES), nuclear 
localization signal (NLS), and transmembrane (TM) domains as determined by NCBI 
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Figure 7.1 The ribokinase/pyridoxal domain is evolutionarily conserved 
A Clustal Omega multiple sequence alignment [34, 35] of Drosophila melanogaster Pdxk 
with that of mammalian and insect homologues shows an evolutionarily conserved kinase 
domain (H.sapiens is Homo sapiens NP_003672.1, M.musculus is Mus musculus 
NP_742146.1, A.gambiae is Anopheles gambiae XP_315959.4, and D.melonogaster is 
Drosophila melanogaster NP_996031.1). The Drosophila transcript shows presence of 
motifs for NLS, a weak NES, MTS, and TM domains. Domains were identified using the 
NCBI Conserved Domain Database Search (CDD) [32] and the Eukaryotic Linear Motif 
resource search [33]. "*" indicate the residues that are identical, ":" indicate the conserved 
substitutions, "." indicate the semi-conserved substitutions. Colours show the chemical 
nature of amino acids. Red is small hydrophobic (including aromatic), Blue is acidic, 
Magenta is basic, and Green is basic with hydroxyl or amine groups.  
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Conserved Domain Database Search (CDD) [32] and Eukaryotic linear motif (ELM) 
resource search [33].  The alignment of protein sequences using Clustal Omega multiple 
sequence alignment [34, 35] demonstrates the high level of conservation of the kinase 
domain. 
Loss of Pdxk decreases lifespan and locomotor ability 
The inhibition of Pdxk in the DA neurons by RNA interference results in flies with a 
decreased lifespan and impaired locomotor function. The median lifespan for Pdxk-RNAi 
flies was determined to be 50 days compared to 71 days for the control flies (Figure 2A). 
When Pdxk was suppressed in the DA neurons the flies had impaired locomotor ability as 
determined by the nonlinear fitting of the climbing curves (Figure 2B). Taken together, 
these results indicate an important role for this kinase in the DA neurons of Drosophila as 
interference with its activity phenocopies some of the well-established phenotypes 
observed in other Drosophila models of PD. 
Inhibiting Pdxk does not suppress α-synuclein-induced phenotypes 
The co-expression of Pdxk-RNAi with the expression of α-synuclein does not alter the 
diminished longevity nor does it change the observed loss of climbing ability over time. 
The median lifespan was 58 days for Pdxk flies compared to 60 days for control flies 
(Figure 3A). A comparison of the climbing curves at 95% CI revealed they were not 
significantly different from each other (Figure 3B). This implies that the inhibition of 
Pdxk in the DA neurons does not influence the neurotoxic effects of α-synuclein.  
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Figure 7.2 Inhibiting Pdxk activity in DA neurons decreases lifespan and impairs 
locomotor function 
A) The directed expression of Pdxk-RNAi in DA neurons using the Ddc-Gal4 transgene 
results in a decrease in median lifespan when compared to control flies expressing UAS-
lacZ. The genotypes are UAS-lacZ/ Ddc-Gal4 and Pdxk-RNAi/ Ddc-Gal4. Longevity is 
shown as percent survival (P < 0.05, determined by the log-rank (Mantel-Cox) test and 
n≥200). B) The inhibition of Pdxk in the DA neurons resulted in a significant decrease in 
climbing ability as determined by nonlinear fitting of the climbing curves and comparing 
95% CI. The genotypes are UAS-lacZ/ Ddc-Gal4 and Pdxk-RNAi/ Ddc-Gal4. Error bars 
indicate SEM and n=50.  
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Figure 7.3 Inhibition of Pdxk in the α–synuclein-induced PD model does not alter 
phenotypes 
A) The inhibition of Pdxk with α-synuclein in the DA neurons showed no significant 
change in lifespan when compared to the control. Genotypes are UAS-α-synuclein; Ddc-
Gal4/ UAS-lacZ and UAS-α-synuclein; Ddc-Gal4/ Pdxk-RNAi. Longevity is shown as 
percent survival (P < 0.05, determined by log-rank (Mantel-Cox) test with n≤200). B) The 
co-expression of Pdxk-RNAi in the α-synuclein model of PD did not result in any 
significant age-dependent loss in climbing ability compared to the control. The genotypes 
are UAS-α-synuclein; Ddc-Gal4/ UAS-lacZ and UAS-α-synuclein; Ddc-Gal4/ Pdxk-RNAi. 
Analysis was done by nonlinear fitting of the climbing curves and significance was 
determined by comparing the 95% confidence intervals. Error bars indicate SEM and 
n=50.  
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The pro-survival Buffy suppresses the loss of Pdxk phenotypes 
The co-expression of the pro-survival Bcl-2 homologue Buffy with Pdxk-RNAi in DA 
neurons results in a slightly increased lifespan and an improved climbing ability. The 
median survival of Pdxk-RNAi flies with co-expression of Buffy was 64 days when 
compared to 60 days for the controls, as determined by Log-rank at a p<0.0001 (Figure 
4A). The climbing ability was slightly improved as determined by a nonlinear fitting of 
the climbing curves and compared at 95% CI (Figure 4B). These results suggest a pro-
survival role for Buffy, slightly increasing survival and significantly improving locomotor 
function when Pdxk is inhibited in the DA neurons. 
Inhibition of Pdxk in the developing eye results in disruption of the ommatidial 
array that can be suppressed by Buffy 
The inhibition of Pdxk in the developing eye directed by the GMR-Gal4 transgene results 
in eyes with a lower mean number of ommatidia and a greater disruption of the 
ommatidial array (Figure 5A) as determined by an unpaired T-test. The inhibition of Pdxk 
with α-synuclein expression did not result in marked differences in either the number of 
ommatidia or the disruption of the eye (Figure 5B). It seems that the inhibition of Pdxk in 
the developing eye along with α-synuclein expression does not result in a more roughened 
eye phenotype. When we co-expressed Pdxk-RNAi with Buffy, the number of ommatidia 
and the disruption of the array was restored to normal mean values as indicated by an 
unpaired T-test (Figure 5C). Taken together, these results suggest that Buffy suppresses 
the developmental eye defects resulting from the inhibition of Pdxk in the developing eye. 
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Figure 7.4 The co-expression of Pdxk-RNAi with Buffy suppresses the Pdxk-induced 
phenotypes 
A) The co-expression of Buffy with Pdxk-RNAi result in the suppression of the observed 
phenotype of decreased survival. Genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ and 
Ddc-Gal4 UAS-Buffy/ Pdxk-RNAi. Longevity is shown as percent survival (P < 0.05, 
determined by log-rank (Mantel-Cox) test with n≤200). B) The co-expression of Pdxk-
RNAi with Buffy in the DA neurons results in the suppression of the age-dependent loss in 
climbing ability. The genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ and Ddc-Gal4 UAS-
Buffy/ Pdxk-RNAi. Analysis was done by nonlinear fitting of the climbing curves and 
significance was determined by comparing the 95% confidence interval. Error bars 
indicate SEM and n=50.  
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Figure 7.5 The conditional expression of Pdxk in the Drosophila eye results in 
reduced ommatidia number and increased disruption of the eyes and is suppressed 
upon co-expression with Buffy 
A) Scanning electron micrographs when Pdxk is inhibited in the eye (I) GMR-Gal4/ UAS-
lacZ and (II) GMR-Gal4/ Pdxk-RNAi. The biometric analysis of the eyes indicated a slight 
decrease in mean ommatidia number and a higher percent disruption of the eye when 
compared to the control. B) The co-expression of Pdxk-RNAi with α-synuclein-expression 
I) UAS-α-synuclein; GMR-Gal4/ UAS-lacZ and II) UAS-α-synuclein; GMR-Gal4/ Pdxk-
RNAi. Biometric analysis of α-synuclein-expression and Pdxk inhibition in the developing 
eye revealed no significance in the number of ommatidia and the degree of ommatidial 
disruption. C) Co-expression of Buffy with Pdxk-RNAi I) UAS-Buffy; GMR-Gal4/ UAS-
lacZ and II) UAS-Buffy; GMR-Gal4/ Pdxk-RNAi. Biometric analysis showed restoration 
of the mean number of ommatidia and ommatidial disruption to control levels. 
Comparisons were determined by unpaired two-tailed T-test (P<0.05), error bars are 
SEM, n=10 and asterisks (*) represent statistical significance.  
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Discussion 
The directed inhibition of Pdxk in the DA neurons of Drosophila melanogaster result in 
decreased lifespan and an age-dependent loss in climbing ability, phenotypes strongly 
associated with models of PD. Pyridoxal kinase is involved in the conversion of pyridoxal 
into pyridoxal-5’-phosphate (PLP), an important enzyme cofactor in intermediary 
metabolism [14]. These B6 vitamers seem to be involved in all vital cellular functions, 
from glucose metabolism to nucleic acid synthesis to being potent antioxidants. Our 
inhibition of this protein kinase in the DA neurons resulted in shortened lifespan and 
impaired climbing ability, while in supportive experiments, its inhibition in the 
developing eye resulted in reduced ommatidia number and a high degree of ommatidial 
disarray. The involvement of PLP in the conversion of dopa to dopamine is an important 
step in its synthesis, it seems therefore, that decreased neuronal PLP can mimic the effects 
of decreased dopamine, a key step in PD development, and possibly of major impact in 
dopamine-containing cells. It is not surprising therefore, that decrease in the availability 
of such an important coenzyme by inhibition of the kinase function involved in its 
conversion results in defective neuronal function that may lead to neurodegeneration.  
The overexpression of α-synuclein in DA neurons can result in PD-like characteristics in 
Drosophila [23]. We investigated the possible existence of a link between α-synuclein-
induced phenotypes and the inhibition of Pdxk in the DA neurons of Drosophila. Our 
results indicate that loss of Pdxk function in DA neurons expressing α-synuclein did not 
enhance the α-synuclein-induced phenotypes of decreased lifespan and impaired climbing 
ability and vice versa. Similarly, when we conducted similar comparisons in the neuron 
rich Drosophila eye, we observed that inhibition of Pdxk did not alter the consequences of 
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α-synuclein expression in the developing eye. Therefore, the toxic effects of α-synuclein 
are sufficient to generate phenotypes but inhibition of Pdxk activity does not confer any 
additional disadvantage. Alternatively, loss-of-Pdxk-induced toxicity may precede the 
effects of α-synuclein accumulation and, as such, additional phenotypes may not be 
observable. Additionally, the multitude of biological functions that are dependent on PLP 
from a dysfunctional antioxidant activity to mitochondrial dysfunction may induce 
neurotoxicity in these sensitive neurons. 
The directed expression of the pro-survival Bcl-2 homologue Buffy with Pdxk RNA 
interference resulted in the suppression of the loss of Pdxk-induced phenotypes of 
decreased survival and impaired locomotor ability. Buffy like many other pro-survival 
Bcl-2 proteins, is thought to be a “guardian” of the mitochondria and confers survival 
advantages by restricting death-promoting molecules [36, 37]. Buffy suppressed the Pdxk-
induced phenotypes of reduced lifespan and locomotor ability and further restored 
ommatidia number and decreased the disruption of the ommatidial array. Not only do 
PLP deficiencies accelerate mitochondrial decay, but they increase ROS radicals [15, 16], 
a property that make neurons more vulnerable. It is possible that Buffy restores this 
balance by yet unknown pathways and cellular interactions via pro-survival signals.  
Conclusions  
Although Pdxk has not been confirmed to be a PD-causative gene, it has been associated 
to increased risk of the disease. The inhibition of this gene activity by the directed 
expression of an RNAi transgene in the DA neurons phenocopies PD-like symptoms in 
Drosophila, and therefore may represent a novel model of PD. This appear to corroborate 
other studies that show several mechanisms involved in the aetiology of PD. More studies 
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are required to chart out a pathway for Pdxk activity in Drosophila, and importantly to 
show at a molecular level the changes associated with the loss-of-function of this kinase 
in the development and function of dopaminergic neurons. 
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Chapter 8 - The Loss of Porin/VDAC function in dopaminergic neurons 
of Drosophila is suppressed by Buffy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in BioMed Central Journal of Biomedical 
Sciences 23: 84 DOI: 10.1186/s12929-016-0300-1 (M’Angale and Staveley, 2016). 
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Abstract 
Mitochondrial porin, also known as the voltage-dependent anion channel (VDAC), is a 
multi-functional channel protein that shuttles metabolites between the mitochondria and 
the cytosol and implicated in cellular life and death decisions. The inhibition of porin 
under the control of neuronal Ddc-Gal4 result in short lifespan and in an age-dependent 
loss in locomotor function, phenotypes that are strongly associated with Drosophila 
models of Parkinson disease. Loss of porin function was achieved through exploitation of 
RNA interference while derivative lines were generated by homologous recombination 
and tested by PCR. The UAS/Gal4 expression system was exploited with directed 
expression in neurons achieved with the use of the Dopa decarboxylase and in the 
developing eye with the Glass multiple reporter transgenes. Statistical analyses for ageing 
assay employed Log rank (Mantel-Cox) test, climbing indices were fitted with a non-
linear curve and confidence intervals compared at 95%. Biometric analysis of the eye 
phenotypes was obtained by a one-way analysis of variance (ANOVA) followed by a 
Dunnett’s post-test. The expression of α-synuclein in neuronal populations that include 
dopamine producing neurons under the control of Ddc-Gal4 produces a robust Parkinson 
disease model, and results in severely reduced lifespan and locomotor dysfunction. In 
addition, the porin-induced phenotypes are greatly suppressed when the pro-survival Bcl-
2 homologue Buffy is overexpressed in these neurons and in the developing eye adding to 
the cellular advantages of altered expression of this anti-apoptotic gene. When we co-
expressed α-synuclein along with porin, it results in a decrease in lifespan and impaired 
climbing ability. This enhancement of the α-synuclein-induced phenotypes observed in 
neurons was demonstrated in the neuron rich eye, where the simultaneous co-expression 
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of porin-RNAi and α-synuclein resulted in an enhanced eye phenotype, marked by 
reduced number of ommatidia and increased disarray of the ommatidia. The inhibition of 
porin in dopaminergic neurons among others result in reduced lifespan and age-
dependent loss in climbing ability, phenotypes that are suppressed by the overexpression 
of the sole pro-survival Bcl-2 homologue Buffy. The inhibition of porin phenocopies 
Parkinson disease phenotypes in Drosophila, while the overexpression of Buffy can 
counteract these phenotypes to improve the overall “healthspan” of the organism. 
Background  
The voltage-dependent anion channel (VDAC), also known as mitochondrial porin, 
consists of small pore-forming proteins present in the outer mitochondrial membrane that 
act to shuttle nucleotides, metabolites and ions between the mitochondria and the 
cytoplasm [1, 2]. Porin is a multi-functional protein and is involved in the regulation of 
metabolism and energetic functions of the mitochondria and a constituent of the 
mitochondrial permeability transition pore (PTP) [3]. Porin is involved in apoptosis, 
metabolite transport, calcium transport and signalling, ATP transport, reactive oxygen 
species transport and endoplasmic reticulum – mitochondrial crosstalk [3-5]. As thus 
porin appears to be a convergence point for cell death and survival signals, mediated by 
its association with a variety of ligands and proteins. Porin is implicated in mitochondria-
mediated apoptosis and in regulation of apoptosis through interaction with pro-survival 
proteins [3]. It interacts with the pro-survival hexokinase to mediate its anti-apoptotic 
activity [3, 6], and the Bcl-2 family of proteins to regulate mitochondria-mediated 
apoptosis [7, 8]. This association can induce cell survival or death. 
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The porin gene is associated with several neurodegenerative disorders including 
Alzheimer disease [9], Down syndrome [10], and dopamine-induced apoptosis [11]. The 
association of porin with Parkinson disease-associated gene products has been 
established, where it recruits parkin to defective mitochondria to promote mitophagy [12], 
and shows high affinity interaction with α-synuclein to regulate mitochondrial-induced 
toxicity [13]. This study suggests that α-synuclein translocate to the mitochondria via 
porin to target complexes of the mitochondrial respiratory chain. The accumulation and 
aggregation of abnormal α-synuclein was shown to down-regulate porin [14] and possibly 
regulate mitochondrial permeability [15]. The association between the PD gene α-
synuclein and the mitochondrial channel porin appears to be important in the progression 
of PD. The first PD model in Drosophila utilized the expression of a human α-synuclein 
transgene to induce the PD-like phenotypes [16]. The success of this model anchors on its 
ability to recapitulate features of human PD such as the age-dependent loss in locomotor 
function and therefore, has found application in the study of α-synuclein-induced 
degeneration [16-23]. The utilization of the UAS/GAL4 spatio-temporal expression 
system [24], and the availability of a plethora of promoters or enhancers of which TH-
Gal4, elav-Gal4 and Ddc-Gal4 are employed in modelling PD in flies [16-23], makes 
Drosophila a useful and albeit a powerful model organism. 
The loss of function of Drosophila porin/VDAC has been shown to result in mitochondrial 
morphological defects [25, 26]. These mitochondrial defects were accompanied by 
locomotor dysfunction and male sterility. In addition, porin mutants displayed 
neurological and muscular defects, mitochondrial respiratory defects, and abnormalities 
in synaptic transmission and mitochondrial distribution in motor neurons. Here we 
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suppressed porin by RNA interference in Drosophila neurons under the control of the 
dopa decarboxylase transgene and analysed longevity and locomotor ability. Further we 
co-expressed porin-RNAi with α-synuclein to investigate its effects in the well-studied 
Drosophila PD model. The association of porin with Bcl-2 members is well documented, 
we have demonstrated the benefits of overexpression of the sole anti-apoptotic Bcl-2 
member Buffy in conditions of stress [27], as thus, we overexpressed Buffy along with 
porin-RNAi. In addition, we altered the expression of porin in the Drosophila developing 
eye and co-expressed with α-synuclein and Buffy. 
Methods 
Bioinformatic analysis 
The protein sequences were sourced from National Center for Biotechnology Information 
(NCBI) (http://www.ncbi.nlm.nih.gov/protein/) and the domains were identified using the 
NCBI Conserved Domain Database (CDD) [28] (http://www.ncbi.nlm.nih.gov/cdd) and 
the Eukaryotic Linear Motif [29] (http://elm.eu.org/) which focuses on annotation and 
detection of eukaryotic linear motifs (ELMs) or short linear motifs (SLiMs). A Clustal 
Omega multiple sequence alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/) [30, 31] 
was used to show conservation of the porin3_VDAC domain in the selected organisms. 
The nuclear export signal (NES) was predicted using the NetNES 1.1 server 
(http://www.cbs.dtu.dk/services/NetNES/) [32] and TMpred, a program that predicts 
membrane-spanning regions and their orientation. The algorithm is based on the statistical 
analysis of TMbase, a database of naturally occurring transmembrane proteins 
(http://www.ch.embnet.org/software/TMPRED_form.html). 
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Drosophila media and culture 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben to inhibit fungal growth. Stocks were 
maintained on solid media for two to three weeks before transfer onto new media to re-
culture. Stocks were kept at room temperature (22°C ± 2°C) while crosses and 
experiments were carried out at 25°C and 29°C. 
Drosophila stocks 
The P{KK107645}VIE-260B hereby referred to as UAS-porin-RNAi (1) was obtained 
from Vienna Drosophila Resource Center, y[1] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.JF03251}attP2/TM3, Sb[1] hereby known as UAS-porin-RNAi (2), GMR-
Gal4 [33] and UAS-lacZ flies were obtained from the Bloomington Drosophila Stock 
Center at Indiana University. UAS-α-synuclein [16] was generously provided by Dr. M. 
Feany of Harvard Medical School, Ddc-Gal4 [34] by Dr. J. Hirsch of University of 
Virginia and UAS-Buffy [35] by Dr. Leonie Quinn of University of Melbourne.  
Drosophila derivative lines 
The UAS-α-synuclein/CyO; Ddc-Gal4/TM3, UAS-α-synuclein/CyO; GMR-Gal4, UAS-
Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; GMR-Gal4 derivative lines were generated 
using standard homologous recombination methods as described elsewhere [36, 37] and 
were used for overexpression of either α-synuclein or Buffy in DA and other neurons 
using the Ddc-Gal4 transgene or in the developing eye using the GMR-Gal4 transgene. 
Ageing assay 
Crosses of each genotype were made and a cohort of critical class male flies were 
collected upon eclosion. At least two hundred flies were aged per genotype at a density of 
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20 or fewer flies per vial to avoid crowding on fresh media which was replenished every 
other day. Flies were observed and scored every two days for the presence of deceased 
adults. Flies were considered dead when they did not display movement upon agitation 
[38]. Longevity data was analysed using the GraphPad Prism version 5.04 and survival 
curves were compared using the log-rank (Mantel-Cox) test. Significance was determined 
at 95%, at a P-value less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
A group of critical class male flies was collected upon eclosion and scored for their 
ability to climb over their lifetime [39]. Every 7 days, 50 males from every genotype were 
assayed for their ability to climb 10 centimetres in 10 seconds in a clean climbing 
apparatus in 10 repetitions. Analysis was performed using the GraphPad Prism version 
5.04 and climbing curves were fitted using non-linear regression and compared using 
95% confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the Drosophila eye 
Several single vial matings were made at 29o C and adult male flies collected upon 
eclosion and aged for three days before being frozen at -80o C. Whole flies were mounted 
on scanning electron microscope stubs, desiccated overnight and photographed with a FEI 
Mineral Liberation Analyzer 650F scanning electron microscope. For each cross at least 
10 eye images were analysed using the National Institutes of Health (NIH) ImageJ 
software [40] and biometric analysis performed using GraphPad Prism version 5.04. The 
percentage disruption of the eye was calculated as previously described [41]. Statistical 
comparisons comprised one-way analyses of variance (ANOVA) and Dunnett's multiple 
comparison tests. P-values less than 0.05 were considered significant. 
  
248 
 
Results 
The human and Drosophila porin domain is conserved 
There is 62% identity and 77% similarity between the human porin (VDAC) and the 
Drosophila melanogaster porin protein sequences, with very high conservation within the 
Porin3_VDAC domain (Figure 1). The putative dimerization interface and putative 
determinants of voltage-gated binding sites are well conserved as determined by an NCBI 
conserved domain search [28]. A Eukaryotic linear motif (ELM) resource search for 
functional sites [42] in the Drosophila transcript indicates the presence of an inhibitor of 
apoptosis binding motif (IBM) that function in the abrogation of caspase inhibition by 
inhibitors of apoptosis (IAPs) at amino acids 1 to 5, an Atg8 binding motif at amino acids 
5 to 9, a nuclear export signal (NES) at amino acids 91 to 98, a PDZ domain at amino 
acids 277 to 282 and a transmembrane domain predicted by TMpred. 
Inhibition of porin in neurons decreases lifespan and severely impairs locomotor 
function, phenotypes that are suppressed by Buffy overexpression 
The expression of porin-RNAi in Ddc-Gal4-expressing neurons results in a slightly 
decreased lifespan and severely impaired locomotor function as shown by the two RNAi 
lines that we tested. The median lifespan for these flies was 48 days and 52 days when 
compared to 68 days for the controls as determined by Log-rank (Mantel-Cox) test with a 
p<0.0001 (Figure 2A). When porin is suppressed in these neurons, the flies have impaired 
locomotor ability as determined by comparison of CI after the nonlinear fit of the 
climbing curves (Figure 2B). These results suggest a role for porin in the normal function 
of neurons in Drosophila since its reduced activity shortens lifespan and prematurely 
retards climbing ability. 
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Figure 8.1 Drosophila porin has a conserved Porin3_VDAC domain 
The Drosophila melanogaster porin gene encodes a 282 amino acids protein and the 
Porin domain is highly conserved when compared to the human homologue. It shows 
presence of a nuclear export signal (NES), a transmembrane domain, and a PDZ domain. 
Domains were identified using the NCBI Conserved Domain Database Search (CDD) 
[28] and the Eukaryotic Linear Motif resource search [29]. A Clustal Omega multiple 
sequence alignment [30, 31] show conservation of the porin3_VDAC domain (Hsap is 
Homo sapiens NP_003366.2, Dmel is Drosophila melanogaster NP_001033899.1 and 
Agam is Anopheles gambiae XP_318947.2). "*" indicate the residues that are identical, 
":" indicate the conserved substitutions, "." indicate the semi-conserved substitutions. 
Colours show the chemical nature of amino acids. Red is small hydrophobic (including 
aromatic), Blue is acidic, Magenta is basic, and Green is basic with hydroxyl or amine 
groups. 
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Figure 8.2 Loss of porin activity decreases survival and impairs climbing ability 
A) The inhibition of porin in neurons using the Ddc-Gal4 transgene results in decreased 
median lifespan of 48 and 52 days when compared to 68 days for control flies that 
expresses UAS-lacZ. The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-porin-
RNAi (1) and Ddc-Gal4/ UAS-porin-RNAi (2). Longevity is shown as percent survival (P 
< 0.05, determined by the log-rank (Mantel-Cox) test and n≥200). B) The inhibition of 
porin in the Ddc-Gal4-expressing neurons resulted in a significant decrease in climbing 
ability as determined by nonlinear fitting of the climbing curves and comparing 95% CI. 
The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-porin-RNAi (1) and Ddc-Gal4/ 
UAS-porin-RNAi (2). Error bars indicate SEM and n=50.   
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The directed overexpression of the pro-survival Bcl-2 homologue Buffy in these neurons 
resulted in increased lifespan and improved climbing ability. When Buffy is co-expressed 
with the porin-RNAi lines, the results indicate a median lifespan of 70 and 69 days when 
compared to 72 days for Buffy co-expression with lacZ control flies as determined by 
Log-rank test (Figure 3A). The climbing ability of the porin-RNAi flies was significantly 
improved as determined by comparison of climbing curves of porin-RNAi flies at 95% CI 
(Figure 2B) with the flies that express porin-RNAi along with Buffy and with the control 
flies that co-expressed Buffy along with lacZ (Figure 3B). Taken together these results 
suggest a pro-survival role for Buffy as observed by significant increases in the 
“healthspan” of porin-deficient flies. 
Inhibition of porin enhances α-synuclein-dependent phenotypes 
The expression of α-synuclein in Ddc-Gal4-expressing neurons results in impaired 
locomotor function that has been attributed to cellular toxicity due to the accumulation of 
this protein. The co-expression of the porin-RNAi lines along with α-synuclein, decreased 
survival and impaired climbing ability over time (Figure 4). The median lifespan was 50 
and 56 days for flies that expressed porin-RNAi along with α-synuclein, compared to 60 
days for control flies that co-expressed α-synuclein along with lacZ, a significant decrease 
in survival for both RNAi lines (Figure 4A) as determined by Log-rank (Mantel-Cox) test 
(p<0.0001). A comparison of the climbing curves by nonlinear fitting at 95% CI revealed 
they were significantly different (Figure 4B), with CI of 0.04691 to 0.06795 and 0.030 to 
0.050 for flies that expressed porin-RNAi along with α-synuclein, compared to 0.06842 to  
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Figure 8.3 Loss of porin activity is suppressed by Buffy 
A) The co-expression of Buffy with porin-RNAi result in the rescue of the observed 
phenotype of decreased survival, with a median survival of 70 and 69 days when 
compared to 72 days for controls. Genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ, Ddc-
Gal4 UAS-Buffy/ UAS-porin-RNAi (1) and Ddc-Gal4 UAS-Buffy/ UAS-porin-RNAi (2). 
Longevity is shown as percent survival (P < 0.05, determined by log-rank (Mantel-Cox) 
test with n≤200). B) The inhibition of porin along with the overexpression of Buffy in the 
DA neurons results in the suppression of the age-dependent loss in climbing ability. The 
genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ, Ddc-Gal4 UAS-Buffy/ UAS-porin-RNAi 
(1) and Ddc-Gal4 UAS-Buffy/ UAS-porin-RNAi (2). Analysis was done by nonlinear 
fitting of the climbing curves and significance was determined by comparing the 95% CI. 
Error bars indicate SEM and n=50. 
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Figure 8.4 Loss of porin function enhances the α-synuclein-induced reduction in 
lifespan and age-dependent loss of climbing ability 
A) The directed inhibition of porin along with α-synuclein expression in the neurons 
decreased lifespan with a median survival of 50 and 56 days when compared to 60 days 
for the control flies that express α-synuclein along with the lacZ transgene. Genotypes are 
UAS-α-synuclein; Ddc-Gal4/ UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ UAS-porin-RNAi 
(1) and UAS-α-synuclein; Ddc-Gal4/ UAS-porin-RNAi (2). Longevity is shown as percent 
survival (P < 0.05, determined by log-rank (Mantel-Cox) test with n≤200). B) The co-
expression of porin-RNAi with α-synuclein resulted in reduction of climbing ability over 
time when compared to the controls. The genotypes are UAS-α-synuclein; Ddc-Gal4/ 
UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/ UAS-porin-RNAi (1) and UAS-α-synuclein; Ddc-
Gal4/ UAS-porin-RNAi (2). Analysis was done by nonlinear fitting of the climbing curves 
and significance was determined by comparing the 95% CI. Error bars indicate SEM and 
n=50. 
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0.08366 for control flies that co-expressed α-synuclein along with lacZ. This suggests that 
the inhibition of porin together with the expression of α-synuclein in these neurons 
confers a significant health disadvantage, with marked decreases in survival and 
premature loss of climbing ability. 
Inhibition of porin in the eye decreases ommatidia number and increases ommatidial 
disarray, phenotypes that are rescued by Buffy overexpression 
When porin-RNAi is directed in the developing eye using the GMR-Gal4 transgene, it 
results in eyes with decreased number of ommatidia and higher disruption of the 
ommatidial array (Figure 5ii, iii and x) as determined by a one-way analysis of variance 
followed by a Dunnett’s multiple comparison test p<0.0001. Co-expression of porin with 
Buffy restored the mean number of ommatidia and the percentage disruption to control 
levels as determined by a one-way analysis of variance followed by a Dunnett’s multiple 
comparison test p>0.05 (Figure 5v, vi and xi). Taken together, these results suggest that 
porin may play a role in the development of the Drosophila eye and that Buffy suppresses 
the developmental eye defects that result from the inhibition of porin. The inhibition of 
porin along with α-synuclein overexpression resulted in a significant decrease in the 
number of ommatidia due to fusion of ommatidia and an increase in the percentage 
disruption of the eye (Figure 5viii, ix and xii) as determined by a one-way analysis of 
variance followed by a Dunnett’s multiple comparison test p<0.0001. This suggests an 
enhancement of the neurotoxic effects of the α-synuclein-induced developmental eye 
defects in the presence of reduced porin activity. 
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Figure 8.5 Inhibition of porin in the developing eye results in phenotypes that may 
be suppressed by Buffy and enhanced by α-synuclein 
(i – ix) Scanning electron micrographs when porin is inhibited in the developing eye and 
co-expressed along with either Buffy or α-synuclein. The genotypes are (i) GMR-Gal4/ 
UAS-lacZ, (ii) GMR-Gal4/ UAS-porin-RNAi (1), (iii) GMR-Gal4/ UAS-porin-RNAi (2), 
(iv) UAS-Buffy; GMR-Gal4/ UAS-lacZ, (v) UAS-Buffy; GMR-Gal4/ UAS-porin-RNAi (1), 
(vi) UAS-Buffy; GMR-Gal4/ UAS-porin-RNAi (2), (vii) UAS-α-synuclein; GMR-Gal4/ 
UAS-lacZ, (viii) UAS-α-synuclein; GMR-Gal4/ UAS-porin-RNAi (1), and (ix) UAS-α-
synuclein; GMR-Gal4/ UAS-porin-RNAi (2). Biometric analysis when (x) porin is 
inhibited in the eye indicated decreased ommatidia number and higher percentage of 
ommatidial disruption when compared to the control. (xi) The overexpression of Buffy 
with porin-RNAi results in restoration of the number of ommatidia and the degree of 
ommatidial disruption to below the control levels. (xii) The inhibition of porin along with 
α-synuclein expression resulted in the enhancement of the eye phenotypes when 
compared to controls as displayed by the low number of ommatidia coupled by the high 
degree of disruption of the ommatidial array. All comparisons were determined by a one-
way analysis of variance followed by a Dunnett’s multiple comparison test (P<0.05), 
error bars are SEM, asterisks (*) represent statistical significance and n=10. 
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Discussion 
The multitude of functions attributed to mitochondrial porin or VDAC and its control of 
the entry and exit of mitochondrial metabolites makes it a key player in the cellular 
decisions that lead to either survival or death [1]. The expression of porin-RNAi in  
neurons under the direction of the Ddc-Gal4 transgene results in shortened lifespan and a 
premature loss in locomotor ability, results that were consistent in both RNAi lines tested 
and that corroborate previous studies [25, 26]. This gene product is involved in 
maintaining mitochondrial morphology, and its disruption leads to a host of phenotypes 
among them locomotor defects. In our study, we disrupted this protein in DA and other 
neurons, the results obtained signifies a close connection between porin and the 
progression of the PD-like phenotypes of shortened lifespan and an age-dependent loss in 
locomotor function. The comparison of climbing indices of flies at 40 days when most of 
them are alive to the control lines indicate a significant change in the phenotypes, these 
appears to be a strong indication of possible neurodegeneration. 
The relationship between mitochondrial porin and PD susceptibility gene products has 
been investigated in other organisms [12-14, 43, 44]. The inhibition of porin along with 
the expression of α-synuclein in Ddc-Gal4-expressing neurons of Drosophila 
melanogaster results in the enhancement of the loss of α-synuclein-induced phenotypes, 
with a decrease in lifespan and an impairment in climbing ability. Some studies have 
attributed the neurotoxicity of α-synuclein to its interaction with electron transport chain 
components among them Complex I [45]. It has been suggested that α-synuclein blocks 
the activity of porin and uses this channel to translocate into the inner mitochondria [13] 
and that it preferentially interacts with mitochondrial membranes compared to other 
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organelle membranes [46]. This association inhibits mitochondrial function and promotes 
reactive oxygen stress. Our study firstly inhibited the mitochondria porin and secondly 
expressed α-synuclein in the same neurons, this resulted in the enhancement of the 
observed phenotypes, with shortened lifespan and severe reduction in climbing ability 
over time. It seems therefore that the combination effect of the directed inhibition of 
porin, and expression of α-synuclein confers a greater disadvantage to “healthspan”, 
albeit when altered in neurons. When altered individually, α-synuclein-induced PD 
model, a well-studied and robust disease model in Drosophila [16, 22] result in shortened 
lifespan and impaired climbing ability. Inhibition of porin in the developing eye results in 
extensive ommatidial disruption and fewer ommatidia number, as a result of intensive 
fusion of the ommatidia with no distinct ommatidia detectable in most of the eyes 
analysed. We suggest that though α-synuclein interacts with the mitochondria to result in 
disruption of mitochondria homeostasis, loss of porin in neurons seem to be independent 
of α-synuclein-induced phenotypes and this highlights the complexity of mechanisms 
involved in the pathogenesis of PD. 
The association of porin with members of the Bcl-2 family is well documented [7], and 
has been suggested to be a point of convergence for cell survival and death signals [3]. 
When we overexpressed Buffy, the sole pro-survival Bcl-2 homologue, in Drosophila 
neurons, along with inhibition of porin via RNAi, the phenotypes associated with the 
loss-of-function of porin, shortened lifespan and impaired climbing ability, were 
suppressed. The survival-induced advantages of Buffy especially under conditions of 
stress are well documented [27, 35], and so is the regulation of porin by Bcl-2 proteins 
that underscores the importance of Bcl-2 protein in life and death decisions. The 
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overexpression of Buffy along with the inhibition of porin in Ddc-Gal4-expressing 
neurons and in the developing eye resulted in a suppression of the phenotypes. The excess 
Buffy product must therefore confer cellular advantages to the target cells and counteracts 
the toxic effects of porin inhibition, and demonstrates a wider role for the Drosophila pro-
survival homologue, with potential involvement in the mitochondria-mediated cell death. 
One study has suggested that porin was not involved in debcl-induced cell death [25] and 
found that apoptosis induced by debcl overexpression was not inhibited by porin loss of 
function. As such it seems that the rescue of porin-induced phenotypes by Buffy are 
consistent with its action on the mitochondria directly or through other proteins in a 
dedicated pro-survival signalling pathway. 
Conclusions 
The inhibition of porin in the Ddc-Gal4-expressing neurons and the developing eye is 
rescued upon the overexpression of Buffy, a pro-survival Bcl-2 homologue. The co-
expression of porin-RNAi along with α-synuclein results in enhanced phenotypes, this 
highlights the complexity of α-synuclein-induced mechanisms in the pathogenesis of PD, 
and in deed demonstrates the multi-faceted mechanisms involved in the aetiology of PD. 
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Chapter 9 - Summary and Future Directions   
The Drosophila Bcl-2 homologue Buffy is pro-survival 
The Bcl-2 family of genes is one of the most conserved gene families and is present in a 
wide range of organisms [1-3]. Earlier studies investigated the presence of Bcl-2 
homologues in Drosophila, after their identification in the nematode and in mammals, the 
fly was the missing link, and in 2000 several groups independently published research 
that showed the presence of this important gene family in Drosophila [4-8]. The pro-
survival Bcl-2 homologue Buffy was identified by Quinn and colleagues [9] and in their 
study they showed its anti-apoptotic functions. Our studies further corroborate the pro-
survival functions of Buffy; it rescues the α-synuclein-induced phenotypes [10] when 
overexpressed in the DA neurons and in the developing eye [11], it increased lifespan, 
significantly improved climbing ability, and restored the roughened eye phenotype that is 
generally associated with cell death [12] to control levels. The overexpression of the pro-
apoptotic Bcl-2 homologue debcl in DA neurons and the developing eye resulted in 
severely shortened lifespan, impaired locomotor function and significant ablation of the 
eye [13]. These phenotypes were suppressed upon the overexpression of the pro-survival 
Buffy. This highlighted the antagonistic relationship between the two Bcl-2 family 
members; debcl overexpression promotes cell death while Buffy overexpression favours 
survival. We also updated the bioinformatic data for the two Drosophila Bcl-2 members, 
we showed the presence of four BH domains, TMD and presence of several motifs that 
may aid in their function [11, 13]. Indeed, the BH4 domain was previously associated 
with the pro-survival Bcl-2 members, but has recently been shown to occur in both anti- 
and pro-apoptotic multi-domain members [14]. This domain is known to interact with 
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pro-apoptotic members such as Bax, and with non-Bcl-2 proteins such as IP3R, ryanodine 
receptor and VDAC to prevent cell death. 
In general, Buffy shows strong pro-survival functions when overexpressed in DA neurons, 
this was demonstrated with different neuronal cell death models. As previously 
mentioned, the overexpression of Buffy along with expression of α-synuclein in DA 
neurons counteracts the α-synuclein-induced phenotypes. The α-synuclein-induced PD 
model in Drosophila makes a robust model for the study of neuronal degeneration and 
death [10]. This survival enhancement was demonstrated in other PD models in 
Drosophila that included the mitochondrial serine protease HtrA2 model, where the loss 
of HtrA2 function in DA neurons or in the developing eye resulted in shortened lifespan, 
impaired locomotor function and developmental eye defects [15, 16]. We show the 
suppression of these phenotypes upon overexpression of Buffy in either the DA neurons to 
enhance survival and locomotor ability in an age-dependent manner, or in the developing 
eye to restore the developmental eye defects to control levels (M’Angale and Staveley, 
unpublished work). We developed novel models of PD in Drosophila by the inhibition of 
anti-apoptotic genes such as the ancient TMBIM family, the loss of function of 
mitochondrial channel proteins such as VDAC and MICU1, and loss of function of Pdxk – 
a kinase that phosphorylates vitamers of vitamin B6 to the metabolically active PLP. 
The inhibition of Bax inhibitor-1 (BI-1/ TMBIM6) in DA neurons resulted in shortened 
lifespan and a precocious loss in climbing ability, whereas its suppression in the 
developing eye appeared to enhance the roughened eye phenotype (M’Angale and 
Staveley, unpublished work). This appears to indicate an involvement of BI-1 in the 
normal function of DA neurons, which might be through its regulation of ER calcium 
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homeostasis. Evolutionarily, the TMBIM family appears to be more ancient than the well-
studied and diverse Bcl-2 family, being present in species where no Bcl-2 members have 
been identified that include plants, yeast, some bacteria and viruses [17]. Regardless, 
present evidence points to interaction between these two regulators of cell death, 
especially with the discovery of putative BH3 domain in some of the TMBIM family 
members. In our experiments, we showed a rescue of the inhibition of BI-1 by Buffy, 
when co-expressed in the DA neurons or in the developing eye (M’Angale and Staveley, 
unpublished work). Though we did not show it in our experiments, pro-survival Bcl-2 
proteins interact with other proteins of the same family or non-Bcl-2 proteins through 
their BH4 or BH3 domains [14, 18]. Other than BI-1, we investigated Lifeguard (LFG/ 
TMBIM2), a member of the TMBIM family that is known to modulate FasL-mediated 
apoptosis [19]. The inhibition of CG3814, the Drosophila LFG homologue in DA neurons 
or in the developing eye produced flies with severely shortened lifespans, highly 
decreased locomotor function and increased degree of ommatidial disarray (M’Angale 
and Staveley, unpublished work). The overexpression of the Bcl-2 pro-survival 
homologue Buffy suppressed the phenotypes that resulted from the inhibition of LFG. 
Additionally, we investigated the suppression of CG2076, the Drosophila homologue of 
Growth hormone-inducible transmembrane protein (GHITM/ TMBIM5), an inner 
mitochondrial localized TMBIM member that is involved in the regulation of 
mitochondrial morphology [20] in DA neurons and in the developing eye. When we 
inhibited the expression of GHITM in the DA neurons or developing eye, it resulted in 
shortened lifespan, impaired climbing ability and a high degree of ommatidial disruption 
(M’Angale and Staveley, unpublished work), phenotypes that were rescued upon 
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overexpression of Buffy. The role of Drosophila Bcl-2 homologues in mitochondrial 
mediated cell death are still very unclear, though recent studies indicate a possible 
involvement under certain cellular conditions [21]. The loss of GHITM/ MICS1 function 
causes mitochondrial fragmentation and cristae disorganization and stimulates the release 
of apoptogenic molecules that include cytochrome c [20]. GHITM appears to facilitate 
the tight association of cytochrome c with the inner membrane, and thus its up-regulation 
can delay the release of cytochrome c. The overexpression of Buffy in this background 
suppresses the GHITM-induced phenotypes, the mechanism for this protection is 
unknown yet, but it is possibly through the association of Buffy with the mitochondria 
and the up-regulation of survival mechanisms in response to changes in mitochondrial 
dynamics and homeostasis. Regardless of the mechanism involved, Buffy counteracts 
these phenotypes by an increase in survival. 
Mitochondrial dysfunction is one of the main mechanisms implicated in the pathogenesis 
of PD [22]; the altered expression of genes with a function at the mitochondria is known 
to result in neurodegeneration as a result of mitochondrial dysfunction [23]. With this 
premise, we pursued the hypothesis that the overexpression of the pro-survival Bcl-2 
homologue Buffy would suppress the phenotypes that result from inhibition of porin, a 
voltage-dependent anion channel (VDAC) and mitochondrial calcium uptake 1 (MICU1). 
The inhibition of porin or VDAC is known to result in mitochondrial morphological 
defects [24]. In our study, the directed inhibition of porin in the DA neurons resulted in 
an age-dependent decrease in survival and locomotor dysfunction coupled with 
developmental eye defects (M’Angale and Staveley, unpublished work). These 
phenotypes were rescued upon the overexpression of Buffy. It seems that Buffy possesses 
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potent pro-survival signalling mechanisms, and as such this is an area of possible research 
to highlight the survival advantages that result from Drosophila Bcl-2 and its potential 
role in mitochondrial dynamics. Similar results were obtained with the inhibition of 
MICU1, and the overexpression of Buffy suppressed the MICU1-induced phenotypes of 
shortened lifespan and impaired climbing ability (M’Angale and Staveley, unpublished 
work). The role of calcium homeostasis in cell death is well known. The rescue of 
MICU1 phenotypes by Buffy points to a wider role of Drosophila Bcl-2 in the regulation 
of mitochondrial dynamics and in the modulation of calcium homeostasis. As to whether 
Buffy interacts with any of the mitochondrial channel proteins is yet to be studied, but 
regardless of this, the potential benefits of Buffy are obvious. 
Buffy influences the autophagy pathway 
Autophagy is one of the mechanisms implicated in the pathogenesis of PD [25, 26]. The 
accumulation of Lewy bodies suggests the involvement of the autophagic-lysosomal 
pathway in their clearance. In our study, we inhibited Atg6 and Pi3K59F; which are 
important in the formation of the autophagosome, in DA neurons and in the developing 
eye (M’Angale and Staveley, unpublished work). This resulted in flies with compromised 
survival and locomotor function and ommatidial disarray. These results suggest a strong 
involvement of autophagy or at least Atg6 and Pi3K59F in PD pathogenesis and in the 
normal function of neurons. We obtained strong evidence that showed the importance of 
this cellular process in disease pathogenesis by the expression of α-synuclein along with 
the inhibition of either Atg6 or Pi3K59F. This co-expression did not alter either of the 
phenotypes obtained by the expression of α-synuclein or inhibition of Atg6 or Pi3K59F, 
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that ruled out synergy and suggested that the impairment of the autophagy pathway result 
in PD-like phenotypes in Drosophila. This is a key finding from our study that indicate 
the complexity of the aetiology of PD; several failed cellular processes can in deed result 
in disease states. 
 The Bcl-2 pro-survival members are implicated in the regulation of autophagy, Atg6 or 
Beclin-1 is considered a BH3-only Bcl-2 protein (BOP) whereas its regulation relies 
heavily on other Bcl-2 members [27]. The formation of the Atg6-PI3K complex is an 
important regulatory step, with Atg6 sequestration being achieved by the association of 
its BH3 domain with Bcl-2 or Bcl-XL. Phosphorylation of the BH3 domain reverses this 
inhibition [28]. When we co-expressed Buffy with Atg6-RNAi, there was an enhancement 
of the phenotypes that suggested interaction between Buffy and Atg6 (M’Angale and 
Staveley, unpublished work). It is possible that Buffy interacts with the putative Atg6 
BH3 domain we discovered through bioinformatic analysis, or Buffy survival signals are 
unable to alleviate the cellular disadvantages that result from the inhibition of Atg6, but 
regardless of the mechanism of action, it appears that Buffy overexpression enhances the 
Atg6-induced phenotypes. The putative BH3 domain present in Atg6 may be the 
interaction point between Buffy and Atg6, but this remain to be determined by further 
studies and will possibly highlight the role of Drosophila Bcl-2 in autophagic 
homeostasis. 
Buffy has a complex effect on the Pink1/Parkin pathway 
The Pink1/Parkin pathway is a key process in the regulation of mitochondrial dynamics 
and homeostasis [29, 30]. The Pink1/Parkin pathway is responsible for the turnover of 
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defective mitochondria via mitophagy. The Pink1 [31-34] and parkin [35] models of PD 
are well-studied, and in our study we utilized these models to investigate the effect of the 
overexpression of Buffy. In the Pink1 model, the overexpression of Buffy resulted in the 
suppression of the loss of Pink1-induced phenotypes, with a general increase in 
“healthspan”  [32] M’Angale and Staveley, unpublished work). This rescue of Pink1 LOF 
increases evidence for the involvement of Buffy in mitochondrial-mediated cell death. 
Our study shows the beneficial overexpression of Buffy, by increasing lifespan and 
restoring locomotor ability to control levels. 
In contrast, parkin LOF was enhanced by overexpression of Buffy (M’Angale and 
Staveley, unpublished work). This finding indicates the involvement of Buffy in a pro-
apoptotic signalling mechanism that is potentially triggered by the excess Buffy product, 
coupled by the diminished levels of parkin. This is an important finding that first, shows 
that the Pink1/Parkin pathway converge at the mitochondria and Pink1 and parkin have 
additional cellular roles independent of the Pink1/Parkin pathway. Second, Buffy has 
additional cellular roles that need to be determined to provide insight into the neuronal 
consequences of parkin LOF and Buffy overexpression. And finally, Buffy stimulates 
survival under strict cellular conditions that appear to require certain molecules among 
them parkin, and deficiencies in parkin tips the survival balance in favour of cell death. 
As to whether Buffy and parkin participate in the same survival pathway remains to be 
elucidated and until such experimental evidence is obtained, this attractive pathway that 
can serve as a therapeutic target will remain elusive. 
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Debcl is pro-cell death 
The only identified pro-apoptotic Bcl-2 homologue in Drosophila is Debcl [4-6, 8], it 
shares sequence similarity with the mammalian pro-apoptotic Bok. The overexpression of 
debcl in DA neurons resulted in severely shortened lifespan and a significant impairment 
of climbing ability (M’Angale and Staveley, unpublished work). Previously it has been 
shown that the overexpression of debcl in the developing eye causes severe eye ablation 
[5], which was corroborated by our studies. The overexpression of debcl along with the 
expression of the human transgene α-synuclein in the DA enhanced the debcl- and α-
synuclein-induced phenotypes. The debcl-induced eye ablation was worsened with co-
expression of α-synuclein, the combined effect appears to worsen either of the 
phenotypes. Anti-apoptotic and pro-apoptotic Bcl-2 proteins antagonizes each other to 
balance life and death signals, in our study the co-expression of debcl with the pro-
survival Buffy resulted in suppression of the debcl-induced phenotypes, these flies had a 
longer lifespan, climbed better and had the eye ablation slightly restored to control levels. 
It is evident that Buffy confers survival advantages in conditions of stress and appears to 
overcome the cellular disadvantages of debcl overexpression. 
Ddc-Gal4-expressing neurons are highly sensitive to altered gene 
expression 
Ddc-Gal4-expressing neurons appear to be selectively sensitive to cellular stress due to 
their high oxygen consumption, high generation of reactive oxygen and nitrogen species 
from neurochemical reactions and the deposition of metal ions in the brain that comes 
with ageing [36]. As such alterations in gene products appear to impact these sensitive 
neurons greatly, and thus make an excellent model to study subtle differences in gene 
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products. We took advantage of these neurons to study the effects of gene inhibition, with 
an aim to recapitulate some of the PD-like symptoms such as shortened lifespan and 
impaired climbing ability. The inhibition of Pdxk in DA neurons is such one study we 
performed that resulted in shortened lifespan and an age-dependent loss in climbing 
ability (M’Angale and Staveley, unpublished work). The importance of this kinase is 
underscored by the product of its phosphorylation, pyridoxal-5’-phosphate (PLP), that is 
an important co-factor responsible for more than 100 enzymatic reactions [37], 
predominantly in amino acid metabolism, and is implicated in nervous system function 
(neurotransmitter synthesis), red blood cell formation (heme biosynthesis), vitamin 
formation, one-carbon metabolism (nucleic acid synthesis) and as a potent antioxidant 
[38]. The disruption of Pdxk function therefore has far ranging consequences that can 
result in mitochondrial dysfunction, neuronal decay and degeneration. The survival 
advantages of the overexpression of Buffy extended to phenotypes induced by the 
inhibition of this kinase. 
Future directions 
This study put into perspective the immense pro-survival advantages that result from 
overexpression of the Drosophila Bcl-2 homologue Buffy. We fell short of direct evidence 
for the involvement of Buffy at the mitochondria, but indirectly extended the theory that 
Drosophila Bcl-2 homologues have an active function at the mitochondria. Further 
investigation is required to unequivocally show this. Interaction studies are required 
between Buffy and the several proteins whose inhibition it suppresses. The relationship 
between Buffy and debcl is paramount to decipher the pathways that are involved in 
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Buffy survival signals, the presence of four BH domains in both proteins require further 
studies to determine which domain(s) are involved. This study should extend to Atg6, 
which we showed has a putative BH3 domain, the enhancement of Atg6-induced 
phenotypes points to an interaction between Buffy and Atg6, possibly within the BH3 
domain of Atg6. 
It appears that Buffy may have a role in ER stress response due to its suppression of BI-1-
induced phenotypes. It would be beneficial to investigate ER UPR states when BI-1 is 
inhibited and co-expressed with Buffy. The UPR response is pro-survival and only 
becomes pro-apoptotic after a sustained signal. The combined effects of ER stress and 
Buffy overexpression may likely act synergistically to promote cell survival and may 
prove to be an important therapeutic target. In addition, we need to investigate the 
mitochondrial morphological changes associated with suppression of the inner 
mitochondrial protein GHITM and its suppression by Buffy, this likely could shed more 
light on the involvement of Buffy in mitochondrial dynamics and homeostasis. Finally, 
further investigation into the interaction between Buffy and parkin is needed to explain 
the effects the overexpression of Buffy has on the inhibition of parkin. 
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Appendix 1: Co-expression of Buffy with Buffy-RNAi produces an 
intermediate phenotype in the Drosophila eye. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Drosophila Information Services 99: 14 – 
16 (M’Angale and Staveley, 2017). 
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Introduction 
The use of ribonucleic acid interference (RNAi), a post-transcriptional gene silencing 
mechanism, to inhibit gene function is widely applied to analyse phenotypic 
consequences of gene suppression [1-3]. RNAi is an evolutionary conserved cellular 
mechanism which is present in protozoa, fungi, nematodes, plants, flies and mammals [4]. 
This method is used in genome-wide screens [5], functional genomics, genetic 
therapeutics, crop and animal improvements among many upcoming applications [3]. In 
most of the organisms currently being used for studies, RNAi is systemic and cannot 
therefore, be restricted to a specific cell type [5]. Alternately, in Drosophila melanogaster 
RNAi is cell autonomous, and can be triggered in a spacio-temporal manner using the 
bipartite UAS/Gal4 expression system [5, 6]. Gene function can be analysed using an 
appropriate assay by examining the phenotypic effect of the directed inhibition (RNAi) or 
overexpression. To investigate the phenotypic effect of directed overexpression on 
directed RNA interference, the overexpression of Buffy, the sole pro-cell survival Bcl-2 
homologue [7], and an RNAi based on Buffy was used in the Drosophila developing eye. 
We investigated the possibility that intermediate developmental phenotypes can be 
generated from this interaction that are subject to modification by other genes. 
Materials and Methods 
Drosophila stock and culture: UAS-Buffy [7] was kindly provided by Dr. Leonie Quinn 
(University of Melbourne). UAS-Buffy-RNAi (w[*]; P{w[+mC]=UAS-Buffy.RNAi}c3), 
GMR-Gal4 [8] and UAS-lacZ flies were obtained from the Bloomington Drosophila Stock 
Center at Indiana University. The UAS-Buffy/CyO; GMR-GAL4 line was generated using 
standard recombination methods and was used to overexpress Buffy in the developing eye 
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under the direction of the GMR-Gal4 transgene. Stocks and crosses were maintained on 
standard medium containing cornmeal, molasses, yeast, and agar. Stocks were kept at 
room temperature (23°C ± 2°C) while crosses and experiments were carried out at 29°C. 
Biometric analysis of the Drosophila eye: A number of single vial crosses of each 
genotype were made at 29°C, a cohort of the critical class male flies was collected upon 
eclosion and aged for three days before being frozen at -80°C. Whole flies were mounted 
on scanning electron microscope stubs, desiccated overnight and photographed with a FEI 
Mineral Liberation Analyzer 650F scanning electron microscope. For each cross at least 
10 eye images were analysed using the National Institutes of Health (NIH) ImageJ 
software [9] and biometric analysis performed using GraphPad Prism version 5.04. The 
percent area of eye disruption was calculated as previously described [10]. 
Results and Discussion 
The directed expression of Gal4 in the Drosophila eye at 29o C results in a roughened eye 
phenotype characterised by uneven, enlarged and fused ommatidia [11, 12]. Analysis of 
scanning electron micrographs shows ommatidial disarray as a result of expression of 
Gal4 and the inhibition of Buffy in the developing eye (Figure 1A, I-II). Gal4-expressing 
flies show a disrupted ommatidia morphology, with 20% disruption of the eye (Figure 1B, 
I), whereas Buffy-RNAi flies display a much more severe phenotype of 45% disruption 
(Figure 1B, II). The co-expression of Buffy along with Gal4 results in suppression of the 
roughened eye phenotype with a disruption of 3% (Figure 1B, III). The overexpression of 
Buffy along with its inhibition results in a disruption of the eye with a mean of 22% 
(Figure 1B, IV); intermediate between Buffy overexpression (3%) and its inhibition 
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A1-1 The phenotypic consequences of the directed expression and inhibition of Buffy 
in the Drosophila developing eye. 
A) Scanning electron micrographs of the eye of the following genotypes (I) GMR-Gal4/ 
UAS-lacZ; (II) GMR-Gal4/ UAS-Buffy-RNAi; (III) UAS-Buffy; GMR-Gal4/ UAS-lacZ; 
and (IV) UAS-Buffy; GMR-Gal4/ UAS-Buffy-RNAi. B) The biometric analysis of the 
developing eye showing the percent area of disruption (I-IV). There is suppression of the 
Gal4-expression phenotype by Buffy (III) and an intermediate phenotype when Buffy is 
overexpressed along with Buffy-RNAi (IV) as determined by one-way ANOVA and 
Dunnett's multiple comparison test (P<0.05 and 95% CI), error bars indicate the SEM and 
n=10. (Data for GMR-Gal4/UAS-Buffy-RNAi is adapted from M'Angale and Staveley, 
2016 [13]) 
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(45%). While similar to the control, this intermediate phenotype results from a balance of 
a rescue of the RNAi inhibition by the directed expression of Buffy and interference of the 
overexpression of Buffy by the RNAi transgene. 
Previously, our research group demonstrated the expression of the yeast transcription 
factor Gal4 in the Drosophila eye results in apoptosis-dependent developmental defects of 
the ommatidial array [11]. The overexpression of Buffy, a Bcl-2 pro-cell survival 
homologue results in the suppression of this phenotype, similar to the suppression of 
these developmental defects by Pink1 [12]. These results suggest that the alteration of 
Buffy expression in the developing eye may subtly influence neurogenesis. The 
overexpression of Buffy along with its inhibition results in disrupted area of the eye that is 
intermediate to the two extremes. Intermediate phenotypes are important in determining 
gene function, neuropathology of neurological diseases and therapeutics [14, 15]. The 
inhibition of gene function by RNA interference relies on the degradation of the mRNA 
by the introduction of a dsRNA molecule [16]. One consequence of using RNAi, for 
better or worse, is the generation of phenotypes that may or may not be the equivalent of 
null mutants. 
A priori, if the inhibition of Buffy is extremely efficient, coupled with directed 
overexpression of Buffy-RNAi could be expected to generate a phenotype like Buffy-RNAi 
expression. Interestingly, the resulting intermediate phenotype reveals 1) that Buffy 
partially rescues the effects of Buffy-RNAi; 2) that Buffy-RNAi reduces the consequences 
of the directed expression of Buffy and 3) that both transgenes are biologically functional. 
Alternatively, the overexpression of the pro-cell survival Buffy might be acting in a 
general manner to counteract the downstream effects of an overloaded “RNAi system”, 
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with the elevated levels of Buffy gene product being sufficient to abrogate the Buffy-
RNAi-induced developmental eye defects. In conclusion, GMR-Gal4 produces a cell 
death-dependent rough eye phenotype that can be suppressed by the pro-survival Buffy, 
enhanced by its loss of function and the co-expression of Buffy along with its inhibition 
by RNAi results in an intermediate phenotype. 
References 
1. Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by anti-
sense RNA: a molecular approach to genetic analysis. Cell 1984; 36:1007-1015. 
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and 
specific genetic interference by double-stranded RNA in Caenorhabditis elegans. 
Nature 1998; 391:806-811. 
3. Ambesajir A, Kaushik A, Kaushik JJ, Petros ST. RNA interference: A futuristic 
tool and its therapeutic applications. S J Biol Sci 2012; 19:395-403. 
4. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee 
SK. RNA interference: biology, mechanism, and applications. Microbiology and 
molecular biology reviews : MMBR 2003; 67:657-685. 
5. Dietzl G, Chen D, Schnorrer F, Su K-CC, Barinova Y, Fellner M et al. A genome-
wide transgenic RNAi library for conditional gene inactivation in Drosophila. 
Nature 2007; 448:151-156. 
6. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates 
and generating dominant phenotypes. Development 1993; 118:401-415. 
7. Quinn L, Coombe M, Mills K, Daish T, Colussi P, Kumar S et al. Buffy, a 
Drosophila Bcl-2 protein, has anti-apoptotic and cell cycle inhibitory functions. 
EMBO J 2003; 22:3568-3579. 
8. Freeman M. Reiterative use of the EGF receptor triggers differentiation of all cell 
types in the Drosophila eye. Cell 1996; 87:651-660. 
9. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of 
image analysis. Nat Methods 2012; 9:671-675. 
10. M'Angale PG, Staveley BE. Effects of α-synuclein expression in the developing 
Drosophila eye. Dros Info Serv 2012; 95:85-89. 
11. Kramer JM, Staveley BE. GAL4 causes developmental defects and apoptosis 
when expressed in the developing eye of Drosophila melanogaster. Gen Mol Res 
2003; 2:43-47. 
12. Todd AM, Staveley BE. Pink1 Rescues Gal4-Induced Developmental Defects in 
the Drosophila Eye. Advances in Parkinson's Disease 2015. 
13. M'Angale PG, Staveley BE. The Bcl-2 homologue Buffy rescues alpha-synuclein-
induced Parkinson disease-like phenotypes in Drosophila. BMC Neurosci 2016; 
17:24. 
  
282 
 
14. Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. 
Nat Rev Genet 2014; 15:34-48. 
15. Leuchter AF, Hunter AM, Krantz DE, Cook IA. Intermediate phenotypes and 
biomarkers of treatment outcome in major depressive disorder. Dialogues in 
clinical neuroscience 2014; 16:525-537. 
16. Boettcher M, McManus MT. Choosing the Right Tool for the Job: RNAi, TALEN, 
or CRISPR. Mol Cell 2015; 58:575-585. 
 
  
283 
 
Appendix 2: Overexpression of Buffy has differing effects on the 
Pink1 and parkin Drosophila models of Parkinson disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Genome (M’Angale and Staveley, 2017) 
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Abstract  
Mutations in parkin and Pink1 are responsible for autosomal recessive early onset 
Parkinson disease (PD). This has been attributed to the failure of the cell to clear 
dysfunctional mitochondria that lead to nigrostriatal neuronal loss. The Pink1/parkin 
pathway is a quality control checkpoint for defective mitochondria and its failure results 
in phenotypes marked by reduced lifespan, impaired locomotor ability, among others. Our 
inhibition of parkin or Pink1 in the Ddc-Gal4-expressing neurons through a stable 
inducible RNAi results in compromised survival and precocious loss in climbing ability, 
results that corroborate other studies that supress the activity of these PD-associated 
genes. To evaluate the effects of the overexpression of the Bcl-2 homologue Buffy, we 
analysed lifespan and climbing ability in both parkin-RNAi and Pink1-RNAi flies, in 
addition to investigating the effect of Buffy overexpression in parkin-induced 
developmental eye defects. Our results show that Buffy overexpression had differing 
effects on parkin-RNAi and Pink1-RNAi, the parkin-induced phenotypes were enhanced 
whereas the Pink1-enhanced phenotypes were suppressed. Interestingly, the 
overexpression of Buffy along with the inhibition of parkin in the neuron rich eye results 
in the suppression of the developmental eye defects. 
Introduction  
Parkinson disease is the most common human neurodegenerative movement disease 
which is mainly characterized by the selective degeneration and loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) region of the midbrain. Some of its 
more common symptoms include muscle rigidity, resting tremors, postural instability, and 
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bradykinesia paired in some cases with non-motor symptoms such as autonomic, 
cognitive and psychiatric problems [1, 2]. The majority of PD cases are sporadic with no 
known causative agents, but familial forms with a genetic link have been identified and 
studied extensively in model organisms [3, 4]. Mutations in parkin, a gene that encodes a 
cytosolic ubiquitin E3 ligase that selectively targets misfolded proteins to the ubiquitin 
proteasome system (UPS) for degradation [5, 6], and Pink1, that encodes the Phosphatase 
and tensin homologue (PTEN)-induced kinase1 (Pink1) [7-9], are associated with 
autosomal recessive early onset PD. Pink1 and parkin are implicated in the same pathway 
that clears dysfunctional mitochondria via a specialized form of autophagy called 
mitophagy [10-12]. The Pink1/parkin pathway is responsible for aspects of mitochondrial 
quality control. 
Studies in Drosophila and cell systems demonstrated that parkin is recruited by Pink1 to 
depolarized mitochondria to mediate the selective autophagic removal of damaged 
mitochondria [13]. Pink1 localizes to damaged mitochondria then directly phosphorylates 
and activates parkin [14] to ubiquitinate targets on the defective mitochondria to mark 
them for autophagic removal [10, 15]. Although parkin and Pink1 participate in this 
important cellular pathway, they have been shown to function in separate cellular 
pathways that supplement mitophagy such as the action of parkin on UPS, autophagy and 
the lysosomal system. Mutant parkin flies show a reduction in lifespan, locomotor defects 
among other phenotypes [16], similar to those observed in Pink1 mutant flies [17-21]. It 
is this similarity in phenotypes that aided in the elucidation of the Pink1/parkin pathway. 
The sole pro-survival Bcl-2 homologue in Drosophila melanogaster, Buffy, has been 
shown to contribute to cell survival [22-24]. Previous studies have shown the suppression 
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of loss of Pink1-induced phenotypes by the overexpression of Buffy [19]. Here we 
determined the effect of directed overexpression of Buffy along with the inhibition of 
parkin or Pink1 via directed expression of stable RNAi transgenes in the Ddc-Gal4-
expressing neurons of Drosophila. We also co-expressed Buffy along with parkin-RNAi in 
the developing eye under the direction of the GMR-Gal4 transgene and evaluated the role 
of this overexpression on the parkin-induced developmental eye defects. 
Materials and Methods 
Drosophila stocks, derivative lines and media 
The UAS-parkin-RNAi and UAS-Pink1-RNAi were provided by Dr. B. Lu [21, 25], UAS-
Buffy [24] by Dr. Leonie Quinn, and Ddc-Gal4 [26] by Dr. J. Hirsch. GMR-Gal4 [27] and 
UAS-lacZ were obtained from the Bloomington Drosophila Stock Center. The UAS-Buffy 
Ddc-Gal4/ CyO and UAS-Buffy GMR-Gal4/ CyO complex lines were generated and 
tested by PCR as previously described (M’Angale and Staveley, in press). They were 
used to overexpress Buffy in neurons under the direction of the Ddc-Gal4 transgene or in 
the developing eye using the GMR response elements. Stocks and crosses were 
maintained on standard cornmeal/molasses/yeast/agar media treated with propionic acid 
and methylparaben in plastic vials. Stocks were kept at room temperature while crosses 
and experiments were carried out at 25°C and 29°C. 
Ageing assay 
Males flies of the selected critical class genotypes were carefully aged following a 
standard protocol [22, 28]. Briefly, more than two hundred male flies were aged per 
genotype and scored every two days for evidence of dead adults [29]. Male flies were 
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selected for ageing experiments to avoid the reproductive stresses associated with female 
fertility. Longevity data was analysed with GraphPad Prism version 5.04 and survival 
curves were compared using the Log-rank (Mantel-Cox) test.  Significance was 
determined at 95%, at a P-value less than or equal to 0.05 with Bonferroni correction. 
Climbing assay 
The climbing assays were performed as described in previous studies [30] and climbing 
indices were generated and analysed using GraphPad Prism version 5.04. As before, the 
climbing curves were fitted using non-linear regression and compared using 95% 
confidence interval with a 0.05 P-value. 
Scanning electron microscopy of the drosophila eye 
The eyes for scanning electron microscopy were prepared using our research group’s 
standard protocol [22]. For each cross at least 10 different eye images per critical class 
genotype were analysed using the National Institutes of Health (NIH) ImageJ software 
[31]. The ratio of disruption of the eye was calculated as previously described [32] and 
biometric analysis performed using GraphPad Prism version 5.04. Comparisons were 
determined by an unpaired two-tailed T-test (P<0.05). 
 Results  
Inhibition of parkin or Pink1 in Ddc-Gal4-expressing neurons decreases lifespan and 
severely impairs locomotor function 
The directed expression of parkin-RNAi in the Ddc-Gal4-expressing neurons results in 
decreased lifespan and severely impaired locomotor function. The median lifespan for 
these flies was 58 days compared to 70 days for the controls that express the benign lacZ 
transgene as compared by Log-rank (Mantel-Cox) test (Figure 1A). Similarly, the 
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inhibition of Pink1 in these neurons results in a decreased lifespan with a median survival 
of 60 days when compared to the controls. When either parkin or Pink1 is suppressed in 
these neurons, the flies display a marked impairment of locomotor ability as determined 
by the nonlinear fitting of the climbing curves (Figure 1B). These results corroborate 
previous studies that show a role for parkin and Pink1 in the protection of neurons in 
Drosophila as its reduced activity severely shortens lifespan and prematurely retards 
climbing ability. 
Overexpression of Buffy enhances the loss of parkin-induced phenotypes 
The directed overexpression of the pro-survival Bcl-2 homologue Buffy in Ddc-Gal4-
expressing neurons results in increased lifespan and improved climbing ability [22]. 
When Buffy is co-expressed with parkin-RNAi, the results show a significant decrease in 
lifespan with a median lifespan of 36 days when compared to 74 days for Buffy co-
expression with the benign lacZ control flies as determined by Log-rank test (Figure 2A). 
The climbing ability of the parkin-RNAi flies was slightly depressed as determined by 
comparison of the climbing curves (Figure 2B) with the control curve of Buffy co-
expression with the benign lacZ at 95% CI. Taken together these results suggest the pro-
cell survival role for Buffy is not active when parkin is inhibited and, it seems, may be 
anti-survival when the function of parkin is inhibited.  
  
289 
 
A. 
Days
P
e
rc
e
n
t 
s
u
rv
iv
a
l
0 20 40 60 80
0
20
40
60
80
100
parkin-RNAi
UAS-lacZ
Pink1-RNAi
 
B. 
Days
5
- 
c
lim
b
in
g
 i
n
d
e
x
0 20 40 60 80
0
1
2
3
4
5
parkin-RNAi
lacZ
Pink1-RNAi
 
Figure A2.1 Loss of parkin or Pink1 activity in neurons decreases survival and 
impairs climbing ability 
A) The inhibition of parkin in neurons under the direction of the Ddc-Gal4 transgene 
results in decreased lifespan with a median survival of 58 days compared to 70 days for 
the control flies that express the benign UAS-lacZ transgene. Similarly, the co-expression 
of Pink1-RNAi in the Ddc-Gal4-expressing neurons reduces lifespan, with a median 
survival of 60 days when compared to the controls. The genotypes are Ddc-Gal4/ UAS-
lacZ, Ddc-Gal4/ UAS-parkin-RNAi, and Ddc-Gal4/ UAS-Pink1-RNAi. Longevity is 
shown as percent survival (P < 0.05, determined by the log-rank (Mantel-Cox) test and 
n≥200). B) The inhibition of parkin or Pink1 in these neurons results in a significant 
decrease in climbing ability as determined by nonlinear fitting of the climbing curves and 
comparing the 95% CI. The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-parkin-
RNAi and Ddc-Gal4/ UAS-Pink1-RNAi. Error bars indicate SEM and n=50.  
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Figure A2.2 Pro-survival Buffy enhances the parkin-induced phenotypes and 
suppress the Pink1-induced phenotypes 
A) The co-expression of Buffy with parkin-RNAi in Ddc-Gal4-expressing neurons result 
in enhancement of decreased lifespan, the median survival of these flies was 36 days 
compared to 74 days for the controls that overexpress Buffy along with the benign lacZ 
transgene. In contrast, the overexpression of Buffy along with the inhibition of Pink1 
results in increased lifespan, with a median survival of 68 days compared to 74 days for 
the controls. Genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ, Ddc-Gal4 UAS-Buffy/ UAS-
parkin-RNAi and Ddc-Gal4 UAS-Buffy/ UAS-Pink1-RNAi. Longevity is shown as percent 
survival (P < 0.05, determined by log-rank (Mantel-Cox) test with n≤200). B) The 
inhibition of parkin or Pink1 along with the overexpression of Buffy in these neurons 
results in an enhanced parkin-induced phenotype and suppression of the Pink1-induced 
age-dependent loss in climbing ability. The genotypes are Ddc-Gal4 UAS-Buffy/ UAS-
lacZ, Ddc-Gal4 UAS-Buffy/ UAS-parkin-RNAi and Ddc-Gal4 UAS-Buffy/ UAS-Pink1-
RNAi. Analysis was done by nonlinear fitting of the climbing curves and significance was 
determined by comparing the 95% CI. Error bars indicate SEM and n=50. 
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Co-overexpression of Buffy with Pink1-RNAi suppresses phenotypes 
The directed overexpression of Buffy along with the inhibition of Pink1 in the Ddc-Gal4-
expressing neurons results in the suppression of the reduced survival phenotype observed 
with Pink1-RNAi expression (a median survival of 60 days, see Figure 1B) with a median 
lifespan of 68 days compared to 74 days for Buffy co-expression with the benign lacZ 
control flies. This was a significant increase (Figure 2A). A comparison of the climbing 
curves by nonlinear fitting at 95% CI revealed they were not significantly different 
(Figure 2B). This implies that the overexpression of the pro-survival Buffy confers 
survival advantage when Pink1 is inhibited in the Ddc-Gal4-expressing neurons. 
Loss of parkin-induced developmental eye defects are suppressed by Buffy, while 
inhibition of Pink1 decreases disruption of the eye 
The ectopic expression of parkin-RNAi in the developing eye under the direction of the 
GMR-Gal4 transgene results in decreased number of ommatidia and a higher disruption 
of the ommatidial array (Figure 3A, II and 3B). The inhibition of Pink1 in the developing 
eye results in normal ommatidia numbers and significantly lower levels of disruption of 
the ommatidial array (Figure 3A, III and 3B) as determined by a one-way analysis of 
variance followed by a Dunnett’s multiple comparison test p<0.05. Co-expression of 
parkin-RNAi with Buffy restored the mean number of ommatidia and the percentage 
disruption to control levels (Figure 3A, V and 3C). The co-expression of Pink1-RNAi 
with Buffy in the developing eye results in control level number of ommatidia and 
disruption of the eye (Figure 3A, VI and 3C) as determined by a one-way analysis of 
variance followed by a Dunnett’s multiple comparison test p<0.05. Taken together, these 
results suggest that parkin may play a role in the normal development of the Drosophila  
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Figure A2.3 Inhibition of parkin in the developing eye is suppressed by Buffy 
A) Scanning electron micrographs when parkin and Pink1 are inhibited in the eye and co-
expressed along with Buffy. The genotypes are (I) GMR-Gal4/ UAS-lacZ; (II) GMR-Gal4/ 
UAS-parkin-RNAi; (III) GMR-Gal4/ UAS-Pink1-RNAi; (IV) UAS-Buffy; GMR-Gal4/ 
UAS-lacZ; (V) UAS-Buffy; GMR-Gal4/ UAS-parkin-RNAi and (VI) UAS-Buffy; GMR-
Gal4/ UAS-Pink1-RNAi. B) Biometric analysis of the inhibition of parkin and Pink1 in 
the developing eye show a decrease in ommatidia number and increase in the percentage 
of ommatidial disruption for parkin-RNAi when compared to the control, whereas that of 
Pink1-RNAi resulted in a reduction of the disruption of the ommatidial array. C) The 
overexpression of Buffy with parkin-RNAi and Pink1-RNAi in the developing eye results 
in the suppression of the parkin-RNAi-induced phenotypes: the ommatidia number and 
disruption of the eye were restored to control levels. Comparisons were determined by a 
one-way analysis of variance followed by Dunnett’s multiple comparison test (P<0.05), 
error bars are SEM, asterisks (*) represent statistical significance and n=10. 
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eye and that the activity of Buffy suppresses the developmental eye defects that result 
from the inhibition of parkin. In addition, the inhibition of Pink1 seems to confer some 
survival advantages by counteracting the defects of Gal4 expression in the developing 
eye. 
Discussion  
The inhibition of parkin or Pink1 function in Drosophila is known to produce robust 
models of PD [16, 18-21]. In our study, we showed that the inhibition of parkin or Pink1 
in Ddc-Gal4-expressing neurons results in significant reduction in lifespan and an age-
dependent loss in locomotor function, results that corroborate previous studies. The 
overexpression of Buffy suppressed the loss of Pink1-induced phenotypes in Ddc-Gal4-
expressing neurons, of shortened lifespan and age-dependent loss in climbing ability. A 
previous study showed a rescue of loss of Pink1-induced phenotypes when overexpressed 
under the direction of hs-Gal4, but did not report the suppression of the shortened 
lifespan we have shown here [19]. Importantly, this study indicated that the survival 
benefits conferred by Buffy were from its protection of the mitochondria, as it restored 
mtDNA and ATP levels. All together this suggests that overexpression of Buffy strongly 
counteracts the phenotypes that result from the inhibition of Pink1. 
Recent studies have shown an increased array of parkin functions, in addition to its role in 
the Pink1/Parkin pathway [10, 11]. Contrary to the finding that the overexpression of 
Buffy suppressed the loss of Pink1-induced phenotypes, the loss of parkin-induced 
phenotypes was severely enhanced. The overexpression of Buffy in a parkin-RNAi 
background significantly shortened lifespan and severely impaired climbing ability. The 
neuroprotective function of the ubiquitin E3 ligase parkin has been shown by its 
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regulation of the proapoptotic Bax through ubiquitination [33]. The parkin-dependent 
ubiquitination of Bax prevented its translocation under basal and stress conditions to the 
mitochondria [34]. This appears to be an important function for parkin as it prevents overt 
cell death and supports cell viability during mitochondrial injury and repair. A loss in 
parkin function failed to inhibit the translocation of Bax to the mitochondria. We 
speculate that since parkin is well conserved in Drosophila, some of the neuroprotective 
functions are maintained. The BH3 domain of Bcl-2 proteins has been determined to be 
important for interaction between parkin and the Bcl-2 proteins [34]. The Bcl-2 
homologues in Drosophila Buffy and Debcl both possess a BH3 domain [24, 35]. It is 
possible that parkin influences neuronal apoptosis through its interaction with Debcl and 
Buffy. Its action on Buffy may be at several levels of regulation, first, the overexpression 
of Buffy may inhibit mitochondrial quality control as it antagonizes the parkin-dependent 
mitophagy [36]. Pro-survival Bcl-2 proteins inhibit the translocation of parkin to the 
mitochondria and thus antagonizes the elimination of defective mitochondria by the 
Pink1/Parkin pathway. Multifaceted roles for parkin and Pink1 have been demonstrated 
when co-expressed with Foxo [37], with differences in the severity of the Foxo-induced 
eye phenotypes. It therefore appears that parkin and Pink1 have specific unique cellular 
functions, separate from their role in the Pink1/parkin pathway. 
The overexpression of pro-survival Bcl-2 homologues has been shown to inhibit the 
translocation of parkin to the mitochondria and further suppress the activity of the 
Pink1/Parkin pathway [36]. Consistent with our studies, the overexpression of the pro-
survival Buffy enhanced the parkin-induced phenotypes, this could be due to the 
accumulation of defective and dysfunctional mitochondria, that leads to an increase in 
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oxidative stress, release of apoptogenic molecules from the mitochondria and depressed 
mitochondria turnover. As thus the zealous protection of the mitochondria by excess 
Buffy product countermand the pro-survival signal into a pro-apoptotic signal. A 
secondary theory for the mechanism and that require to be tested in future experiments is 
that the pro-survival actions of Buffy require ubiquitination of Buffy by parkin, that is, 
parkin activates Buffy by ubiquitination. It seems therefore the pro-survival function of 
Buffy requires normal parkin function This may be cell specific, as we only observed this 
in Ddc-Gal4-expressing neurons and not in the developing eye. 
Conclusion 
The overexpression of Buffy differentially affects the Pink1/Parkin pathway, it enhances 
the loss of parkin-induced phenotypes and counteracts the loss of Pink1-induced 
phenotypes. 
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Appendix 3: Loss of MICU1 function in Drosophila neurons alters 
longevity and motor ability 
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Abstract 
The mitochondrial calcium uptake 1 (MICU1) is a regulatory subunit of the mitochondrial 
calcium uniporter that function in calcium sensing. MICU1 contain two EF hand domains 
that are well conserved across diverse species from protozoa, to plants and metazoans. 
The loss of function in MICU1 is attributed to several neurological disorders that include 
movement dysfunction. The inhibition of MICU1 in the Ddc-Gal4-expressing neurons of 
Drosophila melanogaster presented with reduction in survival coupled with a precocious 
loss in locomotor ability. We attempted to rescue these phenotypes by overexpressing the 
sole Bcl-2 homologue in Drosophila Buffy. The co-expression of MICU1-RNAi along 
with Buffy resulted in the suppression of the loss of MICU1-induced phenotypes. 
Subsequently, the inhibition of MICU1 in the Drosophila developing eye resulted in 
reduced number of ommatidia paired with highly fused ommatidial array. These 
developmental eye defects were rescued by the overexpression of Buffy. 
Introduction 
The mitochondrial calcium uptake 1 (MICU1) encodes a mitochondrial EF hand protein 
essential for the uptake of calcium [1]. It is the regulatory component of the calcium 
uniporter that is proposed to regulate signalling, energy metabolism and cell death [1-3]. 
The mitochondrial calcium uniporter (MCU) is the pore-forming subunit while MICU1 
together with other subunits are the regulatory components [4]. MICU1 is a peripheral 
membrane protein that possess two EF-hand domains that are used for calcium sensing. 
MICU1 is evolutionarily diverse being present in some protozoa, protists, plants, and 
metazoans [5]. It is in most cases found strongly co-expressed with MCU and in some 
cases, share a potential promoter. 
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MICU1 is required for MCU-mediated calcium uptake [1] and plays an essential 
gatekeeping role to regulate cell survival [6]. The two MICU1 calcium binding EF-hands 
are key to its inhibitory functions. The knockdown of MICU1 inhibits mitochondrial 
calcium uptake [7], additionally mutations that abrogates EF-hand functions result in 
MICU1 knockdown-like phenotypes [6]. Loss of function mutations in the MICU1 gene 
were found to cause a brain and muscle disorder that was linked to mitochondrial calcium 
signalling [8]. Individuals suffering from this disorder suffered from proximal myopathy, 
learning difficulties and a progressive extrapyramidal movement disorder. This study 
shows a genetic link between mutations in MICU1 and a neuromuscular disease in 
children. Homozygous deletions in this gene have been additionally implicated with 
fatigue and lethargy in children [9], while single nucleotide polymorphisms analysis 
indicate a role for the EF-hand in bipolar disorder. 
The Bcl-2 family of genes are key regulators of cell death and survival in animals and 
regulate cell fate decisions following developmental or stress signals [10]. The family is 
classified into pro-death and pro-survival members, with the later said to be the 
“guardians of the mitochondria”. The Bcl-2 family member homologues in Drosophila 
melanogaster are limited to the single anti-apoptotic Buffy and the pro-apoptotic Debcl 
[11]. The overexpression of Buffy is reported to confer survival benefits in response to 
external stimuli and under conditions of stress [12-15]. To determine the pro-survival 
effect of the Bcl-2 homologue Buffy, and that of MICU1, we attempted to suppress the 
MICU1-induced phenotypes by overexpressing Buffy along with MICU1 in the Ddc-
Gal4-expressing neurons and in the Drosophila developing eye.  
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We propose that CG4495, through bioinformatic analysis to be the MICU1 homologue in 
Drosophila. Additionally, we show that the inhibition of CG4495/MICU1 in Drosophila 
neurons under the direction of the Dopa decarboxylase transgene results in shortened 
lifespan and locomotor dysfunction. Interestingly, these phenotypes are counteracted by 
the overexpression of the sole pro-survival Bcl-2 homologue Buffy. 
Materials and Methods 
Bioinformatic analysis 
The protein sequences were sourced from the National Center for Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov/protein/). The functional domains were 
identified using the NCBI Conserved Domain Database 
(http://www.ncbi.nlm.nih.gov/cdd) [16] and the Eukaryotic Linear Motif (ELM) resource 
(http://elm.eu.org/) [17] which focuses on annotation and detection of eukaryotic linear 
motifs (ELMs), also known as short linear motifs (SLiMs). The Clustal Omega multiple 
sequence alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/) [18, 19] was performed to 
indicate conservation of the domains. Transmembrane domains were identified by 
TMpred (http://www.ch.embnet.org/software/TMPRED_form.html) [20]. Further 
analysis of protein domains, modelling, prediction and analysis was performed with 
Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) [21]. More 
information on this protein is available on http://www.uniprot.org/uniprot/A2VEI2. 
Drosophila media, stocks and derivative lines 
Stocks and crosses were maintained on standard cornmeal/molasses/yeast/agar media 
treated with propionic acid and methylparaben. Stocks were raised at room temperature 
while crosses and experiments were performed at 25°C and 29°C. The CG4495 RNA 
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interference lines, w1118; P{GD4927}v49349 and w1118; P{GD4927}v49350 hereby 
referred to as UAS-MICU1-RNAi (1) and UAS-MICU1-RNAi (2) respectively were 
obtained from the Vienna Drosophila Resource Center (Vienna, Austria). The UAS-Buffy 
[11] was kindly provided by Dr. L. Quinn (University of Melbourne) and Ddc-Gal4 flies 
[22] by Dr. J. Hirsch (University of Virginia). GMR-Gal4 [23] and UAS-lacZ flies were 
obtained from the Bloomington Drosophila Stock Center (Indiana University). 
The UAS-Buffy/CyO; Ddc-Gal4 and UAS-Buffy/CyO; GMR-Gal4 derivative lines were 
generated using standard homologous recombination methods and were used for 
overexpression of Buffy in neurons using the Ddc-Gal4 transgene or in the developing eye 
using the GMR response elements following a standard protocol that has previously been 
described [24, 25]. 
Survival assay 
Crosses of each genotype were made and a cohort of male flies collected upon eclosion 
and survival analysis assessed using a standard protocol [15, 26, 27]. At least two 
hundred flies were assayed per genotype and observed every 2 days for presence of 
deceased adults. Longevity data were analysed using the GraphPad Prism version 5.04 
(GraphPad Software, Inc., La Jolla, CA, USA). Survival curves were compared using the 
Log-rank (Mantel-Cox) test and significance was determined at a 95% confidence 
interval (P ≤ 0.05 with Bonferroni correction. 
Climbing assay 
A cohort of male flies was collected upon eclosion and scored for their ability to climb 
every 7 days [28]. Climbing analysis was performed using the GraphPad Prism version 
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5.04 from climbing indices. The climbing curves were fitted using non-linear regression 
and compared using 95% confidence intervals with a P-value of 0.05. 
Scanning electron microscopy of the Drosophila eye 
Crosses were made of each genotype at 29o C and a batch of male flies collected upon 
eclosion and prepared for scanning electron microscopy following a standard protocol 
that has been previously described [15]. A minimum of 10 different eye images per 
genotype were analysed using ImageJ software (National Institutes of Health) [29] and 
biometric analysis performed using GraphPad Prism version 5.04. Disruption area of the 
eye was calculated as previously described [30]. Statistical comparisons comprised one-
way analyses of variance and Dunnett's multiple comparison tests. P-values less than 0.05 
were considered significant. 
Results 
Human MICU1 and Drosophila CG4495 EF-Hand domains are highly conserved 
The Drosophila CG4495 and human MICU1 homologue contains 2 EF-hand domains 
that are closely related and evolutionarily conserved as determined by NCBI Conserved 
Domain Database (CDD) [16]. CG4495 is composed of 525 amino acids and shows 57% 
identity and 75% similarity to the 476 amino acids human MICU1 (Figure1). The 
Drosophila homologue has 2 EF-hand domains at amino acids 272 to 300 and 463 to 491, 
while in the human transcript they are located at amino acids 222 to 250 and 412 to 440 
as determined by CDD and the Eukaryotic linear motif (ELM) [17]. Two to three 
transmembrane (TM) domains in the Drosophila and human transcripts are predicted 
using TMpred [20]. A nuclear localisation signal (NLS) was detected in both CG4495 
(390 to 404) and human MICU1 (87 to 105) using ELM. A multiple sequence alignment  
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Figure 1 - Drosophila CG4495/MICU1 has two EF-hand motifs that are 
evolutionarily conserved 
The 2 EF-hand domains are highly conserved and were identified using the NCBI 
Conserved Domain Database (CDD) [16] and the Eukaryotic Linear Motif (ELM) [17], in 
addition to the nuclear localisation signal. The membrane-spanning domains were 
identified using TMpred [20] and Phyre2 [21]. The mitochondrial targeting sequence in 
both human and Drosophila MICU1 were identified by TargetP [31]. Clustal Omega 
multiple sequence alignment [18, 19] of Drosophila CG4495 protein (D.melanogaster = 
Drosophila melanogaster NP_001097110.1) with the human (H.sapiens = Homo sapiens 
NP_001182447.1), mouse (M.musculus = Mus musculus NP_659071.1), zebra fish 
(D.rerio = Danio rerio NP_001077302.1), frog (X.tropicalis = Xenopus (Silurana) 
tropicalis NP_001106411.2), and mosquito (A.gambiae = Anopheles gambiae 
XP_319870.3) homologues shows conservation of the 2 EF-hand domains. "*" indicate 
the residues that are identical, ":" indicate the conserved substitutions, "." indicate the 
semi-conserved substitutions. Colours show the chemical nature of amino acids. Red is 
small hydrophobic (including aromatic), Blue is acidic, Magenta is basic, and Green is 
basic with hydroxyl or amine groups. A 3D modeling of both proteins using Phyre2 [21] 
is shown in the bottom panel. 
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of protein sequences using Clustal Omega [18, 19] shows high conservation of the EF-
hand domains (Figure 1A). CG4495/MICU1 is localised to the mitochondria and has a 
mitochondrial targeting peptide with a presequence cleavage site at amino acid 115, 
human MICU1 has a presequence length of 33 amino acids as predicted using TargetP 
[31]. A 3D modelling of both proteins using Phyre2 [21] is shown (Figure 1B). 
Inhibition of MICU1 in the Ddc-GAL4-expressing neurons shortens lifespan and 
impairs climbing ability 
To suppress MICU1 in the DA neurons, two different RNAi lines were utilised to 
determine the specificity of the effects of inhibition of this gene and to rule out possible 
off-target effects. The inhibition of this gene results in shortened lifespan coupled with 
age-dependent loss in climbing ability. The median survival of MICU1-RNAi flies was 63 
and 64 days when compared to 70 days for the controls that express the benign lacZ as 
determined by Log-rank (Mantel-Cox) test (Figure 2A). The directed inhibition of 
MICU1 in the Ddc-GAL4-expressing neurons produces flies with significantly impaired 
climbing ability as determined by a nonlinear fit of the climbing curves (Figure 2B). The 
comparison of the confidence intervals (CI) at 95% indicate a significant difference 
between the MICU1-RNAi flies and the controls. These results suggest that MICU1 is 
essential for the normal function of these neurons in Drosophila. 
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Figure 2 - Inhibition of MICU1 shortens lifespan and severely impairs climbing 
ability and is counteracted by the overexpression of Buffy 
A) The inhibition of CG4495/MICU1 in the neurons under the control of the Dopa 
decarboxylase transgene results in reduced lifespan, with a median survival of 42 days 
and 46 days when compared to 70 days for control flies that expresses the benign lacZ 
transgene. The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-MICU1-RNAi (1) 
and Ddc-Gal4/ UAS-MICU1-RNAi (2). Longevity is shown as percent survival (P < 0.05, 
determined by the log-rank (Mantel-Cox) test and N≥200). B) The directed suppression of 
CG4495/MICU1 in the Ddc-Gal4-expressing neurons resulted in premature loss in 
climbing ability as determined by nonlinear fitting of the climbing curves and comparing 
95% CI. The genotypes are Ddc-Gal4/ UAS-lacZ, Ddc-Gal4/ UAS-MICU1-RNAi (1) and 
Ddc-Gal4/ UAS-MICU1-RNAi (2). Error bars indicate standard error of the mean and 
N=50.  
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Buffy counteracts the loss of MICU1-induced phenotypes 
The overexpression of the pro-survival Bcl-2 homologue Buffy along with the suppression 
of MICU1 in the Ddc-GAL4-expressing neurons results in a significant increase in 
lifespan and improved climbing ability. The co-expression of Buffy with MICU1-RNAi 
results in increased median survival of 70 and 71 days when compared to Buffy control 
flies with a median survival of 74 days as determined by Log-rank test (Figure 3A). The 
climbing ability of the MICU1-RNAi flies was improved as determined by comparison of 
the climbing curves at 95% CI with 0.039 to 0.052 compared with 0.039 to 0.051 which 
was not significant (Figure 3B). These results suggest a protective role for Buffy as it 
improves the lifespan and locomotor function in MICU1 deficient neurons. 
Inhibition of MICU1 in the developing eye decreases ommatidia number and 
increases disruption of the ommatidial array 
The inhibition of MICU1 in the eye under the direction of the GMR-Gal4 transgene 
decreases ommatidia number and results in significant disruption of the ommatidial array 
in the two RNAi lines tested when compared to the control flies (Figure 4A-C and 4G) as 
determined by a one-way analysis of variance (ANOVA) p<0.0001. The overexpression 
of Buffy along with the inhibition of MICU1 restored the number of ommatidia and the 
percentage disruption to control levels as determined by a one-way analysis of variance, 
p>0.50 (Figure 4D-F and 4H). Taken together, these results suggest that CG4495/MICU1 
may play a developmental role in the Drosophila eye and that Buffy suppresses the 
developmental eye defects that result from the inhibition of this developmentally 
important gene. 
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Figure 3 - Inhibition of MICU1-induced phenotypes can be counteracted by the 
overexpression of Buffy 
A) The overexpression of Buffy along with MICU1-RNAi results in the suppression of 
decreased survival as indicated by a median survival of 70 days for both RNAi constructs 
when compared to 74 days for the control. Genotypes are Ddc-Gal4 UAS-Buffy/ UAS-
lacZ, Ddc-Gal4 UAS-Buffy/ UAS-MICU1-RNAi (1) and Ddc-Gal4 UAS-Buffy/ UAS-
MICU1-RNAi (2). Longevity is shown as percent survival (P < 0.05, determined by log-
rank (Mantel-Cox) test with N≥200). B) The inhibition of MICU1 along with the 
overexpression of Buffy in these neurons results in the suppression of the age-dependent 
loss in climbing ability. The genotypes are Ddc-Gal4 UAS-Buffy/ UAS-lacZ, Ddc-Gal4 
UAS-Buffy/ UAS-MICU1-RNAi (1) and Ddc-Gal4 UAS-Buffy/ UAS-MICU1-RNAi (2). 
Analysis was done by nonlinear fitting of the climbing curves and significance was 
determined by comparing the 95% CI. Error bars indicate standard error of the mean and 
N=50. 
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Figure 4 – Inhibition of MICU1 in the eye results in decreased ommatidia and 
increased disruption of the ommatidial array 
(A - F) Scanning electron micrographs of the inhibition of CG4495/MICU1 in the 
Drosophila developing eye and its co-expression along with Buffy. The genotypes are (A) 
GMR-Gal4/ UAS-lacZ, (B) GMR-Gal4/ UAS-MICU1-RNAi (1), (C) GMR-Gal4/ UAS-
MICU1-RNAi (2), (D) UAS-Buffy; GMR-Gal4/ UAS-lacZ, (E) UAS-Buffy; GMR-Gal4/ 
UAS-MICU1-RNAi (1), and (F) UAS-Buffy; GMR-Gal4/ UAS-MICU1-RNAi (2). G) 
Biometric analysis of the loss of CG4495/MICU1 function in the developing eye indicates 
decreased ommatidia number and higher percentage of ommatidial disruption when 
compared to the control. H) Similarly, the co-expression of Buffy with MICU1-RNAi 
results in the suppression of the developmental eye phenotypes. Comparisons were 
determined by a one-way analysis of the variance (ANOVA), p<0.05, error bars are 
standard error of the mean, asterisks (*) represent statistical significance and N=10.  
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Discussion 
The importance of mitochondrial calcium uptake 1 as a regulatory subunit of 
mitochondrial calcium uniporter (MCU) is exemplified by the disorders that result from 
its misexpression or in mutations that alter the EF hand function [8, 9, 32, 33]. 
Bioinformatic analysis reveals very conserved EF-hand domains, this may point to an 
evolutionarily conserved cellular pathway that is involved in calcium uptake and possibly 
in calcium signalling. Further analysis show presence of transmembrane domains and a 
nuclear localisation signal motif that contained residues that were not well conserved 
among the species investigated. It therefore appears that CG4495 is the closest 
homologue of MICU1 in Drosophila. 
In both the RNAi fly lines we tested, there was a consistent reduction in lifespan and a 
profound early-onset loss in climbing ability. The loss of MICU1 function in humans 
alters mitochondrial calcium signalling and result in proximal skeletal muscle weakness 
and brain disorder [8]. The MICU1-RNAi flies exhibited erratic climbing and at a very 
early time complete lack of climbing, they attempted to climb on the apparatus but were 
unsuccessful and dropped to the bottom of the climbing tube within the first level. The 
loss in climbing ability was not matched by decreased survival and from Figure 2A and 
2B it is evident that at 40 days when most the flies in both the control and the RNAi lines 
were alive, the MICU1-RNAi flies had lost their climbing ability in an age-dependent 
manner, which is indicative of neuronal degeneration. We established that the suppressed 
activity of MICU1 in Drosophila results in significant reduction in survival and a 
precocious loss in climbing ability. We co-expressed the pro-survival Bcl-2 homologue 
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Buffy along with MICU1-RNAi and observed that this counteracted the induced 
phenotypes. This was an important finding as it includes a role for Buffy in calcium 
signalling and possibly a role in mitochondrial calcium uptake. The pro-survival role of 
Buffy in conditions of stress is well documented [15, 24, 25, 34], while this new role for 
Buffy deserves further investigation and may point to the conserved role for Bcl-2 
proteins in regulation of calcium signalling [35]. Additionally, the rescue by Buffy 
highlights the pro-survival function of MICU1, being protective to the mitochondria as its 
loss can be compensated in yet unknown mechanisms by Buffy.  
In complimentary experiments in the neuron rich Drosophila eyes, the inhibition of 
MICU1 by stable inducible RNA interference under the direction of the GMR-Gal4 
transgene results in a reduction in the number of ommatidia and an increase in the area of 
the eye that had fused ommatidia. MICU1-RNAi (1) showed a greater penetrance of the 
eye phenotypes, with significantly lower numbers of ommatidia and greater disruption of 
the ommatidial array than MICU1-RNAi (2). This indicates that mitochondrial calcium 
homeostasis is important in the development of the Drosophila eye. Indeed, as previously 
observed, the co-expression of Buffy along with MICU1-RNAi in the developing eye 
resulted in the restoration of the eye defects to normal levels. It appears that MICU1 plays 
a significant role in Drosophila Ddc-Gal4-expressing neurons and in the developing eye. 
Conclusions 
The bioinformatic candidate for MICU1 in Drosophila appears to be CG4495, 
experimental evidence shows that the inhibition of this gene in neurons results in reduced 
survival and an age-dependent onset of locomotor dysfunction. These phenotypes are 
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strongly associated with neurodegeneration and are rescued upon overexpression of the 
pro-survival Buffy, highlighting the protective nature of MICU1 in Drosophila neurons. 
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Appendix 4: Parkinson disease genes and their function 
PD locus Gene/ Protein Inheritance Function 
PARK1/4 SNCA  
α-synuclein [1] 
Autosomal 
dominant (AD) 
Unknown, presynaptic 
vesicles 
PARK 2 Parkin [2] Autosomal 
recessive (AR) 
E3 ubiquitin ligase 
PARK 3 Unknown    
PARK 5 Ubiquitin C-terminal 
hydrolase – L1 (Uchl-1) [3] 
AR Thiol protease involved 
in deubiquitinating 
PARK 6 Phosphatase and tensin 
homologue (PTEN) 
induced kinase 1 (Pink1) 
[4] 
AR Protein kinase 
PARK 7 DJ-1 [5] AR Unknown but possibly 
antioxidant and/or 
chaperone 
PARK 8 Leucine rich repeat kinase 
2 (LRRK2) [6, 7] 
AD Multifunctional with 
kinase, GTPase, and 
WD40 domain 
PARK 9 ATP 13A2 [8] AR Lysosomal type 5 P-
type ATPase 
PARK 10 Unknown   
PARK 11 Grb10-interacting GYF 
protein-2 (GIGYF2) [9] 
AD Insulin signalling 
PARK 12 Unknown   
PARK 13 High temperature 
requirement A2 (HTRA2) 
[10] 
AR Mitochondrial serine 
protease 
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PARK 14 Phospholipase A2 
(PLA2G6) [11] 
AR Fatty acid hydrolysis 
PARK 15 F-box only protein 7 
(FBXO7) [12] 
AR Ubiquitination  
PARK 16 Unknown   
PARK 17 Vacuolar protein sorting 35 
(VPS35) [13, 14] 
AD Component of the 
retromer cargo-
recognition complex 
PARK 18 Eukaryotic translation 
initiation factor 4 gamma 1 
(EIF4G1) [15] 
AD mRNA translation 
initiation  
PARK 19 DnaJ homologue subfamily 
C member 6 (DNAJC13) 
[16] 
AR Clathrin–uncoating co-
chaperone (clathrin 
mediated endocytosis) 
PARK 20 Synaptojanin 1 (SYNJ1) 
[17, 18] 
AR Phosphoinositide 
phosphatase (synaptic 
vesicle recycling) 
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Appendix 5: The initiation of apoptosis in three model organisms: a 
comparison of the main apoptotic molecules 
 
 
A comparison of the three main model organisms that are used to study aspects of 
apoptosis to highlight conservation of various molecules used in different stages of 
apoptosis. The different levels are indicated by different coloured molecules. Though the 
mechanisms for apoptosis differ in all three organisms, the molecules involved are 
conserved and interact with other molecules across species. 
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Appendix 6: Pyridoxal kinase and formation of pyridoxal phosphate 
 
 
The vitamin B6 consists of three vitamers, pyridoxine (PN), pyridoxal (PL) and 
pyridoxamine (PM). Pyridoxal kinase phosphorylates them to PNP, PLP and PMP. PLP is 
the active form of vitamin B6 and requires pyridoxal kinase, PNP and PMP are further 
converted into PLP via the action of pyridoxine 5’-phosphate oxidases that requires 
Flavin mononucleotide (FMN) as a cofactor.  
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